Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID JAX:10000003
Name Advanced Solid Tumor
Definition A malignant solid tumor
Source The Jackson Laboratory (a custom term added that does not corresond to an existing term in the disease ontology)
Alt Ids
Path Advanced Solid Tumor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant CUDC-907 Advanced Solid Tumor sensitive detail...
PIK3CA wild-type PX-866 Advanced Solid Tumor sensitive detail...
PIK3CA mutant PX-866 Advanced Solid Tumor sensitive detail...
TP53 mutant Bevacizumab Advanced Solid Tumor sensitive detail...
FGFR2 act mut Debio 1347 Advanced Solid Tumor sensitive detail...
PIK3CA act mut Taselisib Advanced Solid Tumor conflicting detail...
PIK3CA mutant M2698 Advanced Solid Tumor sensitive detail...
TP53 positive MVAp53 Advanced Solid Tumor sensitive detail...
BRAF V600E PLX8394 Advanced Solid Tumor sensitive detail...
BRAF L597R Trametinib Advanced Solid Tumor sensitive detail...
BRAF L597R Vemurafenib Advanced Solid Tumor sensitive detail...
BRAF L597S Vemurafenib Advanced Solid Tumor sensitive detail...
BRAF L597S Trametinib Advanced Solid Tumor sensitive detail...
BRAF K601E Trametinib Advanced Solid Tumor sensitive detail...
BRAF K601E Vemurafenib Advanced Solid Tumor conflicting detail...
BRAF mutant Dabrafenib Advanced Solid Tumor sensitive detail...
TP53 wild-type Pazopanib + Vorinostat Advanced Solid Tumor decreased response detail...
RET mutant Ponatinib Advanced Solid Tumor sensitive detail...
BRAF act mut Binimetinib + Encorafenib Advanced Solid Tumor sensitive detail...
BRAF act mut PLX8394 Advanced Solid Tumor sensitive detail...
FGFR3 R248C Vofatamab Advanced Solid Tumor sensitive detail...
FGFR3 S249C Vofatamab Advanced Solid Tumor sensitive detail...
FGFR3 G372C Vofatamab Advanced Solid Tumor sensitive detail...
FGFR3 Y375C Vofatamab Advanced Solid Tumor sensitive detail...
FGFR3 K652E Vofatamab Advanced Solid Tumor sensitive detail...
FGFR3 mutant Infigratinib Advanced Solid Tumor sensitive detail...
TP53 loss Adavosertib Advanced Solid Tumor sensitive detail...
PTEN negative Talazoparib Advanced Solid Tumor conflicting detail...
PIK3CA mutant XL147 Advanced Solid Tumor sensitive detail...
RET G691S Dovitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 act mut Debio 1347 Advanced Solid Tumor sensitive detail...
FGFR3 act mut Debio 1347 Advanced Solid Tumor sensitive detail...
PIK3CA act mut BAY1125976 Advanced Solid Tumor sensitive detail...
PTEN loss BAY1125976 Advanced Solid Tumor sensitive detail...
PIK3CA act mut Everolimus Advanced Solid Tumor sensitive detail...
PIK3CA E542K Sirolimus Advanced Solid Tumor sensitive detail...
PIK3CA act mut Metformin Advanced Solid Tumor sensitive detail...
PIK3CA E545K Sirolimus Advanced Solid Tumor sensitive detail...
PIK3CA E545K Alpelisib Advanced Solid Tumor sensitive detail...
PIK3CA mutant Onatasertib Advanced Solid Tumor sensitive detail...
PIK3CA act mut Ipatasertib + Paclitaxel Advanced Solid Tumor sensitive detail...
PIK3CA act mut Afuresertib Advanced Solid Tumor sensitive detail...
RAD51D loss Olaparib Advanced Solid Tumor sensitive detail...
JAK3 V722I Tofacitinib Advanced Solid Tumor sensitive detail...
PIK3CA C420R Sirolimus Advanced Solid Tumor sensitive detail...
PIK3CA mutant Alpelisib Advanced Solid Tumor sensitive detail...
PIK3CA mutant Carboxyamidotriazole Orotate Advanced Solid Tumor sensitive detail...
PIK3CA mutant Serabelisib Advanced Solid Tumor sensitive detail...
PIK3CA mutant VS-5584 Advanced Solid Tumor sensitive detail...
RB1 positive Ribociclib Advanced Solid Tumor predicted - sensitive detail...
HRAS G12V Cetuximab Advanced Solid Tumor resistant detail...
HRAS G12V Panitumumab Advanced Solid Tumor resistant detail...
FLT3 D835Y Midostaurin Advanced Solid Tumor sensitive detail...
RET S891A Sorafenib Advanced Solid Tumor sensitive detail...
RET M918T Sorafenib Advanced Solid Tumor sensitive detail...
RET C634R Sorafenib Advanced Solid Tumor sensitive detail...
BRAF mutant Obatoclax Advanced Solid Tumor sensitive detail...
NRAS mutant Obatoclax Advanced Solid Tumor sensitive detail...
RET C634R Ponatinib Advanced Solid Tumor sensitive detail...
RET V804L Ponatinib Advanced Solid Tumor sensitive detail...
RET V804M Ponatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171T Ceritinib Advanced Solid Tumor sensitive detail...
PIK3CA mutant Sapanisertib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y Ensartinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M Ensartinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK S1206Y Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1152R Crizotinib Advanced Solid Tumor resistant detail...
RET V804M Sorafenib Advanced Solid Tumor sensitive detail...
FLT3 Y572C Midostaurin Advanced Solid Tumor sensitive detail...
FLT3 S451F Midostaurin Advanced Solid Tumor decreased response detail...
FLT3 V592G Midostaurin Advanced Solid Tumor sensitive detail...
FLT3 R834Q Midostaurin Advanced Solid Tumor sensitive detail...
FLT3 R834Q PD98059 Advanced Solid Tumor sensitive detail...
PIK3CA M1043V Sirolimus Advanced Solid Tumor sensitive detail...
PIK3CA mutant BAY1082439 Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 D839G Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 Y842C Pexidartinib Advanced Solid Tumor resistant detail...
PALB2 inact mut Olaparib Advanced Solid Tumor sensitive detail...
FGFR3 amp Ponatinib Advanced Solid Tumor predicted - sensitive detail...
KIT V560D Sorafenib Advanced Solid Tumor sensitive detail...
KIT V560D Dasatinib Advanced Solid Tumor sensitive detail...
KIT V560G Nilotinib Advanced Solid Tumor sensitive detail...
FGFR2 N550K Dovitinib Advanced Solid Tumor resistant detail...
FGFR2 N550S Dovitinib Advanced Solid Tumor decreased response detail...
FGFR2 N550H Dovitinib Advanced Solid Tumor decreased response detail...
FGFR2 V565I Dovitinib Advanced Solid Tumor resistant detail...
FGFR2 E566G Dovitinib Advanced Solid Tumor resistant detail...
FGFR2 L618M Dovitinib Advanced Solid Tumor decreased response detail...
FGFR2 K660E Dovitinib Advanced Solid Tumor resistant detail...
FGFR2 I548V Dovitinib Advanced Solid Tumor decreased response detail...
FGFR2 M538I Dovitinib Advanced Solid Tumor decreased response detail...
FGFR2 M536I Dovitinib Advanced Solid Tumor decreased response detail...
FGFR2 N550H PD173074 Advanced Solid Tumor resistant detail...
FGFR2 E566G PD173074 Advanced Solid Tumor resistant detail...
FGFR2 M536I PD173074 Advanced Solid Tumor decreased response detail...
FGFR2 M538I PD173074 Advanced Solid Tumor decreased response detail...
FGFR2 I548V PD173074 Advanced Solid Tumor decreased response detail...
FGFR2 N550S PD173074 Advanced Solid Tumor decreased response detail...
FGFR2 L618M PD173074 Advanced Solid Tumor decreased response detail...
FGFR2 V565I Ponatinib Advanced Solid Tumor resistant detail...
FGFR2 M538I Ponatinib Advanced Solid Tumor decreased response detail...
FGFR2 K660E Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 M536I Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 I548V Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 N550H Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 N550K Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 N550S Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 E566G Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 S267_D273dup Infigratinib Advanced Solid Tumor sensitive detail...
FGFR2 W290_I291delinsC Infigratinib Advanced Solid Tumor sensitive detail...
FGFR2 S267_D273dup Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 W290_I291delinsC Ponatinib Advanced Solid Tumor sensitive detail...
PIK3CA mutant A-443654 Advanced Solid Tumor sensitive detail...
PIK3CA E545K A66 Advanced Solid Tumor resistant detail...
PIK3CA H1047R A66 Advanced Solid Tumor sensitive detail...
PIK3CA mutant AT-7867 Advanced Solid Tumor sensitive detail...
PIK3CA mutant Taselisib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y Alectinib Advanced Solid Tumor sensitive detail...
ALK C1156Y Alectinib Advanced Solid Tumor sensitive detail...
RET Y806C Ponatinib Advanced Solid Tumor sensitive detail...
RET A883F Ponatinib Advanced Solid Tumor sensitive detail...
RET Y791F Ponatinib Advanced Solid Tumor sensitive detail...
RET E768D Ponatinib Advanced Solid Tumor sensitive detail...
RET L790F Ponatinib Advanced Solid Tumor sensitive detail...
RET D898V Ponatinib Advanced Solid Tumor sensitive detail...
RET M918T Ponatinib Advanced Solid Tumor sensitive detail...
RET C634Y Ponatinib Advanced Solid Tumor sensitive detail...
RET E884K Ponatinib Advanced Solid Tumor sensitive detail...
RET S891A Ponatinib Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins Midostaurin Advanced Solid Tumor sensitive detail...
FLT3 wild-type Midostaurin Advanced Solid Tumor sensitive detail...
FGFR2 S252W Dovitinib Advanced Solid Tumor conflicting detail...
FGFR2 N550K PD173074 Advanced Solid Tumor resistant detail...
FGFR2 V565I PD173074 Advanced Solid Tumor resistant detail...
FGFR2 L618M Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 K660E PD173074 Advanced Solid Tumor decreased response detail...
PIK3CA mutant Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus Advanced Solid Tumor sensitive detail...
FBXW7 inact mut Entinostat Advanced Solid Tumor sensitive detail...
FBXW7 inact mut Docetaxel Advanced Solid Tumor resistant detail...
FBXW7 inact mut Belinostat Advanced Solid Tumor sensitive detail...
FBXW7 inact mut REC-2282 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK V1180L Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171T Alectinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK V1180L TAE684 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171T TAE684 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK V1180L Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK V1180L Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171T Brigatinib Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ASP3026 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK V1180L ASP3026 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171T ASP3026 Advanced Solid Tumor resistant detail...
TP53 mutant Pazopanib + Vorinostat Advanced Solid Tumor sensitive detail...
RET E768D Vandetanib Advanced Solid Tumor sensitive detail...
RET L790F Vandetanib Advanced Solid Tumor sensitive detail...
RET Y791F Vandetanib Advanced Solid Tumor sensitive detail...
RET S891A Vandetanib Advanced Solid Tumor sensitive detail...
RET M918T Vandetanib Advanced Solid Tumor sensitive detail...
RET A883F Vandetanib Advanced Solid Tumor sensitive detail...
RET V804L Vandetanib Advanced Solid Tumor resistant detail...
RET V804M Vandetanib Advanced Solid Tumor resistant detail...
RET C634R Vandetanib Advanced Solid Tumor sensitive detail...
RET C634R RET V804G Vandetanib Advanced Solid Tumor sensitive detail...
FGFR1 act mut Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 act mut Ponatinib Advanced Solid Tumor sensitive detail...
FGFR3 act mut Ponatinib Advanced Solid Tumor sensitive detail...
FGFR1 act mut Dovitinib Advanced Solid Tumor sensitive detail...
FGFR2 act mut Dovitinib Advanced Solid Tumor sensitive detail...
FGFR3 act mut Dovitinib Advanced Solid Tumor sensitive detail...
FGFR1 act mut Cediranib Advanced Solid Tumor decreased response detail...
FGFR2 act mut Cediranib Advanced Solid Tumor decreased response detail...
FGFR3 act mut Cediranib Advanced Solid Tumor decreased response detail...
FGFR1 act mut Nintedanib Advanced Solid Tumor decreased response detail...
FGFR2 act mut Nintedanib Advanced Solid Tumor decreased response detail...
FGFR3 act mut Nintedanib Advanced Solid Tumor decreased response detail...
FGFR2 act mut Brivanib Advanced Solid Tumor decreased response detail...
FGFR1 act mut Brivanib Advanced Solid Tumor no benefit detail...
FGFR3 act mut Brivanib Advanced Solid Tumor no benefit detail...
KIT D816V Ponatinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins Cabozantinib Advanced Solid Tumor predicted - sensitive detail...
KIT D816V Sunitinib Advanced Solid Tumor resistant detail...
KIT D816V Nilotinib Advanced Solid Tumor decreased response detail...
KIT D816V Imatinib Advanced Solid Tumor resistant detail...
KIT D816V Cabozantinib Advanced Solid Tumor resistant detail...
KIT D816H Regorafenib Advanced Solid Tumor resistant detail...
KIT D816V Quizartinib Advanced Solid Tumor resistant detail...
RET rearrange RXDX-105 Advanced Solid Tumor sensitive detail...
PTEN del GSK2636771 Advanced Solid Tumor no benefit detail...
PIK3CA mutant AZD8835 Advanced Solid Tumor sensitive detail...
PIK3CA mutant Uprosertib Advanced Solid Tumor predicted - sensitive detail...
RB1 loss Palbociclib Advanced Solid Tumor no benefit detail...
TP53 R175H ReACp53 Advanced Solid Tumor sensitive detail...
FGFR2 wild-type AZ6089 Advanced Solid Tumor predicted - sensitive detail...
FGFR3 over exp LY2874455 Advanced Solid Tumor sensitive detail...
FGFR3 K650E PD98059 Advanced Solid Tumor sensitive detail...
FGFR1 act mut Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 act mut Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 act mut Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 fusion Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 V561M FIIN-1 Advanced Solid Tumor sensitive detail...
FGFR1 fusion Dovitinib Advanced Solid Tumor sensitive detail...
PIK3CA Q546K Trametinib Advanced Solid Tumor sensitive detail...
PIK3CA N345K Trametinib Advanced Solid Tumor sensitive detail...
PIK3CA H1047R Trametinib Advanced Solid Tumor sensitive detail...
PIK3CA G1049R Trametinib Advanced Solid Tumor sensitive detail...
PIK3CA E545K Trametinib Advanced Solid Tumor sensitive detail...
KIT H697Y Sunitinib Advanced Solid Tumor sensitive detail...
KIT H697Y Imatinib Advanced Solid Tumor decreased response detail...
KIT V560del Imatinib Advanced Solid Tumor sensitive detail...
KIT V560del Sunitinib Advanced Solid Tumor sensitive detail...
PTEN del Onatasertib Advanced Solid Tumor sensitive detail...
CSF3R T640N Ruxolitinib Advanced Solid Tumor sensitive detail...
CSF3R T618I Ruxolitinib Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins Pexidartinib Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 F691L Pexidartinib Advanced Solid Tumor sensitive detail...
FLT3 D835V Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D835Y Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D835V Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D835F Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 Y842H Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 M664I Pexidartinib Advanced Solid Tumor decreased response detail...
FLT3 exon 14 ins FLT3 M664I FLT3 F691L Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 N676S Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 N676S FLT3 F691L Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D698N Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D698N Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 R834Q Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 R834Q Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D835E Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835E Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D835G Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835G Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835H Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D835H Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D835N Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835N Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D839A Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D839A Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D839G Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D839H Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 D839N Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 D839N Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 N841K Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 N841K Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 Y842C Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 Y842H Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 Y842S Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 Y842S Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 R845G Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 R845G Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 G846R Pexidartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L FLT3 G846R Pexidartinib Advanced Solid Tumor resistant detail...
PTEN dec exp GSK2636771 Advanced Solid Tumor sensitive detail...
TP53 R248Q Ganetespib Advanced Solid Tumor sensitive detail...
TP53 R175H Alvespimycin + Vorinostat Advanced Solid Tumor sensitive detail...
FLT3 D835Y Pexidartinib Advanced Solid Tumor resistant detail...
PTEN loss SAR260301 Advanced Solid Tumor no benefit detail...
RET C634Y HG-6-63-01 Advanced Solid Tumor sensitive detail...
RET C634Y XMD15-44 Advanced Solid Tumor sensitive detail...
RET C634Y ALW-II-41-27 Advanced Solid Tumor sensitive detail...
RET M918T HG-6-63-01 Advanced Solid Tumor sensitive detail...
RET M918T XMD15-44 Advanced Solid Tumor sensitive detail...
RET M918T ALW-II-41-27 Advanced Solid Tumor sensitive detail...
PIK3CA mutant Apitolisib Advanced Solid Tumor predicted - sensitive detail...
PIK3CA act mut GSK1059615 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171S Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S Ceritinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK I1171S Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S Brigatinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK I1171S ASP3026 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S AZD3463 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174L Crizotinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK F1174L Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174L Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174L Brigatinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK F1174L ASP3026 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174L AZD3463 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK R1192P Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK R1192P Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK R1192P Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK R1192P Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK R1192P ASP3026 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK R1192P AZD3463 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151M Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151M Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151M Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151M AZD3463 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151M Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK T1151M ASP3026 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1269A Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1269A Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1269A Alectinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK G1269A ASP3026 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1269A Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1269A AZD3463 Advanced Solid Tumor sensitive detail...
ATM loss YU238259 Advanced Solid Tumor sensitive detail...
TP53 wild-type CTX-1 Advanced Solid Tumor sensitive detail...
TP53 loss CTX-1 Advanced Solid Tumor decreased response detail...
TP53 mutant CTX-1 Advanced Solid Tumor sensitive detail...
TP53 wild-type CTX-1 + Nutlin-3a Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y Entrectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M Entrectinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK G1202R Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1269A Entrectinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK L1198F Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y ALK L1198F Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y ALK L1198F Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F Lorlatinib Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F Alectinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK C1156Y ALK L1198F Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y Ceritinib Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ALK L1198F Ceritinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK C1156Y ALK L1198F Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK L1198F Brigatinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK C1156Y Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174C Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C ALK L1198F Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174C Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174C ALK L1198F Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174C ALK L1198F Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C Ceritinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK F1174C ALK L1198F Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C Alectinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK F1174C ALK L1198F Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M Alectinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK L1196M Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M ALK L1198F Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK L1198F Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK L1198F Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK L1198F Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK L1198F Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M Lorlatinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK G1202R Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R Brigatinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK L1198F ALK G1202R Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F ALK G1202R Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1202R Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1202R Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1202R Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1269A Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F ALK G1269A Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F ALK G1269A Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1269A Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1269A Alectinib Advanced Solid Tumor resistant detail...
JAK2 V617F Ruxolitinib + ZSTK474 Advanced Solid Tumor sensitive detail...
JAK2 over exp Ruxolitinib + ZSTK474 Advanced Solid Tumor sensitive detail...
JAK2 over exp Pictilisib + Ruxolitinib Advanced Solid Tumor sensitive detail...
JAK2 V617F Pictilisib + Ruxolitinib Advanced Solid Tumor sensitive detail...
JAK2 over exp Dactolisib + Ruxolitinib Advanced Solid Tumor sensitive detail...
JAK2 V617F Dactolisib + Ruxolitinib Advanced Solid Tumor sensitive detail...
JAK2 V617F Ruxolitinib + TGX-221 Advanced Solid Tumor sensitive detail...
JAK2 over exp Ruxolitinib + TGX-221 Advanced Solid Tumor sensitive detail...
ALK wild-type Repotrectinib Advanced Solid Tumor sensitive detail...
ALK G1202R Repotrectinib Advanced Solid Tumor sensitive detail...
ALK L1196M Repotrectinib Advanced Solid Tumor sensitive detail...
ALK G1128A Brigatinib Advanced Solid Tumor sensitive detail...
ALK I1171N Brigatinib Advanced Solid Tumor sensitive detail...
ALK F1174L Brigatinib Advanced Solid Tumor sensitive detail...
ALK R1192P Brigatinib Advanced Solid Tumor sensitive detail...
ALK F1245C Brigatinib Advanced Solid Tumor sensitive detail...
ALK R1275Q Brigatinib Advanced Solid Tumor sensitive detail...
ALK Y1278S Brigatinib Advanced Solid Tumor sensitive detail...
ALK G1269A Brigatinib Advanced Solid Tumor sensitive detail...
PIK3CA H1047R Sirolimus Advanced Solid Tumor sensitive detail...
RET C634R Pz-1 Advanced Solid Tumor sensitive detail...
RET M918T Pz-1 Advanced Solid Tumor sensitive detail...
RET V804L Pz-1 Advanced Solid Tumor predicted - sensitive detail...
RET V804M Pz-1 Advanced Solid Tumor predicted - sensitive detail...
HRAS G12V Pz-1 Advanced Solid Tumor sensitive detail...
BRAF mutant XL147 Advanced Solid Tumor decreased response detail...
KIT act mut PLX9486 Advanced Solid Tumor sensitive detail...
ATM inact mut E7449 Advanced Solid Tumor sensitive detail...
ATRX inact mut E7449 Advanced Solid Tumor sensitive detail...
RAD51C inact mut E7449 Advanced Solid Tumor sensitive detail...
ROS1 rearrange Entrectinib Advanced Solid Tumor predicted - sensitive detail...
ALK fusion Entrectinib Advanced Solid Tumor sensitive detail...
KIT V654A Imatinib Advanced Solid Tumor resistant detail...
KIT V559D Ponatinib Advanced Solid Tumor sensitive detail...
KIT V560G Ponatinib Advanced Solid Tumor sensitive detail...
KIT T670I Ponatinib Advanced Solid Tumor sensitive detail...
KIT D816H Ponatinib Advanced Solid Tumor sensitive detail...
KIT D820E Ponatinib Advanced Solid Tumor sensitive detail...
KIT A829P Ponatinib Advanced Solid Tumor sensitive detail...
KIT V654A Ponatinib Advanced Solid Tumor sensitive detail...
KIT V560D Ponatinib Advanced Solid Tumor sensitive detail...
KIT V560D Sunitinib Advanced Solid Tumor sensitive detail...
KIT V560D Imatinib Advanced Solid Tumor sensitive detail...
KIT V560D Regorafenib Advanced Solid Tumor sensitive detail...
KIT exon9 Ponatinib Advanced Solid Tumor sensitive detail...
KIT exon9 Sunitinib Advanced Solid Tumor sensitive detail...
KIT exon9 Imatinib Advanced Solid Tumor resistant detail...
KIT exon9 Regorafenib Advanced Solid Tumor resistant detail...
KIT W557_K558del Ponatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del Sunitinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del Imatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del Regorafenib Advanced Solid Tumor sensitive detail...
KIT P551_K558del Ponatinib Advanced Solid Tumor sensitive detail...
KIT P551_K558del Sunitinib Advanced Solid Tumor sensitive detail...
KIT P551_K558del Imatinib Advanced Solid Tumor sensitive detail...
KIT P551_K558del Regorafenib Advanced Solid Tumor sensitive detail...
KIT P551_E554del Ponatinib Advanced Solid Tumor sensitive detail...
KIT T417_D419delinsI Imatinib Advanced Solid Tumor conflicting detail...
KIT P551_E554del Sunitinib Advanced Solid Tumor resistant detail...
KIT P551_E554del Imatinib Advanced Solid Tumor resistant detail...
KIT P551_E554del Regorafenib Advanced Solid Tumor resistant detail...
KIT K558delinsNP Ponatinib Advanced Solid Tumor sensitive detail...
KIT K558delinsNP Sunitinib Advanced Solid Tumor sensitive detail...
KIT K558delinsNP Imatinib Advanced Solid Tumor sensitive detail...
KIT K558delinsNP Regorafenib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT V654A Ponatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT V654A Sunitinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT V654A Imatinib Advanced Solid Tumor no benefit detail...
KIT W557_K558del KIT V654A Regorafenib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT T670I Ponatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT T670I Sunitinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT T670I Imatinib Advanced Solid Tumor no benefit detail...
KIT W557_K558del KIT T670I Regorafenib Advanced Solid Tumor decreased response detail...
KIT W557_K558del KIT D816H Ponatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT D816H Sunitinib Advanced Solid Tumor decreased response detail...
KIT W557_K558del KIT D816H Imatinib Advanced Solid Tumor decreased response detail...
KIT W557_K558del KIT D816H Regorafenib Advanced Solid Tumor decreased response detail...
BRAF T529I BRAF V600E SB590885 Advanced Solid Tumor predicted - resistant detail...
BRAF V600E SB590885 Advanced Solid Tumor sensitive detail...
BRAF T529M BRAF V600E SB590885 Advanced Solid Tumor predicted - resistant detail...
BRAF T529N BRAF V600E RAF265 Advanced Solid Tumor resistant detail...
BRAF T529I BRAF V600E RAF265 Advanced Solid Tumor predicted - sensitive detail...
BRAF T529M BRAF V600E RAF265 Advanced Solid Tumor predicted - sensitive detail...
BRAF V600E RAF265 Advanced Solid Tumor sensitive detail...
BRAF T529N BRAF V600E SB590885 Advanced Solid Tumor resistant detail...
BRAF T529M BRAF V600E PLX4720 Advanced Solid Tumor predicted - resistant detail...
BRAF T529I BRAF V600E PLX4720 Advanced Solid Tumor predicted - resistant detail...
BRAF V600E PLX4720 Advanced Solid Tumor sensitive detail...
BRAF T529N BRAF V600E PLX4720 Advanced Solid Tumor resistant detail...
BRAF T529N BRAF V600E Sorafenib Advanced Solid Tumor conflicting detail...
BRAF T529M BRAF V600E Sorafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF T529I BRAF V600E Sorafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF T529N BRAF V600E CI-1040 Advanced Solid Tumor sensitive detail...
BRAF T529M BRAF V600E CI-1040 Advanced Solid Tumor predicted - sensitive detail...
BRAF T529I BRAF V600E CI-1040 Advanced Solid Tumor sensitive detail...
BRAF V600E CI-1040 Advanced Solid Tumor sensitive detail...
KIT W557G Imatinib Advanced Solid Tumor sensitive detail...
KIT Y578C Imatinib Advanced Solid Tumor sensitive detail...
KIT W557C KIT Y578C Imatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT D816G Ponatinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT D820A Ponatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT D820G Ponatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT N822K Ponatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT A829P Ponatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT D816G Sunitinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT D820A Sunitinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT D820G Sunitinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT N822K Sunitinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT A829P Sunitinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT D816G Imatinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT D820A Imatinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT D820G Imatinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT N822K Imatinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT A829P Imatinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT D816G Regorafenib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT D820A Regorafenib Advanced Solid Tumor conflicting detail...
KIT W557_K558del KIT D820G Regorafenib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT N822K Regorafenib Advanced Solid Tumor conflicting detail...
KIT W557_K558del KIT A829P Regorafenib Advanced Solid Tumor conflicting detail...
FGFR1 mutant Pemigatinib Advanced Solid Tumor sensitive detail...
PTEN dec exp Pemetrexed Disodium + Sorafenib Advanced Solid Tumor predicted - sensitive detail...
JAK3 V674A Ruxolitinib Advanced Solid Tumor sensitive detail...
JAK3 L857P Ruxolitinib Advanced Solid Tumor decreased response detail...
JAK3 Y100A JAK3 L857P Ruxolitinib Advanced Solid Tumor decreased response detail...
JAK3 L857P NIBR3049 Advanced Solid Tumor sensitive detail...
JAK3 Y100A JAK3 L857P NIBR3049 Advanced Solid Tumor sensitive detail...
JAK3 V674A NIBR3049 Advanced Solid Tumor decreased response detail...
JAK3 V674A Tofacitinib Advanced Solid Tumor sensitive detail...
JAK3 L857P Tofacitinib Advanced Solid Tumor sensitive detail...
JAK3 Y100A JAK3 L857P Tofacitinib Advanced Solid Tumor sensitive detail...
FGFR3 K650E AZD4547 Advanced Solid Tumor decreased response detail...
FGFR3 N540K AZD4547 Advanced Solid Tumor resistant detail...
FGFR3 K650E Erdafitinib Advanced Solid Tumor sensitive detail...
FGFR3 N540K Erdafitinib Advanced Solid Tumor sensitive detail...
BRAF V600E Lifirafenib Advanced Solid Tumor sensitive detail...
BRAF wild-type Lifirafenib Advanced Solid Tumor no benefit detail...
TP53 mutant KRT-232 Advanced Solid Tumor resistant detail...
TP53 wild-type KRT-232 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1152R Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK S1206Y Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174L Lorlatinib Advanced Solid Tumor sensitive detail...
TP53 positive p28 Advanced Solid Tumor predicted - sensitive detail...
ALK R1275Q Lorlatinib Advanced Solid Tumor sensitive detail...
ALK F1174L Lorlatinib Advanced Solid Tumor sensitive detail...
ALK F1245C Lorlatinib Advanced Solid Tumor sensitive detail...
FGFR2 mutant Pemigatinib Advanced Solid Tumor sensitive detail...
FGFR3 mutant Pemigatinib Advanced Solid Tumor sensitive detail...
FGFR2 wild-type PRN1371 Advanced Solid Tumor sensitive detail...
FGFR2 K660E PRN1371 Advanced Solid Tumor sensitive detail...
FGFR2 K660N PRN1371 Advanced Solid Tumor sensitive detail...
FGFR2 N550K PRN1371 Advanced Solid Tumor sensitive detail...
FGFR3 over exp PRN1371 Advanced Solid Tumor sensitive detail...
FGFR3 K650M PRN1371 Advanced Solid Tumor sensitive detail...
ATM inact mut Veliparib Advanced Solid Tumor sensitive detail...
HRAS G12V Rigosertib Sodium Advanced Solid Tumor sensitive detail...
PIK3CA E545K Rigosertib Sodium Advanced Solid Tumor sensitive detail...
PIK3CA H1047R Rigosertib Sodium Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N Crizotinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK I1171N Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N Lorlatinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK I1171S Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171T Crizotinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK I1171T Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1202R Lorlatinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK G1202del Crizotinib Advanced Solid Tumor decreased response detail...
EML4 - ALK ALK G1202del Ceritinib Advanced Solid Tumor decreased response detail...
EML4 - ALK ALK G1202del Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202del Brigatinib Advanced Solid Tumor decreased response detail...
EML4 - ALK ALK G1202del Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK D1203N Crizotinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK D1203N Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK D1203N Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK D1203N Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK D1203N Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK E1210K Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK E1210K Alectinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK E1210K Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK E1210K Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174C ALK D1203N Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C ALK D1203N Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C ALK D1203N Brigatinib Advanced Solid Tumor decreased response detail...
EML4 - ALK ALK F1174C ALK D1203N Lorlatinib Advanced Solid Tumor decreased response detail...
EML4 - ALK ALK D1203N ALK E1210K Crizotinib Advanced Solid Tumor decreased response detail...
EML4 - ALK ALK D1203N ALK E1210K Ceritinib Advanced Solid Tumor decreased response detail...
EML4 - ALK ALK D1203N ALK E1210K Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK D1203N ALK E1210K Brigatinib Advanced Solid Tumor decreased response detail...
EML4 - ALK ALK D1203N ALK E1210K Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174C ALK D1203N Ceritinib Advanced Solid Tumor resistant detail...
KIT D816V BPR1J373 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 positive Aprutumab ixadotin Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins Brigatinib Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 D835Y Brigatinib Advanced Solid Tumor sensitive detail...
ROS1 fusion Brigatinib Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 F691L Brigatinib Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 F691I Brigatinib Advanced Solid Tumor decreased response detail...
EML4 - ALK ALK T1151dup Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1152R Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1152P Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174V Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK S1206F Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK S1206Y Brigatinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK T1151dup Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1152P Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174V Crizotinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK L1152R Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1152P Ceritinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 N676D Midostaurin Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691I Midostaurin Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691I Sunitinib Advanced Solid Tumor decreased response detail...
FLT3 exon 14 ins FLT3 A848P Sunitinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691I Sorafenib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L Sorafenib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 A848P Sorafenib Advanced Solid Tumor decreased response detail...
FLT3 exon 14 ins FLT3 Y842H Sorafenib Advanced Solid Tumor decreased response detail...
FLT3 exon 14 ins FLT3 N676D Quizartinib Advanced Solid Tumor decreased response detail...
FLT3 exon 14 ins FLT3 Y842H Quizartinib Advanced Solid Tumor decreased response detail...
FLT3 exon 14 ins FLT3 A848P Quizartinib Advanced Solid Tumor decreased response detail...
FLT3 exon 14 ins FLT3 F691I Quizartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L Quizartinib Advanced Solid Tumor resistant detail...
TP53 mutant Adavosertib Advanced Solid Tumor predicted - sensitive detail...
BRAF G464E Vemurafenib Advanced Solid Tumor resistant detail...
BRAF G464V Vemurafenib Advanced Solid Tumor resistant detail...
BRAF G464R Vemurafenib Advanced Solid Tumor resistant detail...
BRAF G469A Vemurafenib Advanced Solid Tumor resistant detail...
BRAF G469V Vemurafenib Advanced Solid Tumor resistant detail...
BRAF L597V Vemurafenib Advanced Solid Tumor resistant detail...
BRAF L597Q Vemurafenib Advanced Solid Tumor resistant detail...
BRAF K601T Vemurafenib Advanced Solid Tumor resistant detail...
BRAF K601N Vemurafenib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 F691L MRX-2843 Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 D835Y MRX-2843 Advanced Solid Tumor sensitive detail...
FLT3 D835Y MRX-2843 Advanced Solid Tumor sensitive detail...
FLT3 D835V MRX-2843 Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 Y842H MRX-2843 Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 Y842C MRX-2843 Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 D835F MRX-2843 Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 D835V MRX-2843 Advanced Solid Tumor sensitive detail...
HRAS mutant Selumetinib Advanced Solid Tumor predicted - sensitive detail...
HRAS mutant Binimetinib Advanced Solid Tumor predicted - sensitive detail...
HRAS mutant Everolimus Advanced Solid Tumor predicted - sensitive detail...
HRAS Q61L Everolimus Advanced Solid Tumor sensitive detail...
HRAS Q61R Everolimus Advanced Solid Tumor sensitive detail...
HRAS G12V Everolimus Advanced Solid Tumor sensitive detail...
HRAS Q61R Binimetinib Advanced Solid Tumor sensitive detail...
HRAS Q61L Binimetinib Advanced Solid Tumor sensitive detail...
HRAS G12V Binimetinib Advanced Solid Tumor sensitive detail...
HRAS G12V Binimetinib + Everolimus Advanced Solid Tumor sensitive detail...
HRAS Q61L Binimetinib + Everolimus Advanced Solid Tumor sensitive detail...
BRAF mutant Tovorafenib Advanced Solid Tumor predicted - sensitive detail...
NRAS G12D N-Arachidonoyl Dopamine Advanced Solid Tumor sensitive detail...
HRAS Q61L NS1 Advanced Solid Tumor sensitive detail...
NRAS G12D NS1 Advanced Solid Tumor no benefit detail...
PTEN inact mut Capivasertib Advanced Solid Tumor sensitive detail...
PTEN loss Capivasertib Advanced Solid Tumor sensitive detail...
IDH1 R132H Talazoparib Advanced Solid Tumor sensitive detail...
IDH1 R132H Berzosertib Advanced Solid Tumor sensitive detail...
IDH1 R132H Olaparib Advanced Solid Tumor sensitive detail...
IDH1 R132H Niraparib Advanced Solid Tumor sensitive detail...
IDH1 R132H Rucaparib Advanced Solid Tumor sensitive detail...
IDH1 R132H Cisplatin + Talazoparib Advanced Solid Tumor sensitive detail...
IDH1 R132H AGI-5198 + Talazoparib Advanced Solid Tumor decreased response detail...
TP53 wild-type Siremadlin Advanced Solid Tumor predicted - sensitive detail...
FGFR3 L608V Infigratinib Advanced Solid Tumor decreased response detail...
FGFR3 K650E Infigratinib Advanced Solid Tumor decreased response detail...
FGFR3 N540K Infigratinib Advanced Solid Tumor resistant detail...
FGFR3 V555L Infigratinib Advanced Solid Tumor decreased response detail...
FGFR3 V555M Infigratinib Advanced Solid Tumor resistant detail...
FGFR3 L608V Ponatinib Advanced Solid Tumor sensitive detail...
FGFR3 V555M Ponatinib Advanced Solid Tumor sensitive detail...
FGFR3 N540K Ponatinib Advanced Solid Tumor sensitive detail...
FGFR3 K650E Ponatinib Advanced Solid Tumor sensitive detail...
FGFR3 K650E Dovitinib Advanced Solid Tumor conflicting detail...
FGFR3 N540K Dovitinib Advanced Solid Tumor sensitive detail...
FGFR3 V555M Dovitinib Advanced Solid Tumor sensitive detail...
FGFR3 L608V Dovitinib Advanced Solid Tumor sensitive detail...
FGFR3 L608V AZD4547 Advanced Solid Tumor decreased response detail...
FGFR3 V555M AZD4547 Advanced Solid Tumor resistant detail...
FGFR3 L608V Debio 1347 Advanced Solid Tumor decreased response detail...
FGFR3 V555M Debio 1347 Advanced Solid Tumor decreased response detail...
FGFR3 N540K Debio 1347 Advanced Solid Tumor decreased response detail...
FGFR3 K650E Debio 1347 Advanced Solid Tumor sensitive detail...
FGFR3 L608V FIIN-2 Advanced Solid Tumor sensitive detail...
FGFR3 K650E FIIN-2 Advanced Solid Tumor sensitive detail...
FGFR3 V555M FIIN-2 Advanced Solid Tumor decreased response detail...
FGFR3 N540K FIIN-2 Advanced Solid Tumor decreased response detail...
FGFR3 L608V LY2874455 Advanced Solid Tumor sensitive detail...
FGFR3 V555M LY2874455 Advanced Solid Tumor sensitive detail...
FGFR3 K650E LY2874455 Advanced Solid Tumor sensitive detail...
FGFR3 N540K LY2874455 Advanced Solid Tumor decreased response detail...
FGFR2 V564F Infigratinib Advanced Solid Tumor resistant detail...
FGFR2 V564F Debio 1347 Advanced Solid Tumor sensitive detail...
FGFR2 V564F AZD4547 Advanced Solid Tumor resistant detail...
FGFR2 V564I Debio 1347 Advanced Solid Tumor resistant detail...
FGFR2 V564L Debio 1347 Advanced Solid Tumor resistant detail...
BRAF V600E PF-00477736 + PF3644022 Advanced Solid Tumor predicted - sensitive detail...
CDKN2A loss PF-00477736 + PF3644022 Advanced Solid Tumor predicted - sensitive detail...
BRAF mutant PF-00477736 + PF3644022 Advanced Solid Tumor predicted - sensitive detail...
ALK rearrange Belizatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M Repotrectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1202R Repotrectinib Advanced Solid Tumor sensitive detail...
MAP2K1 L115P CI-1040 Advanced Solid Tumor resistant detail...
MAP2K1 L115A CI-1040 Advanced Solid Tumor decreased response detail...
MAP2K1 F53S CI-1040 Advanced Solid Tumor sensitive detail...
MAP2K1 I103N CI-1040 Advanced Solid Tumor decreased response detail...
PTEN loss Everolimus Advanced Solid Tumor no benefit detail...
RET C634R RET V804M Vandetanib Advanced Solid Tumor resistant detail...
RET C634R RET Y806C Vandetanib Advanced Solid Tumor resistant detail...
RET C634R RET Y806E Vandetanib Advanced Solid Tumor resistant detail...
RET C634R RET Y806F Vandetanib Advanced Solid Tumor predicted - sensitive detail...
TP53 wild-type MK-8242 Advanced Solid Tumor unknown detail...
TP53 positive Serdemetan Advanced Solid Tumor sensitive detail...
ATM del ATR dec exp PJ34 Advanced Solid Tumor decreased response detail...
JAK3 R172Q Tofacitinib Advanced Solid Tumor sensitive detail...
JAK3 L156P Tofacitinib Advanced Solid Tumor sensitive detail...
JAK3 E183G Tofacitinib Advanced Solid Tumor sensitive detail...
JAK3 A572V Tofacitinib Advanced Solid Tumor sensitive detail...
BRAF mutant KO-947 Advanced Solid Tumor predicted - sensitive detail...
NRAS mutant KO-947 Advanced Solid Tumor predicted - sensitive detail...
BRAF mutant CC-90003 Advanced Solid Tumor no benefit detail...
NRAS mutant CC-90003 Advanced Solid Tumor no benefit detail...
TP53 wild-type ALRN-6924 Advanced Solid Tumor predicted - sensitive detail...
BRAF F247L Trametinib Advanced Solid Tumor sensitive detail...
BRAF F247L Dabrafenib Advanced Solid Tumor sensitive detail...
BRAF F595L Vemurafenib Advanced Solid Tumor resistant detail...
BRAF D594N Vemurafenib Advanced Solid Tumor predicted - resistant detail...
RAD51D S207L Olaparib Advanced Solid Tumor sensitive detail...
RAD51D S207L Talazoparib Advanced Solid Tumor sensitive detail...
JAK3 I87T JANEX-1 Advanced Solid Tumor sensitive detail...
KIT N822I Imatinib Advanced Solid Tumor resistant detail...
KIT N822I Dasatinib Advanced Solid Tumor sensitive detail...
KIT V559D Dasatinib Advanced Solid Tumor sensitive detail...
KIT V559D Imatinib Advanced Solid Tumor sensitive detail...
KIT V560D Motesanib Diphosphate Advanced Solid Tumor sensitive detail...
KIT M552_V559del Motesanib Diphosphate Advanced Solid Tumor sensitive detail...
KIT Y823D Motesanib Diphosphate Advanced Solid Tumor sensitive detail...
KIT V560D KIT V654A Motesanib Diphosphate Advanced Solid Tumor sensitive detail...
KIT V560D KIT T670I Motesanib Diphosphate Advanced Solid Tumor sensitive detail...
KIT W557_K558del Nilotinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del Dasatinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT T670I Dasatinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT T670I Nilotinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT T670I Sorafenib Advanced Solid Tumor sensitive detail...
KIT V560del KIT V654A Nilotinib Advanced Solid Tumor sensitive detail...
KIT V559D KIT D820Y Nilotinib Advanced Solid Tumor sensitive detail...
KIT V559D KIT D820Y Dasatinib Advanced Solid Tumor sensitive detail...
KIT V559D KIT D820Y Sorafenib Advanced Solid Tumor sensitive detail...
KIT exon17 Avapritinib Advanced Solid Tumor sensitive detail...
ALK rearrange ASP3026 Advanced Solid Tumor sensitive detail...
BRAF V600E/K PTEN loss PX-866 + Vemurafenib Advanced Solid Tumor predicted - sensitive detail...
FANCA S1088F Cisplatin Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198P Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198P TAE684 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK D1203N TAE684 Advanced Solid Tumor resistant detail...
HRAS G12V SR9009 Advanced Solid Tumor predicted - sensitive detail...
HRAS G12V SR9011 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 V561M PRN1371 Advanced Solid Tumor sensitive detail...
FGFR1 over exp PRN1371 Advanced Solid Tumor sensitive detail...
FGFR2 over exp PRN1371 Advanced Solid Tumor sensitive detail...
FGFR2 W290C Infigratinib Advanced Solid Tumor sensitive detail...
FGFR2 K660E Infigratinib Advanced Solid Tumor sensitive detail...
FGFR2 K660N Infigratinib Advanced Solid Tumor sensitive detail...
FGFR2 W290C Ponatinib Advanced Solid Tumor sensitive detail...
FGFR2 K660N Ponatinib Advanced Solid Tumor sensitive detail...
FGFR3 S249C Ponatinib Advanced Solid Tumor sensitive detail...
FGFR3 R248C Infigratinib Advanced Solid Tumor sensitive detail...
FGFR3 S249C Infigratinib Advanced Solid Tumor sensitive detail...
FGFR3 S249C Dovitinib Advanced Solid Tumor conflicting detail...
FGFR3 R248C Dovitinib Advanced Solid Tumor conflicting detail...
FGFR2 W290C Pazopanib Advanced Solid Tumor sensitive detail...
FGFR2 K660N Pazopanib Advanced Solid Tumor sensitive detail...
FGFR2 K660E Pazopanib Advanced Solid Tumor sensitive detail...
FGFR3 R248C Pazopanib Advanced Solid Tumor sensitive detail...
FGFR2 W290C Cediranib Advanced Solid Tumor sensitive detail...
FGFR2 K660N Cediranib Advanced Solid Tumor sensitive detail...
FGFR2 K660E Cediranib Advanced Solid Tumor sensitive detail...
FGFR2 K660E AZD4547 Advanced Solid Tumor sensitive detail...
FGFR2 K660N AZD4547 Advanced Solid Tumor sensitive detail...
FGFR2 W290C AZD4547 Advanced Solid Tumor sensitive detail...
FGFR2 K660E Lenvatinib Advanced Solid Tumor sensitive detail...
FGFR2 K660N Lenvatinib Advanced Solid Tumor sensitive detail...
FGFR2 W290C Lenvatinib Advanced Solid Tumor sensitive detail...
FGFR2 over exp Derazantinib Advanced Solid Tumor sensitive detail...
FGFR1 over exp Derazantinib Advanced Solid Tumor sensitive detail...
KIT over exp Derazantinib Advanced Solid Tumor sensitive detail...
BRAF mutant RAF709 Advanced Solid Tumor sensitive detail...
NRAS mutant RAF709 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y ALK I1171T Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK F1174C Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK F1174I Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK F1174V Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK L1196M Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK D1203N Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK L1256F Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S ALK L1196M Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C ALK L1196M Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174L ALK L1196M Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174V ALK L1196M Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1179V ALK L1196M Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK L1256F Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK G1202R Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171T ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
FGFR1 amp AZD4547 Advanced Solid Tumor unknown detail...
FGFR2 amp AZD4547 Advanced Solid Tumor unknown detail...
ROS1 fusion Repotrectinib Advanced Solid Tumor predicted - sensitive detail...
ROS1 fusion ROS1 G2032R Repotrectinib Advanced Solid Tumor predicted - sensitive detail...
ALK fusion Repotrectinib Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 F53L Selumetinib Advanced Solid Tumor sensitive detail...
MAP2K1 Q56P Selumetinib Advanced Solid Tumor sensitive detail...
MAP2K1 K57N Selumetinib Advanced Solid Tumor sensitive detail...
MAP2K1 C121S Selumetinib Advanced Solid Tumor sensitive detail...
MAP2K1 F129L Selumetinib Advanced Solid Tumor sensitive detail...
MAP2K1 I111S Selumetinib Advanced Solid Tumor sensitive detail...
MAP2K1 V211D Selumetinib Advanced Solid Tumor resistant detail...
MAP2K1 V211D PLX4720 Advanced Solid Tumor sensitive detail...
MAP2K1 F53L PLX4720 Advanced Solid Tumor sensitive detail...
MAP2K1 K57N PLX4720 Advanced Solid Tumor sensitive detail...
MAP2K1 I111S PLX4720 Advanced Solid Tumor sensitive detail...
MAP2K1 C121S PLX4720 Advanced Solid Tumor sensitive detail...
MAP2K1 F129L PLX4720 Advanced Solid Tumor sensitive detail...
MAP2K1 V211D PD98059 Advanced Solid Tumor resistant detail...
MAP2K1 F53L PD98059 Advanced Solid Tumor resistant detail...
MAP2K1 Q56P PD98059 Advanced Solid Tumor resistant detail...
MAP2K1 K57N PD98059 Advanced Solid Tumor resistant detail...
MAP2K1 I111S PD98059 Advanced Solid Tumor resistant detail...
MAP2K1 C121S PD98059 Advanced Solid Tumor resistant detail...
MAP2K1 F129L PD98059 Advanced Solid Tumor resistant detail...
MAP2K1 V211D Regorafenib Advanced Solid Tumor resistant detail...
MAP2K1 F53L Regorafenib Advanced Solid Tumor resistant detail...
MAP2K1 Q56P Regorafenib Advanced Solid Tumor resistant detail...
MAP2K1 K57N Regorafenib Advanced Solid Tumor resistant detail...
MAP2K1 I111S Regorafenib Advanced Solid Tumor resistant detail...
MAP2K1 C121S Regorafenib Advanced Solid Tumor resistant detail...
MAP2K1 F129L Regorafenib Advanced Solid Tumor resistant detail...
MAP2K1 V211D GDC0879 Advanced Solid Tumor resistant detail...
MAP2K1 F53L GDC0879 Advanced Solid Tumor resistant detail...
MAP2K1 Q56P GDC0879 Advanced Solid Tumor resistant detail...
MAP2K1 K57N GDC0879 Advanced Solid Tumor resistant detail...
MAP2K1 I111S GDC0879 Advanced Solid Tumor resistant detail...
MAP2K1 C121S GDC0879 Advanced Solid Tumor resistant detail...
MAP2K1 F129L GDC0879 Advanced Solid Tumor resistant detail...
MAP2K1 V211D AZD8330 Advanced Solid Tumor resistant detail...
MAP2K1 F53L AZD8330 Advanced Solid Tumor resistant detail...
MAP2K1 Q56P AZD8330 Advanced Solid Tumor resistant detail...
MAP2K1 K57N AZD8330 Advanced Solid Tumor resistant detail...
MAP2K1 I111S AZD8330 Advanced Solid Tumor resistant detail...
MAP2K1 C121S AZD8330 Advanced Solid Tumor resistant detail...
MAP2K1 F129L AZD8330 Advanced Solid Tumor resistant detail...
MAP2K1 Q56P PLX4720 Advanced Solid Tumor sensitive detail...
KIT V559D Flumatinib Advanced Solid Tumor sensitive detail...
KIT V559D Sunitinib Advanced Solid Tumor sensitive detail...
KIT V559_V560del Sunitinib Advanced Solid Tumor sensitive detail...
KIT V559_V560del Imatinib Advanced Solid Tumor sensitive detail...
KIT V559_V560del Flumatinib Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup Imatinib Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup Flumatinib Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup Sunitinib Advanced Solid Tumor sensitive detail...
KIT V559D KIT V654A Sunitinib Advanced Solid Tumor sensitive detail...
KIT V559D KIT T670I Sunitinib Advanced Solid Tumor sensitive detail...
KIT V559D KIT N822K Sunitinib Advanced Solid Tumor no benefit detail...
KIT V559D KIT Y823D Sunitinib Advanced Solid Tumor no benefit detail...
KIT V559D KIT A829P Sunitinib Advanced Solid Tumor no benefit detail...
KIT V560D KIT V654A Flumatinib Advanced Solid Tumor resistant detail...
KIT V560D KIT T670I Flumatinib Advanced Solid Tumor resistant detail...
KIT V559D KIT D820G Flumatinib Advanced Solid Tumor sensitive detail...
KIT V559D KIT N822K Flumatinib Advanced Solid Tumor sensitive detail...
KIT V559D KIT Y823D Flumatinib Advanced Solid Tumor sensitive detail...
KIT I571_D579dup Sunitinib Advanced Solid Tumor predicted - resistant detail...
KIT V559D KIT A829P Flumatinib Advanced Solid Tumor sensitive detail...
KIT I571_D579dup Imatinib Advanced Solid Tumor predicted - resistant detail...
KIT I571_D579dup Flumatinib Advanced Solid Tumor predicted - resistant detail...
KIT V559D KIT Y823D Imatinib Advanced Solid Tumor no benefit detail...
KIT D816V Flumatinib Advanced Solid Tumor resistant detail...
KIT D816Y Flumatinib Advanced Solid Tumor resistant detail...
KIT D816Y Sunitinib Advanced Solid Tumor resistant detail...
KIT D816Y Imatinib Advanced Solid Tumor resistant detail...
KIT D816H Flumatinib Advanced Solid Tumor predicted - sensitive detail...
KIT D816H Sunitinib Advanced Solid Tumor predicted - sensitive detail...
KIT N822K Imatinib Advanced Solid Tumor resistant detail...
KIT N822K Flumatinib Advanced Solid Tumor predicted - sensitive detail...
KIT N822K Sunitinib Advanced Solid Tumor predicted - sensitive detail...
KIT T417_D419delinsI Flumatinib Advanced Solid Tumor sensitive detail...
KIT T417_D419delinsI Sunitinib Advanced Solid Tumor sensitive detail...
RET M918T Selpercatinib Advanced Solid Tumor sensitive detail...
CSF3R T618I Ibrutinib Advanced Solid Tumor sensitive detail...
CSF3R Q741* Ibrutinib Advanced Solid Tumor sensitive detail...
CSF3R Q741* Ruxolitinib Advanced Solid Tumor sensitive detail...
CSF3R T618I Ibrutinib + Ruxolitinib Advanced Solid Tumor sensitive detail...
CSF3R Q741* Ibrutinib + Ruxolitinib Advanced Solid Tumor sensitive detail...
KIT D816F Imatinib Advanced Solid Tumor resistant detail...
EML4 - ALK Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK Ensartinib Advanced Solid Tumor sensitive detail...
CSF3R N610H Ruxolitinib Advanced Solid Tumor sensitive detail...
CSF3R N610S Ruxolitinib Advanced Solid Tumor sensitive detail...
CSF3R N610S Trametinib Advanced Solid Tumor predicted - sensitive detail...
CSF3R N610H Trametinib Advanced Solid Tumor predicted - sensitive detail...
BRAF V600E Vemurafenib Advanced Solid Tumor sensitive detail...
BRAF G596R Vemurafenib Advanced Solid Tumor no benefit detail...
BRAF N581S Vemurafenib Advanced Solid Tumor no benefit detail...
BRAF G466V Vemurafenib Advanced Solid Tumor no benefit detail...
BRAF G606E Vemurafenib Advanced Solid Tumor no benefit detail...
BRAF P731T Vemurafenib Advanced Solid Tumor no benefit detail...
EML4 - ALK Repotrectinib Advanced Solid Tumor sensitive detail...
BRAF N486_T491delinsK Cobimetinib Advanced Solid Tumor predicted - sensitive detail...
TP53 mutant Unspecified VEGFR inhibitor Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT D816H AZD3229 Advanced Solid Tumor sensitive detail...
EML4 - ALK Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y Iruplinalkib Advanced Solid Tumor sensitive detail...
FGFR1 amp Debio 1347 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 amp Debio 1347 Advanced Solid Tumor predicted - sensitive detail...
FGFR3 amp Debio 1347 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 fusion Debio 1347 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 fusion Debio 1347 Advanced Solid Tumor predicted - sensitive detail...
FGFR3 fusion Debio 1347 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 mutant Debio 1347 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 mutant Debio 1347 Advanced Solid Tumor predicted - sensitive detail...
FGFR3 mutant Debio 1347 Advanced Solid Tumor predicted - sensitive detail...
ATM negative Elimusertib Advanced Solid Tumor predicted - sensitive detail...
ATM inact mut Elimusertib Advanced Solid Tumor predicted - sensitive detail...
BRAF mutant LXH 254 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 V211D Binimetinib Advanced Solid Tumor predicted - resistant detail...
MAP2K1 V211D Cobimetinib Advanced Solid Tumor predicted - resistant detail...
BRAF V504_R506dup Sorafenib Advanced Solid Tumor predicted - resistant detail...
BRAF V504_R506dup Vemurafenib Advanced Solid Tumor resistant detail...
BRAF V504_R506dup Trametinib Advanced Solid Tumor sensitive detail...
KIT L576P Axitinib Advanced Solid Tumor sensitive detail...
KIT V559D Axitinib Advanced Solid Tumor sensitive detail...
KIT V559A Axitinib Advanced Solid Tumor sensitive detail...
KIT V559G Axitinib Advanced Solid Tumor sensitive detail...
KIT V654A Axitinib Advanced Solid Tumor sensitive detail...
KIT V559D KIT V654A Axitinib Advanced Solid Tumor sensitive detail...
KIT T670I Axitinib Advanced Solid Tumor sensitive detail...
KIT A829P Axitinib Advanced Solid Tumor sensitive detail...
KIT V654A Sunitinib Advanced Solid Tumor sensitive detail...
KIT T670I Sunitinib Advanced Solid Tumor sensitive detail...
BRAF mut TP53 wild-type Pimasertib + SAR405838 Advanced Solid Tumor predicted - sensitive detail...
NRAS mut TP53 wild-type Pimasertib + SAR405838 Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ALK S1206Y Alectinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK T1151dup Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1152R ASP3026 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1152R Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y ASP3026 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M ASP3026 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ASP3026 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK S1206Y ASP3026 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK S1206Y Crizotinib Advanced Solid Tumor resistant detail...
PIK3CA H1047R Alpelisib Advanced Solid Tumor predicted - sensitive detail...
KIT V654A KIT D816V Midostaurin Advanced Solid Tumor resistant detail...
KIT T670I KIT D816V Midostaurin Advanced Solid Tumor decreased response detail...
KIT N655K KIT D816V Midostaurin Advanced Solid Tumor resistant detail...
KIT Y672C KIT D816V Midostaurin Advanced Solid Tumor decreased response detail...
KIT D677N KIT D816V Midostaurin Advanced Solid Tumor resistant detail...
KIT D816V Midostaurin Advanced Solid Tumor sensitive detail...
KIT D816V Avapritinib Advanced Solid Tumor sensitive detail...
KIT V654A KIT D816V Avapritinib Advanced Solid Tumor predicted - sensitive detail...
KIT N655K KIT D816V Avapritinib Advanced Solid Tumor predicted - sensitive detail...
KIT Y672C KIT D816V Avapritinib Advanced Solid Tumor predicted - sensitive detail...
KIT D677N KIT D816V Avapritinib Advanced Solid Tumor predicted - sensitive detail...
KIT T670I KIT D816V Avapritinib Advanced Solid Tumor resistant detail...
KIT T670A KIT D816V Avapritinib Advanced Solid Tumor sensitive detail...
KIT T670V KIT D816V Avapritinib Advanced Solid Tumor predicted - resistant detail...
KIT T670A KIT D816V Midostaurin Advanced Solid Tumor sensitive detail...
KIT T670V KIT D816V Midostaurin Advanced Solid Tumor sensitive detail...
KIT V560D KIT V654A Avapritinib Advanced Solid Tumor decreased response detail...
KIT D816V Ripretinib Advanced Solid Tumor sensitive detail...
KIT D816V Regorafenib Advanced Solid Tumor resistant detail...
PIK3CA mutant Alpelisib + Infigratinib Advanced Solid Tumor no benefit detail...
HRAS G12V WM-8014 Advanced Solid Tumor sensitive detail...
BRAF V600X Dabrafenib Advanced Solid Tumor predicted - sensitive detail...
FLT3 exon 14 ins LAM-003 Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 F691L LAM-003 Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins Crenolanib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y ALK G1269A Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y ALK G1269A Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK G1269A Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK G1269A Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174L ALK G1202R Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK D1203N Lorlatinib Advanced Solid Tumor resistant detail...
JAK2 V617F JAK2 R971G Ruxolitinib Advanced Solid Tumor resistant detail...
JAK2 V617F JAK2 L983F Ruxolitinib Advanced Solid Tumor resistant detail...
JAK2 V617F JAK2 E987D Ruxolitinib Advanced Solid Tumor resistant detail...
PALB2 A1025R Olaparib Advanced Solid Tumor sensitive detail...
PALB2 I944N Olaparib Advanced Solid Tumor sensitive detail...
PALB2 L24S Olaparib Advanced Solid Tumor sensitive detail...
PALB2 L1070P Olaparib Advanced Solid Tumor sensitive detail...
PALB2 L35P Olaparib Advanced Solid Tumor sensitive detail...
PALB2 Q60Rfs*7 Olaparib Advanced Solid Tumor sensitive detail...
PALB2 S172fs Olaparib Advanced Solid Tumor sensitive detail...
PALB2 E230* Olaparib Advanced Solid Tumor sensitive detail...
PALB2 Y409* Olaparib Advanced Solid Tumor sensitive detail...
PALB2 Y551* Olaparib Advanced Solid Tumor sensitive detail...
PALB2 E669fs Olaparib Advanced Solid Tumor predicted - sensitive detail...
PALB2 C882fs Olaparib Advanced Solid Tumor predicted - sensitive detail...
PALB2 Q988* Olaparib Advanced Solid Tumor sensitive detail...
PALB2 P1009Lfs*6 Olaparib Advanced Solid Tumor sensitive detail...
PALB2 W1038* Olaparib Advanced Solid Tumor sensitive detail...
PALB2 Y1183* Olaparib Advanced Solid Tumor sensitive detail...
TP53 R181E Nutlin-3a Advanced Solid Tumor no benefit detail...
TP53 R181E Doxorubicin + Nutlin-3a Advanced Solid Tumor sensitive detail...
TP53 R181E Doxorubicin + SAR405838 Advanced Solid Tumor sensitive detail...
TP53 R181E Doxorubicin + Idasanutlin Advanced Solid Tumor sensitive detail...
TP53 R181E Doxorubicin + RG7112 Advanced Solid Tumor sensitive detail...
PALB2 P8L Olaparib Advanced Solid Tumor sensitive detail...
PALB2 R37H Olaparib Advanced Solid Tumor conflicting detail...
PALB2 L1119P Olaparib Advanced Solid Tumor sensitive detail...
PALB2 T1030I Olaparib Advanced Solid Tumor sensitive detail...
PALB2 W1140G Olaparib Advanced Solid Tumor sensitive detail...
PALB2 L947F Olaparib Advanced Solid Tumor sensitive detail...
JAK2 V617F JAK2 Y931C Fedratinib Advanced Solid Tumor sensitive detail...
JAK2 V617F JAK2 Y931C JAK2 S1025C Fedratinib Advanced Solid Tumor resistant detail...
JAK2 V617F JAK2 Y931C JAK2 Y1045W Fedratinib Advanced Solid Tumor resistant detail...
JAK2 V617F JAK2 Y931C JAK2 F1061W Fedratinib Advanced Solid Tumor resistant detail...
JAK2 V617F JAK2 Y931C JAK2 V1075F Fedratinib Advanced Solid Tumor resistant detail...
BRAF mutant LY3009120 Advanced Solid Tumor no benefit detail...
NRAS mutant LY3009120 Advanced Solid Tumor no benefit detail...
EML4 - ALK Taletrectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171S ALK G1269A Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S ALK G1269A Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S ALK G1269A Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171S ALK G1269A Brigatinib Advanced Solid Tumor sensitive detail...
RET R886W Sorafenib Advanced Solid Tumor sensitive detail...
BRAF mutant Trametinib Advanced Solid Tumor no benefit detail...
BRAF G466V Trametinib Advanced Solid Tumor no benefit detail...
ARID1A mutant unspecified PD-1 antibody Advanced Solid Tumor predicted - sensitive detail...
ARID1A mutant unspecified PD-L1 antibody Advanced Solid Tumor predicted - sensitive detail...
RET fusion Pralsetinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 act mut AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 act mut AZD4547 Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1202R TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171T TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1269S TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1269A TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M ALK L1198F TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y ALK L1198F TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y ALK G1202R TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M ALK G1202R TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F ALK G1202R TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1202R ALK G1269A TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A TPX-0131 Advanced Solid Tumor sensitive detail...
KIT C809G Imatinib Advanced Solid Tumor predicted - resistant detail...
MAP2K1 E41_L54del Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 E41_L54del Selumetinib Advanced Solid Tumor sensitive detail...
MAP2K1 E41_L54del Cobimetinib Advanced Solid Tumor sensitive detail...
MAP2K1 E41_L54del LY3009120 Advanced Solid Tumor no benefit detail...
JAK3 T1022I Tofacitinib Advanced Solid Tumor sensitive detail...
FLT3 exon 14 ins FLT3 D698N Gilteritinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 N676T Quizartinib Advanced Solid Tumor resistant detail...
FLT3 exon 14 ins FLT3 N676T Midostaurin Advanced Solid Tumor resistant detail...
ATM inact mut Radiotherapy Advanced Solid Tumor predicted - sensitive detail...
BRAF V600X Lifirafenib Advanced Solid Tumor predicted - sensitive detail...
KIT W557_K558del KIT V654A AZD3229 Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT V654A Avapritinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT V654A Ripretinib Advanced Solid Tumor resistant detail...
KIT V560D AZD3229 Advanced Solid Tumor sensitive detail...
KIT V560D Avapritinib Advanced Solid Tumor sensitive detail...
KIT V560D Ripretinib Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup AZD3229 Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup Regorafenib Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup Avapritinib Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup Ripretinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del AZD3229 Advanced Solid Tumor sensitive detail...
KIT W557_K558del Avapritinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del Ripretinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT T670I AZD3229 Advanced Solid Tumor sensitive detail...
BRIP1 del CX-5461 Advanced Solid Tumor sensitive detail...
BRIP1 K52R CX-5461 Advanced Solid Tumor sensitive detail...
BRIP1 C283S CX-5461 Advanced Solid Tumor sensitive detail...
BRIP1 C283R CX-5461 Advanced Solid Tumor sensitive detail...
BRIP1 A349P CX-5461 Advanced Solid Tumor sensitive detail...
BRIP1 M299I CX-5461 Advanced Solid Tumor no benefit detail...
BRIP1 L340F CX-5461 Advanced Solid Tumor no benefit detail...
KIT V560D KIT V654A AZD3229 Advanced Solid Tumor sensitive detail...
KIT V560D KIT V654A Sunitinib Advanced Solid Tumor sensitive detail...
KIT V560D KIT V654A Imatinib Advanced Solid Tumor resistant detail...
KIT V560D KIT V654A Regorafenib Advanced Solid Tumor resistant detail...
KIT V560D KIT V654A Ripretinib Advanced Solid Tumor decreased response detail...
KIT A502_Y503dup KIT V654A AZD3229 Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup KIT V654A Sunitinib Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup KIT V654A Imatinib Advanced Solid Tumor resistant detail...
KIT A502_Y503dup KIT V654A Regorafenib Advanced Solid Tumor resistant detail...
KIT A502_Y503dup KIT V654A Avapritinib Advanced Solid Tumor resistant detail...
KIT A502_Y503dup KIT V654A Ripretinib Advanced Solid Tumor decreased response detail...
KIT W557_K558del KIT T670I Avapritinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT T670I Ripretinib Advanced Solid Tumor decreased response detail...
KIT W557_K558del KIT D816H Avapritinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT D816H Ripretinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT N822K AZD3229 Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT N822K Ripretinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT N822K Avapritinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT D820A Avapritinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT D820A Ripretinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT D820A AZD3229 Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT Y823D Ripretinib Advanced Solid Tumor decreased response detail...
KIT W557_K558del KIT Y823D Regorafenib Advanced Solid Tumor predicted - sensitive detail...
KIT W557_K558del KIT Y823D Avapritinib Advanced Solid Tumor decreased response detail...
KIT W557_K558del KIT Y823D Sunitinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT Y823D Imatinib Advanced Solid Tumor resistant detail...
KIT W557_K558del KIT Y823D AZD3229 Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT A829P AZD3229 Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT A829P Ripretinib Advanced Solid Tumor sensitive detail...
KIT W557_K558del KIT A829P Avapritinib Advanced Solid Tumor sensitive detail...
KIT V560D KIT D816H AZD3229 Advanced Solid Tumor sensitive detail...
KIT V560D KIT D816H Imatinib Advanced Solid Tumor resistant detail...
KIT V560D KIT D816H Sunitinib Advanced Solid Tumor resistant detail...
KIT V560D KIT D816H Regorafenib Advanced Solid Tumor resistant detail...
KIT V560D KIT D820A Avapritinib Advanced Solid Tumor decreased response detail...
KIT V560D KIT D816H Avapritinib Advanced Solid Tumor decreased response detail...
KIT V560D KIT D816H Ripretinib Advanced Solid Tumor sensitive detail...
KIT V560D KIT D820A Ripretinib Advanced Solid Tumor sensitive detail...
KIT V560D KIT D820A AZD3229 Advanced Solid Tumor sensitive detail...
KIT V560D KIT D820A Imatinib Advanced Solid Tumor resistant detail...
KIT V560D KIT D820A Sunitinib Advanced Solid Tumor resistant detail...
KIT V560D KIT D820A Regorafenib Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup KIT D816H Imatinib Advanced Solid Tumor resistant detail...
KIT A502_Y503dup KIT D816H Sunitinib Advanced Solid Tumor resistant detail...
KIT A502_Y503dup KIT D816H Regorafenib Advanced Solid Tumor resistant detail...
KIT A502_Y503dup KIT D816H AZD3229 Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup KIT D816H Avapritinib Advanced Solid Tumor sensitive detail...
KIT A502_Y503dup KIT D816H Ripretinib Advanced Solid Tumor decreased response detail...
FGFR1 over exp Rogaratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 over exp Rogaratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 over exp Rogaratinib Advanced Solid Tumor predicted - sensitive detail...
IDH1 R132L DS-1001b Advanced Solid Tumor predicted - sensitive detail...
IDH1 R132G DS-1001b Advanced Solid Tumor predicted - sensitive detail...
IDH1 R132S DS-1001b Advanced Solid Tumor predicted - sensitive detail...
IDH1 R132C DS-1001b Advanced Solid Tumor predicted - sensitive detail...
IDH1 R132H DS-1001b Advanced Solid Tumor predicted - sensitive detail...
HRAS G12V HRAS R135K NS1 Advanced Solid Tumor resistant detail...
HRAS G12V HRAS R135A NS1 Advanced Solid Tumor resistant detail...
KIT wild-type PLX9486 Advanced Solid Tumor sensitive detail...
KIT D816V PLX9486 Advanced Solid Tumor sensitive detail...
KIT V560G KIT D816V Imatinib Advanced Solid Tumor resistant detail...
KIT V560G KIT D816V PLX9486 Advanced Solid Tumor sensitive detail...
PIK3CA act mut Palbociclib + Taselisib Advanced Solid Tumor predicted - sensitive detail...
KIT W557_K558del Cabozantinib Advanced Solid Tumor sensitive detail...
KIT T670I Regorafenib Advanced Solid Tumor sensitive detail...
KIT T670I Cabozantinib Advanced Solid Tumor sensitive detail...
KIT N655K Imatinib Advanced Solid Tumor predicted - sensitive detail...
KIT N655K Sunitinib Advanced Solid Tumor decreased response detail...
KIT N655K Regorafenib Advanced Solid Tumor decreased response detail...
KIT N655K Cabozantinib Advanced Solid Tumor decreased response detail...
KIT N655K Avapritinib Advanced Solid Tumor predicted - sensitive detail...
KIT N655K Ripretinib Advanced Solid Tumor predicted - sensitive detail...
KIT T670I Imatinib Advanced Solid Tumor resistant detail...
BRAF V600E Trametinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 fusion Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 amp Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 amp Futibatinib Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK Entrectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171T Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171T Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171S Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151K Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151K Entrectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151K Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151K Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151K Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151K Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151K Crizotinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK V1180L Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK V1180L Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK V1180L Entrectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK V1180L Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174I Crizotinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK F1174V Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174I Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174I Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174V Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174I Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174I Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174V Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174I Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174V Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174V Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174I Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F Entrectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196Q Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196Q Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196Q Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196Q Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196Q Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196Q Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196Q Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1202R Gilteritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK D1203N Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK D1203N Gilteritinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK F1245V Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1245V Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1245V Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1245V Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1245V Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1245V Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1245V Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1256F Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1256F Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1256F Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1256F Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1256F Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1256F Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1256F Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1269A Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK F1174I Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK F1174I Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK F1174L Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK F1174L Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK F1174L Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK F1174L Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK F1174L Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK F1174L Crizotinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK I1171N ALK F1174L Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK L1198H Crizotinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK I1171N ALK L1198F Crizotinib Advanced Solid Tumor conflicting detail...
EML4 - ALK ALK I1171N ALK L1198F Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1198H Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1198H Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1198F Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1198F Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1198H Brigatinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK I1171N ALK L1198F Entrectinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK I1171N ALK L1198H Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1198F Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1198H Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1198F Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK L1198H Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK L1196M Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK L1196M Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1196M Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1196M Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK L1196M Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK L1196M Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1196M Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK G1269A Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK G1269A Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK G1269A Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S ALK G1269A Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171S ALK G1269A Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK G1269A Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK G1269A Ceritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK G1269A Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK L1256F Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1256F Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK L1256F Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1256F Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1256F Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK L1256F Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1256F Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M ALK G1202R Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK G1202R Gilteritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK G1202R Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK G1202R Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK G1202R Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK G1202R Ceritinib Advanced Solid Tumor resistant detail...
RET over exp Cabozantinib Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ALK L1198F ALK G1202R Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1202R Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M ALK D1203N Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK D1203N Brigatinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK L1196M ALK D1203N Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK D1203N Gilteritinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK L1196M ALK D1203N Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196M ALK D1203N Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK D1203N ALK F1245V Ceritinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK D1203N ALK F1245V Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK D1203N ALK F1245V Entrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK D1203N ALK F1245V Gilteritinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK D1203N ALK F1245V Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK D1203N ALK F1245V Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK D1203N ALK F1245V Crizotinib Advanced Solid Tumor resistant detail...
PTEN mutant Talazoparib Advanced Solid Tumor no benefit detail...
PIK3CA act mut TAS-117 Advanced Solid Tumor no benefit detail...
PIK3CA act mut LY3023414 + Prexasertib Advanced Solid Tumor predicted - sensitive detail...
PALB2 L1027R Olaparib Advanced Solid Tumor sensitive detail...
PALB2 G1043V Olaparib Advanced Solid Tumor sensitive detail...
PALB2 A38V Olaparib Advanced Solid Tumor no benefit detail...
FGFR1 mutant ICP-192 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 mutant ICP-192 Advanced Solid Tumor predicted - sensitive detail...
FGFR3 mutant ICP-192 Advanced Solid Tumor predicted - sensitive detail...
TP53 Y220C PC14586 Advanced Solid Tumor predicted - sensitive detail...
BRAF mutant Binimetinib + Encorafenib Advanced Solid Tumor predicted - sensitive detail...
MLH1 negative Dostarlimab-gxly Advanced Solid Tumor sensitive detail...
MSH6 negative Dostarlimab-gxly Advanced Solid Tumor sensitive detail...
NRAS act mut Selumetinib Advanced Solid Tumor no benefit detail...
HRAS act mut Selumetinib Advanced Solid Tumor no benefit detail...
BRAF V600E Selumetinib Advanced Solid Tumor no benefit detail...
RET V804M RET M918T Selpercatinib Advanced Solid Tumor predicted - sensitive detail...
RET V804M RET G810C RET M918T Selpercatinib Advanced Solid Tumor resistant detail...
RET V804M RET G810S RET M918T Selpercatinib Advanced Solid Tumor resistant detail...
NRAS G12X Binimetinib Advanced Solid Tumor no benefit detail...
NRAS G13X Binimetinib Advanced Solid Tumor no benefit detail...
NRAS Q61X Binimetinib Advanced Solid Tumor unknown detail...
RB1 positive Dalpiciclib Advanced Solid Tumor sensitive detail...
RB1 dec exp Dalpiciclib Advanced Solid Tumor no benefit detail...
NRAS Q61R Belvarafenib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1269S Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK S1206R Crizotinib Advanced Solid Tumor resistant detail...
FGFR2 N549H E7090 Advanced Solid Tumor sensitive detail...
FGFR2 N549H Futibatinib Advanced Solid Tumor sensitive detail...
FGFR2 N549K AZD4547 Advanced Solid Tumor resistant detail...
FGFR2 N549K Infigratinib Advanced Solid Tumor resistant detail...
FGFR2 N549K Erdafitinib Advanced Solid Tumor resistant detail...
FGFR2 N549K Pemigatinib Advanced Solid Tumor resistant detail...
FGFR2 N549K E7090 Advanced Solid Tumor conflicting detail...
FGFR2 N549D AZD4547 Advanced Solid Tumor resistant detail...
FGFR2 N549D Infigratinib Advanced Solid Tumor resistant detail...
FGFR2 N549D Erdafitinib Advanced Solid Tumor resistant detail...
FGFR2 N549D Futibatinib Advanced Solid Tumor sensitive detail...
FGFR2 N549D Pemigatinib Advanced Solid Tumor resistant detail...
FGFR3 K650N Infigratinib Advanced Solid Tumor sensitive detail...
FGFR3 K650N E7090 Advanced Solid Tumor sensitive detail...
FGFR3 K650N Erdafitinib Advanced Solid Tumor sensitive detail...
FGFR3 K650N Futibatinib Advanced Solid Tumor sensitive detail...
FGFR3 K650N Pemigatinib Advanced Solid Tumor sensitive detail...
FGFR2 N549K Dovitinib Advanced Solid Tumor resistant detail...
FGFR2 N549D Dovitinib Advanced Solid Tumor resistant detail...
FGFR3 K650T Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR3 K650M Dovitinib Advanced Solid Tumor resistant detail...
FGFR3 K650M AZD4547 Advanced Solid Tumor resistant detail...
FGFR1 N546K AZD4547 Advanced Solid Tumor predicted - resistant detail...
FGFR1 N546K Infigratinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 N546K Erdafitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 N546K Futibatinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 N546K Pemigatinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 N546K Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 N549S Infigratinib Advanced Solid Tumor sensitive detail...
FGFR2 N549S E7090 Advanced Solid Tumor sensitive detail...
FGFR2 N549S Erdafitinib Advanced Solid Tumor sensitive detail...
FGFR2 N549S Futibatinib Advanced Solid Tumor sensitive detail...
FGFR2 N549S Pemigatinib Advanced Solid Tumor sensitive detail...
FGFR2 N549S Dovitinib Advanced Solid Tumor resistant detail...
FGFR1 K656E Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 K656E Pemigatinib Advanced Solid Tumor conflicting detail...
FGFR1 K656E Erdafitinib Advanced Solid Tumor conflicting detail...
FGFR1 K656E Infigratinib Advanced Solid Tumor conflicting detail...
FGFR1 K656M AZD4547 Advanced Solid Tumor predicted - resistant detail...
FGFR1 K656M E7090 Advanced Solid Tumor predicted - resistant detail...
FGFR1 K656M Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 S252W Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S252W Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S252W Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S252W E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S252W Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S252W AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y375C AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y375C Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y375C E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y375C Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y375C Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y375C Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y375C Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 C382R AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C382R Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C382R Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C382R Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C382R Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C382R Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 K659E Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K659E Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K659E Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K659E Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 K659N Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 K659N Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K659N Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K659N Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K659N E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K659N Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K659N AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR3 S249C E7090 Advanced Solid Tumor predicted - resistant detail...
FGFR3 G370C Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR3 G370C E7090 Advanced Solid Tumor predicted - resistant detail...
FGFR3 G370C Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 S371C Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 S371C E7090 Advanced Solid Tumor predicted - resistant detail...
FGFR3 S371C Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR3 Y373C Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR3 Y373C E7090 Advanced Solid Tumor predicted - resistant detail...
FGFR3 Y373C Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 G380R Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 G380R Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 G380R Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 G380R Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR3 A391E Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 A391E AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR3 A391E Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 A391E Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 A391E Dovitinib Advanced Solid Tumor predicted - resistant detail...
BRAF L485_P490del Vemurafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485_P490del LY3009120 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V564M Infigratinib Advanced Solid Tumor resistant detail...
MLH1 negative Pembrolizumab Advanced Solid Tumor sensitive detail...
MSH6 negative Pembrolizumab Advanced Solid Tumor sensitive detail...
FGFR1 S125L AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S125L Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S125L E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S125L Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S125L Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S125L Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S125L Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 T141R AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T141R Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T141R E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T141R Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T141R Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T141R Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 P150S Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 P150S E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 P150S Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 P150S AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R250W AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R250W Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R250W E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R250W Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R250W Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R250W Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A268S Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A268S Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A268S E7090 Advanced Solid Tumor predicted - resistant detail...
FGFR1 A268S Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A268S AZD4547 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 L98_K104delinsQ Trametinib Advanced Solid Tumor resistant detail...
MAP2K1 L98_K104delinsQ MK2206 Advanced Solid Tumor resistant detail...
MAP2K1 L98_K104delinsQ U0126 Advanced Solid Tumor resistant detail...
MAP2K1 L98_K104delinsQ SCH772984 Advanced Solid Tumor resistant detail...
FGFR1 A21T AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A21T Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A21T E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A21T Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A21T Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A21T Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T26I Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T26I Dovitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T26I Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T26I Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T26I E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T26I Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T26I AZD4547 Advanced Solid Tumor predicted - resistant detail...
FGFR1 A121D AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A121D Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A121D E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A121D Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A121D Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A121D Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 A121D Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 D128N AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D128N Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D128N E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D128N Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D128N Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D128V Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D128V Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D128V Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D128V E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D128V Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D128V AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D133N AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D133N Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D133N E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D133N Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D133N Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D133N Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R189C AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R189C Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R189C Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 S238N Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 S238N Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S238N Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S238N Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S238N E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S238N Infigratinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 S238N AZD4547 Advanced Solid Tumor predicted - resistant detail...
FGFR1 T319A AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T319A Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T319A E7090 Advanced Solid Tumor predicted - resistant detail...
FGFR1 T319A Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T319A Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T319A Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 D320N AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D320N Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D320N E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D320N Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D320N Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 D320N Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T340M Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T340M Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T340M Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T340M E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T340M Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 T340M AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S436F AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S436F Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S436F E7090 Advanced Solid Tumor predicted - resistant detail...
FGFR1 S436F Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S436F Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S436F Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
PIK3CA act mut Docetaxel + Ipatasertib Advanced Solid Tumor predicted - sensitive detail...
PIK3CA act mut Fluorouracil + Ipatasertib + Leucovorin + Oxaliplatin Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R445W AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R445W Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R445W E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R445W Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R445W Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 M456V Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 M456V Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 M456V Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 M456V Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 M456V E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 M456V Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 M456V AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E467K AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E467K Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E467K E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E467K Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E467K Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E467K Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 G703S Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 G703S Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 G703S E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 G703S Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 G703S AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E592G AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E592G Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E592G E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E592G Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 E592G Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S588T Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S588T Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S588T Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S588T E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 S588T AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R475Q AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R475Q Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R475Q Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R475Q Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 P483L AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 P483L Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 P483L E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 P483L Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 P483L Futibatinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 P483L Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
RET M918T LOX-18228 Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ALK L1196M ALK G1202R NUV-655 Advanced Solid Tumor sensitive detail...
EML4 - ALK NUV-655 Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ALK G1202R NUV-655 Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ALK G1202R ALK G1269A NUV-655 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 V751A AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 V751A Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 V751A E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 V751A Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 V751A Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 V751A Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R809Q Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R809Q Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R809Q Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R809Q E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R809Q Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 R809Q AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R6P AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R6P Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R6P E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R6P Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R6P Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R6P Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R6P Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 L33S Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 L33S Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 I111A CI-1040 Advanced Solid Tumor decreased response detail...
MAP2K1 I111D CI-1040 Advanced Solid Tumor predicted - resistant detail...
MAP2K1 I111P CI-1040 Advanced Solid Tumor predicted - resistant detail...
MAP2K1 I111R CI-1040 Advanced Solid Tumor predicted - resistant detail...
MAP2K1 I139G CI-1040 Advanced Solid Tumor predicted - resistant detail...
MAP2K1 I139R CI-1040 Advanced Solid Tumor decreased response detail...
MAP2K1 I139N CI-1040 Advanced Solid Tumor decreased response detail...
MAP2K1 L118G CI-1040 Advanced Solid Tumor decreased response detail...
MAP2K1 L118Q CI-1040 Advanced Solid Tumor predicted - resistant detail...
MAP2K1 L118P CI-1040 Advanced Solid Tumor predicted - resistant detail...
MAP2K1 L118D CI-1040 Advanced Solid Tumor predicted - resistant detail...
FGFR2 L33S AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L33S Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L33S E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L33S Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L33S Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C62Y AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C62Y Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C62Y E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C62Y Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C62Y Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C62Y Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 C62Y Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 A67V AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A67V Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A67V E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A67V Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A67V Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A67V Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N82K AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N82K Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N82K E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N82K Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N82K Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N82K Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 D101Y Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 D101Y Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 D101Y Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 D101Y E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 D101Y Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 D101Y AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 D101Y Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 E160K Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 E160K Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E160K Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E160K Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E160K E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E160K Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E160K AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E163K AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E163K Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E163K E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E163K Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E163K Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E163K Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E163K Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 M186T AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M186T Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M186T E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M186T Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M186T Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M186T Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M186T Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 R203C Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 R203C Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203C Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203C Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203C E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203C Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203C AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203H AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203H Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203H E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203H Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203H Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R203H Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R210Q Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R210Q Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R210Q Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R210Q E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R210Q Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R210Q AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Q212K AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Q212K Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Q212K E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Q212K Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Q212K Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Q212K Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Q212K Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 G227E AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G227E Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G227E E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G227E Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G227E Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G227E Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G227E Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 H242Y AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H242Y Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H242Y E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H242Y Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H242Y Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H242Y Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R251Q Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R251Q Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R251Q Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R251Q E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R251Q Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R251Q AZD4547 Advanced Solid Tumor predicted - sensitive detail...
ALK positive Ceritinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G305R Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 G305R Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G305R Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G305R Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G305R E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G305R Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G305R AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P303L AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P303L Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P303L E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P303L Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P303L Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P303L Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P303L Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 P253L Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 P253L Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253L Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253L Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253L E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253L Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253L AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253R AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253R Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253R E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253R Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253R Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253R Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P253R Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 A264T Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 A264T Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A264T Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A264T Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A264T E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A264T Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A264T AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 W290C E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 W290C Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 W290C Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 W290C Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 W290C Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 K310R AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K310R Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K310R E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K310R Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K310R Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K310R Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K310R Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 Y328N Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 Y328N Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y328N Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y328N Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y328N E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y328N Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 Y328N AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R330W AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R330W Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R330W E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R330W Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R330W Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R330W Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R330W Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 G364E AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G364E Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G364E E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G364E Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G364E Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G364E Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A371V Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A371V Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A371V Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A371V E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A371V Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A371V AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A389T AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A389T Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A389T E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A389T Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A389T Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 A389T Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V392A Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V392A Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V392A Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V392A E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V392A Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V392A AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R399Q AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R399Q Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R399Q E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R399Q Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R399Q Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R399Q Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H416R Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H416R Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H416R Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H416R E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H416R Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H416R AZD4547 Advanced Solid Tumor predicted - sensitive detail...
BRAF N486_P490del BRAF R509H Vemurafenib Advanced Solid Tumor resistant detail...
BRAF N486_P490del BRAF R509H BRAF V600E Vemurafenib Advanced Solid Tumor resistant detail...
BRAF N486_P490del BRAF R509H BRAF V600E GDC0879 Advanced Solid Tumor sensitive detail...
BRAF N486_P490del BRAF R509H GDC0879 Advanced Solid Tumor sensitive detail...
BRAF R509H BRAF V600E GDC0879 Advanced Solid Tumor sensitive detail...
BRAF R509H BRAF V600E Vemurafenib Advanced Solid Tumor sensitive detail...
FGFR2 I422V AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 I422V Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 I422V E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 I422V Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 I422V Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 I422V Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 I422V Dovitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E475K AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E475K Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E475K E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E475K Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E475K Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E475K Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H544Q Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H544Q Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H544Q Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H544Q E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H544Q Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H544Q AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L560F AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L560F Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L560F E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L560F Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L560F Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L560F Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 H544Q Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 P582L AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P582L Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P582L E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P582L Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P582L Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 P582L Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E596K Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E596K Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E596K Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E596K E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E596K Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E596K AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G613S AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G613S Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G613S E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G613S Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G613S Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G613S Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 G613S Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 M640I AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M640I Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M640I E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M640I Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M640I Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 M640I Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R664W Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R664W Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R664W Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R664W E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R664W Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 R664W AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E718K AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E718K Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E718K E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E718K Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E718K Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E718K Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E718K Dovitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S791T AZD4547 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S791T Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S791T E7090 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S791T Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S791T Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S791T Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 S791T Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR3 G380E Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 G380E Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 G380E Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 G380E Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR3 R248_S249insC E7090 Advanced Solid Tumor predicted - resistant detail...
FGFR3 R248_S249insC Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR3 H284fs Dovitinib Advanced Solid Tumor predicted - resistant detail...
FGFR3 H284fs Pemigatinib Advanced Solid Tumor predicted - resistant detail...
FGFR3 H284fs E7090 Advanced Solid Tumor predicted - resistant detail...
FGFR3 H284fs Infigratinib Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK XMU-MP-5 Advanced Solid Tumor sensitive detail...
MAP2K1 D67N Selumetinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1202R XMU-MP-5 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M XMU-MP-5 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1269A XMU-MP-5 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171T XMU-MP-5 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y XMU-MP-5 Advanced Solid Tumor sensitive detail...
KIT exon 11 del KIT A829P THE-630 Advanced Solid Tumor predicted - sensitive detail...
KIT exon 11 del KIT D816G THE-630 Advanced Solid Tumor predicted - sensitive detail...
KIT exon 11 del KIT D816H THE-630 Advanced Solid Tumor predicted - sensitive detail...
KIT exon 11 del KIT D820A THE-630 Advanced Solid Tumor predicted - sensitive detail...
KIT exon 11 del KIT D820G THE-630 Advanced Solid Tumor predicted - sensitive detail...
KIT exon 11 del KIT N822K THE-630 Advanced Solid Tumor predicted - sensitive detail...
KIT exon 11 del KIT T670I THE-630 Advanced Solid Tumor predicted - sensitive detail...
KIT exon 11 del KIT V654A THE-630 Advanced Solid Tumor predicted - sensitive detail...
KIT exon 11 del KIT Y823D THE-630 Advanced Solid Tumor predicted - sensitive detail...
KIT exon 9 ins KIT D816G THE-630 Advanced Solid Tumor predicted - sensitive detail...
KIT exon 9 ins KIT V654A THE-630 Advanced Solid Tumor predicted - sensitive detail...
BRAF V600X Belvarafenib + Cobimetinib Advanced Solid Tumor predicted - sensitive detail...
PIK3CA act mut RLY-2608 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 amp HQP1351 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 K656E HQP1351 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 K656E Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 K656N Erdafitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 K656N HQP1351 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 K656N Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 K656N Futibatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 K656N Pemigatinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 V561F Erdafitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 V561F HQP1351 Advanced Solid Tumor sensitive detail...
FGFR1 V561F Infigratinib Advanced Solid Tumor resistant detail...
FGFR1 V561F Pemigatinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 V561F Futibatinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 V561M Erdafitinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 V561M Ponatinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 V561M HQP1351 Advanced Solid Tumor sensitive detail...
FGFR1 V561M Futibatinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 V561M Infigratinib Advanced Solid Tumor predicted - resistant detail...
FGFR1 V561M Pemigatinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 amp HQP1351 Advanced Solid Tumor predicted - sensitive detail...
ATM inact mut Ceralasertib + Olaparib Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ALK F1174L XMU-MP-5 Advanced Solid Tumor predicted - resistant detail...
KIT V559D Nintedanib Advanced Solid Tumor sensitive detail...
KIT V559G Nintedanib Advanced Solid Tumor sensitive detail...
KIT L576P Nintedanib Advanced Solid Tumor sensitive detail...
KIT V654A Nintedanib Advanced Solid Tumor sensitive detail...
KIT T670E Nintedanib Advanced Solid Tumor sensitive detail...
KIT V559D KIT T670I Nintedanib Advanced Solid Tumor sensitive detail...
KIT T670I Nintedanib Advanced Solid Tumor sensitive detail...
KIT D816E Nintedanib Advanced Solid Tumor sensitive detail...
KIT A829P Nintedanib Advanced Solid Tumor sensitive detail...
KIT Y823D Nintedanib Advanced Solid Tumor sensitive detail...
KIT D820E Nintedanib Advanced Solid Tumor sensitive detail...
RET G810R TPX-0046 Advanced Solid Tumor predicted - sensitive detail...
RET G810C TPX-0046 Advanced Solid Tumor predicted - sensitive detail...
RET G810S TPX-0046 Advanced Solid Tumor predicted - sensitive detail...
KIT D820G Nintedanib Advanced Solid Tumor sensitive detail...
KIT D820Y Nintedanib Advanced Solid Tumor sensitive detail...
KIT V559D KIT V654A Nintedanib Advanced Solid Tumor predicted - sensitive detail...
KIT L576P Imatinib Advanced Solid Tumor sensitive detail...
KIT L576P Sunitinib Advanced Solid Tumor sensitive detail...
KIT V559G Imatinib Advanced Solid Tumor sensitive detail...
KIT V559G Sunitinib Advanced Solid Tumor sensitive detail...
KIT T670E Sunitinib Advanced Solid Tumor sensitive detail...
KIT T670E Avapritinib Advanced Solid Tumor resistant detail...
KIT T670E Ripretinib Advanced Solid Tumor resistant detail...
KIT T670E Imatinib Advanced Solid Tumor resistant detail...
KIT D816H Imatinib Advanced Solid Tumor resistant detail...
KIT D816E Imatinib Advanced Solid Tumor sensitive detail...
KIT D816E Sunitinib Advanced Solid Tumor sensitive detail...
KIT V559D KIT T670I Avapritinib Advanced Solid Tumor resistant detail...
KIT V559D KIT V654A Avapritinib Advanced Solid Tumor resistant detail...
KIT V559D KIT T670I Imatinib Advanced Solid Tumor resistant detail...
KIT V559D KIT V654A Ripretinib Advanced Solid Tumor resistant detail...
KIT V559D KIT T670I Ripretinib Advanced Solid Tumor resistant detail...
IDH1 R132H Ceralasertib Advanced Solid Tumor sensitive detail...
IDH1 R132H Elimusertib Advanced Solid Tumor sensitive detail...
IDH1 R132H Ceralasertib + Olaparib Advanced Solid Tumor sensitive detail...
IDH1 R132H Elimusertib + Olaparib Advanced Solid Tumor sensitive detail...
IDH1 R132H Ceralasertib + Niraparib Advanced Solid Tumor sensitive detail...
IDH1 R132H Ceralasertib + Talazoparib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M TPX-0131 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK L1198F TPX-0131 Advanced Solid Tumor sensitive detail...
ALK C1156Y TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK S1206C ALK E1210K TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK C1156Y ALK L1198F TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK L1196M ALK L1198F TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK E1210K TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK L1196M TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK T1151M TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK G1202del TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK T1151dup TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK V1180L TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK G1269A TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK F1174C TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK F1174L TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK I1171N TPX-0131 Advanced Solid Tumor decreased response detail...
ALK L1152P TPX-0131 Advanced Solid Tumor decreased response detail...
ALK D1203N TPX-0131 Advanced Solid Tumor decreased response detail...
ALK D1203N ALK E1210K TPX-0131 Advanced Solid Tumor decreased response detail...
ALK G1269S TPX-0131 Advanced Solid Tumor decreased response detail...
ALK S1206R TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK L1198F ALK G1202R TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK F1245C TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK R1275Q TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK L1198F TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK L1152R TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
ALK F1174S TPX-0131 Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ALK C1156Y ALK G1202R Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK G1269A Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK G1202R Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK G1269A Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK G1202R Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK G1269A Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK G1202R Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK G1269A Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK G1202R Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
ROS1 G2032R SAF-189s Advanced Solid Tumor predicted - sensitive detail...
ROS1 L2026M SAF-189s Advanced Solid Tumor predicted - sensitive detail...
ROS1 S1986F SAF-189s Advanced Solid Tumor predicted - sensitive detail...
ROS1 S1986Y SAF-189s Advanced Solid Tumor predicted - sensitive detail...
ROS1 D2033N SAF-189s Advanced Solid Tumor predicted - sensitive detail...
FGFR2 fusion Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
ROS1 fusion Entrectinib Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ALK F1174L Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1202R Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174C Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1269A Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171S Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK T1151dup Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174V Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK V1180L Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1152R Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1152P Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171T Iruplinalkib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N Iruplinalkib Advanced Solid Tumor sensitive detail...
ROS1 G2032R Lorlatinib Advanced Solid Tumor predicted - sensitive detail...
ROS1 L2026M Lorlatinib Advanced Solid Tumor predicted - sensitive detail...
ROS1 S1986F Lorlatinib Advanced Solid Tumor predicted - sensitive detail...
ROS1 S1986Y Lorlatinib Advanced Solid Tumor predicted - sensitive detail...
ROS1 D2033N Lorlatinib Advanced Solid Tumor predicted - sensitive detail...
RET V804M RET Y806C Selpercatinib Advanced Solid Tumor decreased response detail...
RET V804M RET Y806C RET M918T Selpercatinib Advanced Solid Tumor predicted - resistant detail...
ROS1 G2032R Ceritinib Advanced Solid Tumor predicted - resistant detail...
ROS1 G2032R Crizotinib Advanced Solid Tumor predicted - resistant detail...
BRAF V600E Dabrafenib + Trametinib Advanced Solid Tumor sensitive detail...
RET G810R APS03118 Advanced Solid Tumor predicted - sensitive detail...
RET V804M APS03118 Advanced Solid Tumor predicted - sensitive detail...
RET M918T APS03118 Advanced Solid Tumor predicted - sensitive detail...
RET G810S APS03118 Advanced Solid Tumor predicted - sensitive detail...
KIT D419del Imatinib Advanced Solid Tumor predicted - sensitive detail...
RET G810C APS03118 Advanced Solid Tumor predicted - sensitive detail...
RET V804L APS03118 Advanced Solid Tumor predicted - sensitive detail...
RET V804E APS03118 Advanced Solid Tumor predicted - sensitive detail...
RET M918T Pralsetinib Advanced Solid Tumor sensitive detail...
RET T930K Selpercatinib Advanced Solid Tumor sensitive detail...
RET T930K Pralsetinib Advanced Solid Tumor sensitive detail...
RET T930P Selpercatinib Advanced Solid Tumor sensitive detail...
RET T930P Pralsetinib Advanced Solid Tumor sensitive detail...
RET D898_E901del Selpercatinib Advanced Solid Tumor sensitive detail...
RET D898_E901del Pralsetinib Advanced Solid Tumor sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib Advanced Solid Tumor sensitive detail...
ALK C1156Y ALK L1198F Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N ALK D1203N Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK S1206F Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK S1206F ALK G1269A Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK S1206F Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK S1206F ALK G1269A Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK D1203N Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK S1206F Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK S1206F ALK G1269A Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK S1206F Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK S1206F ALK G1269A Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK D1203N Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK S1206F Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R ALK S1206F ALK G1269A Lorlatinib Advanced Solid Tumor resistant detail...
PALB2 L24F PALB2 Y551* Olaparib Advanced Solid Tumor sensitive detail...
PALB2 L35F PALB2 Y551* Olaparib Advanced Solid Tumor sensitive detail...
PALB2 L35P PALB2 Y551* Olaparib Advanced Solid Tumor sensitive detail...
ALK rearrange TQ-B3101 Advanced Solid Tumor predicted - sensitive detail...
ROS1 rearrange TQ-B3101 Advanced Solid Tumor predicted - sensitive detail...
PALB2 K16M PALB2 Y551* Olaparib Advanced Solid Tumor no benefit detail...
RET fusion Selpercatinib Advanced Solid Tumor sensitive detail...
BRAF act mut CC-91516 Advanced Solid Tumor predicted - sensitive detail...
CTNNB1 act mut CC-91516 Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK TQ-B3139 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK R1275Q TQ-B3139 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1152R TQ-B3139 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK C1156Y TQ-B3139 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M TQ-B3139 Advanced Solid Tumor sensitive detail...
ALK L1196M APG-2449 Advanced Solid Tumor predicted - sensitive detail...
ALK G1269A APG-2449 Advanced Solid Tumor predicted - sensitive detail...
ALK S1206Y APG-2449 Advanced Solid Tumor predicted - sensitive detail...
ALK G1202R APG-2449 Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK APG-2449 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171T APG-2449 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK R1275Q APG-2449 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174L APG-2449 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1196M APG-2449 Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1202R APG-2449 Advanced Solid Tumor sensitive detail...
RET C630del Pralsetinib Advanced Solid Tumor sensitive detail...
NRAS mutant FCN-159 Advanced Solid Tumor predicted - sensitive detail...
ATM inact mut RP-3500 Advanced Solid Tumor predicted - sensitive detail...
CDK12 inact mut RP-3500 Advanced Solid Tumor predicted - sensitive detail...
ATM mutant Olaparib Advanced Solid Tumor conflicting detail...
TP53 wild-type BI 907828 + Ezabenlimab Advanced Solid Tumor predicted - sensitive detail...
HRAS G13R PTEN inact mut AZD8186 + Tipifarnib Advanced Solid Tumor predicted - sensitive detail...
HRAS G13R PTEN inact mut Tipifarnib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N549H 3D185 Advanced Solid Tumor predicted - sensitive detail...
FGFR1 V561M 3D185 Advanced Solid Tumor predicted - sensitive detail...
BRAF R506_K507insLLR Vemurafenib Advanced Solid Tumor resistant detail...
BRAF R506_K507insLLR Dabrafenib Advanced Solid Tumor resistant detail...
BRAF V504_R506dup Dabrafenib Advanced Solid Tumor resistant detail...
BRAF R506_K507insLLR PLX8394 Advanced Solid Tumor resistant detail...
BRAF V504_R506dup PLX8394 Advanced Solid Tumor resistant detail...
BRAF R506_K507insLLR LY3009120 Advanced Solid Tumor predicted - resistant detail...
BRAF V504_R506dup LY3009120 Advanced Solid Tumor predicted - resistant detail...
BRAF R506_K507insLLR Trametinib Advanced Solid Tumor sensitive detail...
BRAF R506_K507insLLR Sorafenib Advanced Solid Tumor predicted - resistant detail...
BRAF R506_K507insLLR Cobimetinib Advanced Solid Tumor predicted - sensitive detail...
BRAF R506_K507insLLR Selumetinib Advanced Solid Tumor predicted - sensitive detail...
BRAF R506_K507insLLR Binimetinib Advanced Solid Tumor predicted - sensitive detail...
BRAF L505H Vemurafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485F Vemurafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L505H PLX8394 Advanced Solid Tumor predicted - resistant detail...
BRAF L485F PLX8394 Advanced Solid Tumor predicted - resistant detail...
BRAF L505H Dabrafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485F Dabrafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L505H LY3009120 Advanced Solid Tumor predicted - resistant detail...
BRAF L485F LY3009120 Advanced Solid Tumor predicted - sensitive detail...
BRAF V600X PLX8394 Advanced Solid Tumor predicted - sensitive detail...
ALK G1128A Repotrectinib Advanced Solid Tumor sensitive detail...
ALK I1171N Repotrectinib Advanced Solid Tumor sensitive detail...
ALK F1174L Repotrectinib Advanced Solid Tumor sensitive detail...
ALK R1192P Repotrectinib Advanced Solid Tumor sensitive detail...
ALK F1245C Repotrectinib Advanced Solid Tumor sensitive detail...
ALK Y1278S Repotrectinib Advanced Solid Tumor sensitive detail...
ALK R1275Q Repotrectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK I1171N Repotrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1202R Ensartinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N Ensartinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK E1129V ALK G1202R Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C ALK G1202R Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174I ALK G1202R Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK E1129V ALK I1171N Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK I1171N Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK E1129V ALK G1202R Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C ALK G1202R Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174I ALK G1202R Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK E1129V ALK I1171N Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK I1171N Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK E1129V ALK G1202R Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C ALK G1202R Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174I ALK G1202R Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK E1129V ALK I1171N Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK I1171N Alectinib Advanced Solid Tumor resistant detail...
ATM inact mut Avelumab + Talazoparib Advanced Solid Tumor no benefit detail...
EML4 - ALK ALK E1129V ALK G1202R TPX-0131 Advanced Solid Tumor sensitive detail...
ALK R753Q Crizotinib Advanced Solid Tumor sensitive detail...
ALK F856S Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174I ALK G1202R TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174C ALK G1202R TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK E1129V ALK I1171N TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK I1171N TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK I1171N ALK L1256F TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK E1129V ALK G1202R Gilteritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK G1202R Gilteritinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174C ALK G1202R Gilteritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK F1174I ALK G1202R Gilteritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1156Y ALK I1171N Gilteritinib Advanced Solid Tumor sensitive detail...
MAP2K1 I99_K104del Trametinib Advanced Solid Tumor resistant detail...
MAP2K1 E102_I103del Trametinib Advanced Solid Tumor resistant detail...
MAP2K1 P105_A106del Trametinib Advanced Solid Tumor resistant detail...
MAP2K1 L115P Trametinib Advanced Solid Tumor resistant detail...
MAP2K1 R49L Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 F53_Q58delinsL Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 F53C Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 F53I Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 F53L Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 L42_K57del Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 F53V Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 Q56P Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 K57_G61del Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 K57E Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 K57N Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 K57T Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 Q58_E62del Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 K59del Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 V60E Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 G61_D65del Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 L63_D67del Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 C121S Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 G128D Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 F129L Trametinib Advanced Solid Tumor sensitive detail...
MAP2K1 E203K Trametinib Advanced Solid Tumor sensitive detail...
FGFR2 V565L TYRA-200 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V565F TYRA-200 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V565I TYRA-200 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K660E TYRA-200 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K660N TYRA-200 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E566A TYRA-200 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N550H TYRA-200 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N550K TYRA-200 Advanced Solid Tumor predicted - sensitive detail...
ALK L1196M Conteltinib Advanced Solid Tumor predicted - sensitive detail...
ALK F1174L Conteltinib Advanced Solid Tumor predicted - sensitive detail...
ALK G1202R Conteltinib Advanced Solid Tumor predicted - sensitive detail...
ALK G1269S Conteltinib Advanced Solid Tumor predicted - sensitive detail...
ALK R1275Q Conteltinib Advanced Solid Tumor predicted - sensitive detail...
RET E632_L633del Selpercatinib Advanced Solid Tumor conflicting detail...
RET E632_L633del Pralsetinib Advanced Solid Tumor conflicting detail...
BRAF V600E Erlotinib + Vemurafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF L525R Selumetinib Advanced Solid Tumor sensitive detail...
BRAF L525R Dactolisib + Selumetinib Advanced Solid Tumor predicted - sensitive detail...
BRAF L525R Dactolisib Advanced Solid Tumor sensitive detail...
MAP2K1 L42F Trametinib Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 N109_R113del Trametinib Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 T55P Trametinib Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 H119Q Trametinib Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 H119Y Trametinib Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 L177M Trametinib Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 K57N SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 I103N SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 H119Q SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 N122D SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 L177M SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 E203K SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 E102_I103del SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 N109_R113del SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 I103_K104del SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 P105_A106del SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 P105_I107delinsL SCH772984 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 I103_K104del Trametinib Advanced Solid Tumor decreased response detail...
MAP2K1 P105_I107delinsL Trametinib Advanced Solid Tumor decreased response detail...
RAD51C T132P Olaparib Advanced Solid Tumor sensitive detail...
ALK rearrange Entrectinib Advanced Solid Tumor predicted - sensitive detail...
BRAF class 1 BDTX-4933 Advanced Solid Tumor predicted - sensitive detail...
BRAF class 2 BDTX-4933 Advanced Solid Tumor predicted - sensitive detail...
BRAF class 3 BDTX-4933 Advanced Solid Tumor predicted - sensitive detail...
MAP2K1 Q56_G61delinsR Trametinib Advanced Solid Tumor sensitive detail...
RET V804M TY-1091 Advanced Solid Tumor predicted - sensitive detail...
RET V804L TY-1091 Advanced Solid Tumor predicted - sensitive detail...
RET V804E TY-1091 Advanced Solid Tumor predicted - sensitive detail...
RET G810S TY-1091 Advanced Solid Tumor predicted - sensitive detail...
RET V804M RET G810S TY-1091 Advanced Solid Tumor predicted - sensitive detail...
RET G810S RET M918T TY-1091 Advanced Solid Tumor predicted - sensitive detail...
PTEN inact mut Temsirolimus Advanced Solid Tumor predicted - sensitive detail...
BRAF class 1 Exarafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF class 2 Exarafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF class 3 Exarafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF class 1 DCC-3084 Advanced Solid Tumor predicted - sensitive detail...
BRAF class 2 DCC-3084 Advanced Solid Tumor predicted - sensitive detail...
BRAF class 3 DCC-3084 Advanced Solid Tumor predicted - sensitive detail...
BRAF fusion DCC-3084 Advanced Solid Tumor predicted - sensitive detail...
ALK F1174L CCC-003 Advanced Solid Tumor sensitive detail...
BRAF fusion PLX8394 Advanced Solid Tumor predicted - sensitive detail...
PIK3CA mutant TOS-358 Advanced Solid Tumor predicted - sensitive detail...
RAD51C T336P Olaparib Advanced Solid Tumor sensitive detail...
RAD51C G162E Olaparib Advanced Solid Tumor sensitive detail...
RAD51C L138F Olaparib Advanced Solid Tumor sensitive detail...
RAD51C G153D Olaparib Advanced Solid Tumor sensitive detail...
RAD51C R312W Olaparib Advanced Solid Tumor sensitive detail...
RAD51C L27P Olaparib Advanced Solid Tumor sensitive detail...
RAD51C T336P Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C L138F Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C G162E Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C G153D Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C L27P Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C R312W Cisplatin Advanced Solid Tumor sensitive detail...
FGFR2 V564F RLY-4008 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N549D RLY-4008 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V564L RLY-4008 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 E565A RLY-4008 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 L617V RLY-4008 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 N549H RLY-4008 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K641N RLY-4008 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 K659M RLY-4008 Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V564F Futibatinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 V564F Pemigatinib Advanced Solid Tumor resistant detail...
FGFR2 V564F Erdafitinib Advanced Solid Tumor predicted - resistant detail...
FGFR2 V564L Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V564L Infigratinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V564I Infigratinib Advanced Solid Tumor predicted - sensitive detail...
RAD51C D348V Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C D348V Olaparib Advanced Solid Tumor sensitive detail...
RAD51C A155E Olaparib Advanced Solid Tumor sensitive detail...
RAD51C A155E Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C D159Y Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C D159Y Olaparib Advanced Solid Tumor sensitive detail...
RAD51C V140E Olaparib Advanced Solid Tumor sensitive detail...
RAD51C V140E Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C G114V Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C G114V Olaparib Advanced Solid Tumor sensitive detail...
RAD51C A279P Olaparib Advanced Solid Tumor sensitive detail...
RAD51C A279P Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C T132R Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C T132R Olaparib Advanced Solid Tumor sensitive detail...
RAD51C G150E Olaparib Advanced Solid Tumor sensitive detail...
RAD51C G150E Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C R237P Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C R237P Olaparib Advanced Solid Tumor sensitive detail...
RAD51C T102I Olaparib Advanced Solid Tumor sensitive detail...
RAD51C T102I Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C K131I Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C K131I Olaparib Advanced Solid Tumor sensitive detail...
RAD51C G302V Olaparib Advanced Solid Tumor sensitive detail...
RAD51C G302V Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C D108G Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C D108G Olaparib Advanced Solid Tumor sensitive detail...
RAD51C V156D Olaparib Advanced Solid Tumor sensitive detail...
RAD51C V156D Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C Q133E Olaparib Advanced Solid Tumor sensitive detail...
RAD51C Q133E Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C G306R Olaparib Advanced Solid Tumor sensitive detail...
RAD51C S163R Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C S163R Olaparib Advanced Solid Tumor sensitive detail...
RAD51C D159A Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C D159A Olaparib Advanced Solid Tumor sensitive detail...
RAD51C D242N Olaparib Advanced Solid Tumor sensitive detail...
RAD51C D242N Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C T132I Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C T132I Olaparib Advanced Solid Tumor sensitive detail...
RAD51C G125V Olaparib Advanced Solid Tumor sensitive detail...
RAD51C G125V Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C G130R Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C G130R Olaparib Advanced Solid Tumor sensitive detail...
RAD51C R168G Olaparib Advanced Solid Tumor sensitive detail...
RAD51C R168G Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C C135Y Cisplatin Advanced Solid Tumor sensitive detail...
RAD51C G114R Cisplatin Advanced Solid Tumor sensitive detail...
FGFR3 K652E Infigratinib Advanced Solid Tumor sensitive detail...
FGFR3 N542K Infigratinib Advanced Solid Tumor sensitive detail...
FGFR3 S249C Dasatinib Advanced Solid Tumor resistant detail...
FGFR3 S249C Dasatinib + Infigratinib Advanced Solid Tumor sensitive detail...
FGFR3 N542K Dasatinib + Infigratinib Advanced Solid Tumor sensitive detail...
FGFR3 K652E Dasatinib + Infigratinib Advanced Solid Tumor sensitive detail...
PIK3CA act mut Temsirolimus Advanced Solid Tumor predicted - sensitive detail...
BRAF V600X ABM-1310 Advanced Solid Tumor predicted - sensitive detail...
NRAS G12D IHMT-RAF-128 Advanced Solid Tumor sensitive detail...
BRAF V600E IHMT-RAF-128 Advanced Solid Tumor sensitive detail...
BRAF K601E IHMT-RAF-128 Advanced Solid Tumor sensitive detail...
BRAF G469A IHMT-RAF-128 Advanced Solid Tumor sensitive detail...
HRAS G12D MRTX-1133 Advanced Solid Tumor no benefit detail...
NRAS G12D MRTX-1133 Advanced Solid Tumor no benefit detail...
HRAS G12D HRAS Q95H MRTX-1133 Advanced Solid Tumor sensitive detail...
NRAS G12D NRAS L95H MRTX-1133 Advanced Solid Tumor sensitive detail...
CDKN2A loss Palbociclib Advanced Solid Tumor no benefit detail...
CDKN2A loss Ribociclib Advanced Solid Tumor no benefit detail...
RET C634R Selpercatinib Advanced Solid Tumor sensitive detail...
RET C634R Pralsetinib Advanced Solid Tumor sensitive detail...
RET C620R Selpercatinib Advanced Solid Tumor sensitive detail...
RET C620R Pralsetinib Advanced Solid Tumor sensitive detail...
RET D631Y Selpercatinib Advanced Solid Tumor sensitive detail...
RET D631Y Pralsetinib Advanced Solid Tumor sensitive detail...
RET D631_L633delinsE Selpercatinib Advanced Solid Tumor sensitive detail...
RET D631_L633delinsE Pralsetinib Advanced Solid Tumor sensitive detail...
RET D567N Selpercatinib Advanced Solid Tumor sensitive detail...
RET D567N Pralsetinib Advanced Solid Tumor sensitive detail...
RET D567Y Selpercatinib Advanced Solid Tumor sensitive detail...
RET D567Y Pralsetinib Advanced Solid Tumor sensitive detail...
RET G607C Selpercatinib Advanced Solid Tumor sensitive detail...
RET G607C Pralsetinib Advanced Solid Tumor sensitive detail...
RET D571N Selpercatinib Advanced Solid Tumor sensitive detail...
RET D571N Pralsetinib Advanced Solid Tumor sensitive detail...
RET E574D Selpercatinib Advanced Solid Tumor sensitive detail...
RET E574D Pralsetinib Advanced Solid Tumor sensitive detail...
RET D584N Selpercatinib Advanced Solid Tumor sensitive detail...
RET D584N Pralsetinib Advanced Solid Tumor sensitive detail...
IDH1 R132H HMPL-306 Advanced Solid Tumor predicted - sensitive detail...
IDH2 R140Q HMPL-306 Advanced Solid Tumor predicted - sensitive detail...
IDH2 R172K HMPL-306 Advanced Solid Tumor predicted - sensitive detail...
RET D898_E901del Cabozantinib Advanced Solid Tumor resistant detail...
RET D898_E901del Vandetanib Advanced Solid Tumor predicted - sensitive detail...
PIK3CA act mut Copanlisib Advanced Solid Tumor predicted - sensitive detail...
FGFR1 fusion Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 fusion Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 fusion Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
ROS1 D2113N Crizotinib Advanced Solid Tumor sensitive detail...
ROS1 D2113N Lorlatinib Advanced Solid Tumor sensitive detail...
ROS1 D2113N NUV-520 Advanced Solid Tumor sensitive detail...
ROS1 D2113N Repotrectinib Advanced Solid Tumor sensitive detail...
ROS1 D2113G Crizotinib Advanced Solid Tumor sensitive detail...
ROS1 D2113G Lorlatinib Advanced Solid Tumor sensitive detail...
ROS1 D2113G NUV-520 Advanced Solid Tumor sensitive detail...
ROS1 D2113G Repotrectinib Advanced Solid Tumor sensitive detail...
ROS1 D2113N TNO155 Advanced Solid Tumor sensitive detail...
ROS1 D2113N RMC-4550 Advanced Solid Tumor sensitive detail...
ROS1 D2113N Selumetinib Advanced Solid Tumor sensitive detail...
ROS1 D2113G TNO155 Advanced Solid Tumor sensitive detail...
ROS1 D2113G RMC-4550 Advanced Solid Tumor sensitive detail...
ROS1 D2113G Selumetinib Advanced Solid Tumor sensitive detail...
RET V804M FHND5071 Advanced Solid Tumor predicted - sensitive detail...
RET M918T FHND5071 Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_T488delinsF Sorafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_T488delinsF LXH 254 Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_T488delinsF Dabrafenib Advanced Solid Tumor predicted - resistant detail...
RET M918T Vepafestinib Advanced Solid Tumor sensitive detail...
CHEK2 mutant Olaparib Advanced Solid Tumor no benefit detail...
PTEN del Atezolizumab + Ipatasertib Advanced Solid Tumor no benefit detail...
PTEN inact mut Atezolizumab + Ipatasertib Advanced Solid Tumor no benefit detail...
PIK3CA act mut Atezolizumab + Ipatasertib Advanced Solid Tumor no benefit detail...
BRAF fusion Belvarafenib + Cobimetinib Advanced Solid Tumor predicted - sensitive detail...
PIK3CA act mut Copanlisib + Nivolumab Advanced Solid Tumor predicted - sensitive detail...
PTEN inact mut Copanlisib + Nivolumab Advanced Solid Tumor predicted - sensitive detail...
FGFR2 V564I Pemigatinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 V555M Pemigatinib Advanced Solid Tumor resistant detail...
PIK3CA P539R PIK3CA H1047R STX-478 Advanced Solid Tumor sensitive detail...
PIK3CA D350N PIK3CA H1047R STX-478 Advanced Solid Tumor sensitive detail...
RET mutant EP0031 Advanced Solid Tumor predicted - sensitive detail...
FBXW7 del Ceralasertib Advanced Solid Tumor sensitive detail...
FBXW7 del Adavosertib Advanced Solid Tumor sensitive detail...
FBXW7 del AZD7762 Advanced Solid Tumor sensitive detail...
FBXW7 del RP-6306 Advanced Solid Tumor sensitive detail...
ATM inact mut Ipilimumab + Nivolumab Advanced Solid Tumor no benefit detail...
EML4 - ALK ALK E1210K Ensartinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1123S Ensartinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK L1198F Ensartinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1269A Ensartinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1152R Ensartinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1174V Ensartinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK V1180L Ensartinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1123S Crizotinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1123S Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK G1123S Alectinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1123S Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1245C Brigatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK G1123S Lorlatinib Advanced Solid Tumor sensitive detail...
EML4 - ALK ALK F1245C Lorlatinib Advanced Solid Tumor sensitive detail...
BRAF N486_P490del Trametinib Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsF Trametinib Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsY Trametinib Advanced Solid Tumor predicted - sensitive detail...
BRAF V487_P492delinsA Trametinib Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsFS Trametinib Advanced Solid Tumor predicted - sensitive detail...
BRAF N486_P490del Vemurafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485_P490delinsF Vemurafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485_P490delinsY Vemurafenib Advanced Solid Tumor predicted - resistant detail...
BRAF V487_P492delinsA Vemurafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485_P490delinsFS Vemurafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485_P490delinsF Encorafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485_P490delinsY Encorafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485_P490delinsFS Encorafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485_P490delinsFS GDC0879 Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsFS Sorafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsFS Belvarafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsFS Lifirafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsFS Tovorafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsFS TAK-632 Advanced Solid Tumor predicted - sensitive detail...
BRAF N486_P490del Dabrafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsF Dabrafenib Advanced Solid Tumor predicted - resistant detail...
BRAF L485_P490delinsY Dabrafenib Advanced Solid Tumor predicted - resistant detail...
BRAF V487_P492delinsA Dabrafenib Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsFS Dabrafenib Advanced Solid Tumor predicted - resistant detail...
BRAF N486_P490del LXH 254 Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsF LXH 254 Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsY LXH 254 Advanced Solid Tumor predicted - sensitive detail...
BRAF V487_P492delinsA LXH 254 Advanced Solid Tumor predicted - sensitive detail...
BRAF L485_P490delinsFS LXH 254 Advanced Solid Tumor predicted - sensitive detail...
ALK F1174I Lorlatinib Advanced Solid Tumor sensitive detail...
ALK R1192P Lorlatinib Advanced Solid Tumor sensitive detail...
ALK Y1278S Lorlatinib Advanced Solid Tumor sensitive detail...
ALK G1269A Lorlatinib Advanced Solid Tumor sensitive detail...
NRAS G12C JDQ443 Advanced Solid Tumor sensitive detail...
HRAS G12C JDQ443 Advanced Solid Tumor sensitive detail...
HRAS G12C Sotorasib Advanced Solid Tumor sensitive detail...
NRAS G12C Sotorasib Advanced Solid Tumor sensitive detail...
NRAS G12C RM-018 Advanced Solid Tumor sensitive detail...
HRAS G12C RM-018 Advanced Solid Tumor sensitive detail...
ATM inact mut Radiotherapy + RP-3500 Advanced Solid Tumor predicted - sensitive detail...
NRAS mutant IK-595 Advanced Solid Tumor predicted - sensitive detail...
MLH1 negative Nivolumab Advanced Solid Tumor predicted - sensitive detail...
PIK3CA H1047R OKI-219 Advanced Solid Tumor predicted - sensitive detail...
EML4 - ALK ALK L1196P Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196P Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196P Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196P Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196P TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1196P Repotrectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK L1198R Lorlatinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK L1198R Alectinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK L1198R Ceritinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK L1198R Brigatinib Advanced Solid Tumor predicted - resistant detail...
EML4 - ALK ALK C1237Y Crizotinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1237Y Brigatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1237Y Ceritinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1237Y Alectinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1237Y Lorlatinib Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1237Y TPX-0131 Advanced Solid Tumor resistant detail...
EML4 - ALK ALK C1237Y Repotrectinib Advanced Solid Tumor resistant detail...
FGFR1 amp Erdafitinib Advanced Solid Tumor no benefit detail...
FGFR2 amp Erdafitinib Advanced Solid Tumor no benefit detail...
FGFR3 amp Erdafitinib Advanced Solid Tumor no benefit detail...
FGFR1 mutant Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR2 mutant Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
FGFR3 mutant Erdafitinib Advanced Solid Tumor predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00006199 Phase I Tipifarnib Topotecan Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32) Unknown status USA 0
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT00089245 Phase I Omburtamab I-131 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Terminated USA 0
NCT00313599 Phase I Lapatinib + Paclitaxel Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT00463060 Phase Ib/II Sunitinib Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer Completed USA 0
NCT00576654 Phase I Irinotecan Veliparib Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001) Completed USA | AUS 2
NCT00608361 Phase I Dasatinib Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Completed USA 0
NCT00610948 Phase I Everolimus Panitumumab Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment Completed USA 0
NCT00625378 Phase III Sorafenib Sorafenib Long Term Extension Program (STEP) Completed USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 9
NCT00658658 Phase I Panitumumab Panitumumab Pediatric Study Completed USA 0
NCT00665990 Phase I Bevacizumab + Cyclophosphamide + Sorafenib Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia Completed USA 0
NCT00697632 Phase I Glesatinib Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies Completed USA | CAN 1
NCT00740805 Phase I Aldoxorubicin + Cyclophosphamide + Veliparib Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT00756340 Phase I Bevacizumab + Everolimus A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors Completed USA 0
NCT00761644 Phase I Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus Doxil, Bevacizumab and Temsirolimus Trial Completed USA 0
NCT00770263 Phase I Erlotinib + Temsirolimus Erlotinib and Temsirolimus for Solid Tumors Completed USA 0
NCT00776867 Phase I Perifosine Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors Completed USA 0
NCT00781612 Phase II Ado-trastuzumab emtansine + Trastuzumab Ado-trastuzumab emtansine + Paclitaxel Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Docetaxel Ado-trastuzumab emtansine + Capecitabine Ado-trastuzumab emtansine + Pertuzumab A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies Recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 28
NCT00790816 Phase I Lapatinib + Paclitaxel Lapatinib Lapatinib + Trastuzumab Capecitabine + Lapatinib Lapatinib + Letrozole Capecitabine + Lapatinib + Oxaliplatin Gemcitabine + Lapatinib Docetaxel + Lapatinib Fluorouracil + Lapatinib + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Lapatinib + Leucovorin Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents Completed USA | NLD | ESP | CAN 1
NCT00854152 Phase I Apitolisib A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma Completed USA | GBR 0
NCT00858377 Phase I AMG 900 A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors Completed USA | AUS 0
NCT00889954 Phase I Autologous TGF beta resistant HER2 EBV CTLs Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy Completed USA 0
NCT00909831 Phase I Hydroxychloroquine + Temsirolimus Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment Completed USA 0
NCT00926640 Phase I Belinostat + Cisplatin + Etoposide A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers Completed USA 0
NCT00939770 Phase Ib/II Crizotinib Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed USA | CAN 0
NCT00940381 Phase I Cetuximab + Sirolimus Sirolimus and Cetuximab in Advanced Malignancies Completed USA 0
NCT00981890 Phase I Sunitinib Stereotactic Radiosurgery With Sunitinib for Brain Metastases Completed CAN 0
NCT00996892 Phase I Cobimetinib + Pictilisib Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT00999401 Phase I Sapacitabine + Seliciclib A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors Completed USA 0
NCT01004224 Phase I Infigratinib A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Completed USA | NLD | ITA | FRA | ESP | DEU | AUT | AUS 6
NCT01004861 Phase I Pexidartinib Safety Study of PLX108-01 in Patients With Solid Tumors Completed USA 0
NCT01012817 Phase Ib/II Topotecan + Veliparib Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer Active, not recruiting USA 0
NCT01014936 Phase I Tepotinib First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors Completed USA 0
NCT01015222 Phase I Methylnaltrexone Bromide Dasatinib Paclitaxel Bevacizumab Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies Completed USA 0
NCT01017640 Phase I Veliparib Mitomycin C + Veliparib Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors Completed USA 0
NCT01023737 Phase I Hydroxychloroquine + Vorinostat Hydroxychloroquine + Vorinostat in Advanced Solid Tumors Completed USA 0
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Completed USA 0
NCT01042535 Phase Ib/II Ad.p53-DC vaccine + Indoximod Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer Completed USA 0
NCT01058707 Phase I Sapanisertib Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies Completed USA | ESP 0
NCT01061788 Phase I Everolimus + Ganitumab + Panitumumab A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer Completed USA 0
NCT01063075 Phase II Carboplatin + Cetuximab + Fluorouracil A Study in Advanced Solid Tumors Completed USA | CAN 0
NCT01071941 Phase I Oncolytic HSV-1 rRp450 rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors Active, not recruiting USA 0
NCT01081808 Phase I EGFRBi-armed autologous activated T cells Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors Terminated USA 0
NCT01087554 Phase I Temsirolimus Everolimus Sirolimus Vorinostat Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer Active, not recruiting USA 0
NCT01087983 Phase I Lapatinib + Sirolimus Lapatinib + Metformin Lapatinib With Sirolimus or Metformin Completed USA 0
NCT01099358 Phase II Cetuximab + Cisplatin Fluorouracil Study in Advanced Solid Tumors Completed USA | CAN 0
NCT01106599 Phase I GDC-0623 A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 0
NCT01107522 Phase I Carboxyamidotriazole Orotate + Temozolomide Carboxyamidotriazole Orotate Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas Active, not recruiting USA 0
NCT01113476 Phase I Bevacizumab + Gemcitabine + Nab-paclitaxel Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies Completed USA 0
NCT01121588 Phase I Crizotinib An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) Terminated USA | ITA 5
NCT01122199 Phase I Everolimus + Ganitumab Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors Completed USA 0
NCT01138085 Phase I Trametinib + Uprosertib Safety, Pharmacokinetics (PK) of AKT and MEK Combination Completed USA 0
NCT01139723 Phase I Bevacizumab MINT1526A A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors Completed USA 0
NCT01164163 Phase I Ruxolitinib INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Completed USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA | GBR | FRA | ESP 0
NCT01184326 Phase I Everolimus + Pazopanib An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer Completed USA 0
NCT01187199 Phase I Bevacizumab Paclitaxel Carboplatin Sorafenib Temsirolimus Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer Active, not recruiting USA 0
NCT01197170 Phase I Erlotinib Everolimus Sorafenib Anastrozole Bevacizumab Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Completed USA 0
NCT01213238 Phase I Oxaliplatin Capecitabine Bevacizumab Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab Completed USA 0
NCT01218555 Phase I Lenalidomide Everolimus Study of Everolimus (RAD001)in Combination With Lenalidomide Completed USA 0
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Terminated USA 0
NCT01219699 Phase I Alpelisib Alpelisib + Fulvestrant A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene Completed USA | NLD | GBR | ESP | DEU 0
NCT01226316 Phase I Capivasertib Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN 3
NCT01231594 Phase I Dabrafenib Trametinib A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 1
NCT01237236 Phase I Ribociclib A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma. Completed USA | NLD | FRA 0
NCT01239134 Phase I TRX518 Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors Completed USA 0
NCT01240590 Phase Ib/II Cisplatin + Crolibulin Cisplatin A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Completed USA 0
NCT01248949 Phase I Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors Completed USA 0
NCT01249443 Phase I Carboplatin Vorinostat Paclitaxel Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Terminated USA 0
NCT01253707 Phase I AMG 337 A Study of AMG 337 in Subjects With Advanced Solid Tumors Completed USA 0
NCT01264432 Phase I Veliparib Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer Completed USA | CAN 0
NCT01266057 Phase I Hydroxychloroquine + Vorinostat Hydroxychloroquine + Sirolimus Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer Completed USA 0
NCT01273155 Phase I Belinostat Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction Completed USA 0
NCT01276210 Phase I Sorafenib Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases Completed USA 0
NCT01281150 Phase I Veliparib Paclitaxel Carboplatin Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 0
NCT01281176 Phase I Carboplatin + Vorinostat Paclitaxel + Vorinostat High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT01283945 Phase Ib/II Lucitanib Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors Completed ITA | FRA | ESP 0
NCT01285037 Phase I Cisplatin Cetuximab Merestinib A Study of LY2801653 in Advanced Cancer Completed USA 0
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed USA | GBR 0
NCT01287546 Phase I Emibetuzumab + Erlotinib Emibetuzumab + Trametinib Emibetuzumab A Study of LY2875358 in Participants With Advanced Cancer Completed USA 0
NCT01288430 Phase I DS-2248 A Study of DS-2248, in Subjects With Advanced Solid Tumors Terminated USA 0
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | CAN | AUS 0
NCT01294670 Phase Ib/II Etoposide + Vorinostat Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Completed USA | CAN 0
NCT01296555 Phase I Fulvestrant Taselisib Letrozole A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer Completed USA | FRA | ESP | CAN 0
NCT01296581 Phase I Vorolanib Safety Study of X-82 in Patients With Advanced Solid Tumors Completed USA 0
NCT01297452 Phase I Buparlisib + Carboplatin + Paclitaxel BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors Completed USA 0
NCT01299636 Phase I PM060184 Study of PM060184 in Patients With Advanced Solid Tumors Completed USA 0
NCT01302405 Phase I PRI-724 Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors Terminated USA 0
NCT01303341 Phase I Riluzole + Sorafenib Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma Active, not recruiting USA 0
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed USA | ITA | FRA | AUS 1
NCT01324479 Phase I Capmatinib Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors Completed USA | NLD | ITA | FRA | ESP | DEU | CAN | AUS 7
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Completed USA | CAN 0
NCT01326702 Phase Ib/II Veliparib Rituximab Bendamustine Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed USA 0
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Completed USA | ESP 1
NCT01336842 Phase I Cisplatin Panobinostat Pemetrexed Disodium Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors Completed USA 0
NCT01339871 Phase I Vorinostat Pazopanib Phase I Study of Pazopanib and Vorinostat Completed USA 0
NCT01346358 Phase I LY3022855 A Study of IMC-CS4 in Subjects With Advanced Solid Tumors Completed USA 0
NCT01347866 Phase I Gedatolisib PD-0325901 Irinotecan Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer Terminated USA | ITA | ESP | CAN 0
NCT01349660 Phase Ib/II Bevacizumab + Buparlisib Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme Completed USA 0
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN 0
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Completed USA | FRA | ESP | DEU 0
NCT01358331 Phase I MK-8353 A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) Terminated 0
NCT01362374 Phase I Enzalutamide Paclitaxel Docetaxel Ipatasertib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors Completed USA | GBR | FRA | ESP 0
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting USA 0
NCT01375699 Phase I Doxorubicin Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers Completed USA 0
NCT01375829 Phase I Ixabepilone + Temsirolimus Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01375842 Phase I Atezolizumab A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | GBR | FRA | ESP 0
NCT01376310 Phase II Docetaxel + Trametinib Erlotinib + Trametinib Trametinib Pemetrexed Disodium + Trametinib Carboplatin + Trametinib Nab-paclitaxel + Trametinib Gemcitabine + Trametinib Everolimus + Trametinib GSK1120212 Rollover Study Terminated USA | NLD | FRA | CAN 2
NCT01376505 Phase I HER2 Vaccine Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Completed USA 0
NCT01391533 Phase I SAR125844 Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Completed USA | ITA | FRA | ESP 0
NCT01392521 Phase I Copanlisib + Refametinib Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer Completed USA | NLD | DEU 0
NCT01393509 Phase I PU-H71 The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies Completed USA 0
NCT01405391 Phase I Lurbinectedin Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks Completed USA 0
NCT01407562 Phase I Carboplatin Paclitaxel Pazopanib Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors Terminated USA 0
NCT01411410 Phase I Copanlisib + Paclitaxel Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer Completed USA 0
NCT01417546 Phase I NHS-IL12 NHS-IL12 for Solid Tumors Completed USA 0
NCT01425008 Phase I Tovorafenib Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma Completed USA | GBR 0
NCT01433991 Phase Ib/II Golvatinib Lenvatinib E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) Terminated USA 0
NCT01434316 Phase I Dinaciclib + Veliparib Veliparib Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT01438554 Phase I Pazopanib + Trametinib Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed USA 0
NCT01443481 Phase I Dovitinib Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function Completed USA | NLD | ITA | DEU | BEL 1
NCT01445509 Phase I Bevacizumab Dasatinib Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors Completed USA 0
NCT01449058 Phase Ib/II Alpelisib + Binimetinib A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | AUS 1
NCT01449370 Phase I Serabelisib Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer Completed USA | GBR | ESP 0
NCT01449461 Phase Ib/II Brigatinib A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Completed 0
NCT01450384 Phase I Pemetrexed Disodium + Sorafenib Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT01458067 Phase I GSK2636771 A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency Completed USA | GBR 1
NCT01468922 Phase I Tivantinib Pazopanib Pazopanib and ARQ 197 for Advanced Solid Tumors Completed USA 0
NCT01470209 Phase I Buparlisib + Everolimus A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies Completed USA 0
NCT01472016 Phase I Docetaxel ABT-700 Cetuximab Erlotinib Fluorouracil + Irinotecan + Leucovorin Study of ABT-700 in Subjects With Advanced Solid Tumors Completed 0
NCT01473095 Phase I Miransertib Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma Completed USA 0
NCT01480154 Phase I Hydroxychloroquine + MK2206 Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Active, not recruiting USA 0
NCT01485042 Phase I Evofosfamide + Pazopanib Dose Escalation Study of Pazopanib Plus TH-302 Completed USA 0
NCT01494688 Phase I Emactuzumab Emactuzumab + Paclitaxel A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors Completed USA | FRA 0
NCT01497392 Phase I Gemcitabine Dovitinib Capecitabine Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers Completed USA 0
NCT01497626 Phase I Bortezomib + Lapatinib Lapatinib and Bortezomib in Patients With Advanced Malignancies Terminated USA 0
NCT01497704 Phase Ib/II Rivoceranib Dose-Escalation and Safety Trial of YN968D1 Completed USA 1
NCT01498484 Phase II EB-VST cells Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Completed USA 0
NCT01505569 Phase I Filgrastim Busulfan + Melphalan Etoposide + Ifosfamide Thiotepa Carboplatin Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Completed USA 0
NCT01508104 Phase Ib/II Dactolisib + Everolimus Everolimus Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors Terminated USA 0
NCT01518413 Phase I Irinotecan + Sorafenib Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Completed USA 0
NCT01520389 Phase I MM-151 Irinotecan Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Completed USA 0
NCT01522820 Phase I Rasdegafusp alfa Sirolimus Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Completed USA 0
NCT01522989 Phase I Fluorouracil + Oxaliplatin + Palbociclib PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies Unknown status USA 0
NCT01524978 Phase II Vemurafenib Cetuximab A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers Completed USA | GBR | FRA | ESP | DEU 1
NCT01525602 Phase I Paclitaxel + Pexidartinib Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Completed USA 0
NCT01526473 Phase I AVX901 A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 Completed USA 0
NCT01528046 Phase I Metformin Irinotecan + Temozolomide + Vincristine Sulfate Metformin in Children With Relapsed or Refractory Solid Tumors Completed USA 0
NCT01529593 Phase I Metformin + Temsirolimus Temsirolimus in Combination With Metformin in Patients With Advanced Cancers Active, not recruiting USA 0
NCT01531361 Phase I Sorafenib + Vemurafenib Crizotinib + Vemurafenib Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations Completed USA 0
NCT01531894 Phase II Afuresertib Continuation Study of the Oral AKT Inhibitor GSK2110183 Completed USA | CAN | AUS 2
NCT01532011 Phase I Erlotinib + Pralatrexate Erlotinib in Combination With Pralatrexate in Advanced Malignancies Completed USA 0
NCT01534598 Phase I 5-Fluoro-2-deoxycytidine + Tetrahydrouridine FdCyd and THU for Advanced Solid Tumors Completed USA 0
NCT01537107 Phase I Sirolimus + Vismodegib Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Completed USA 0
NCT01537744 Phase I Azacitidine + Romidepsin A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer Completed USA 0
NCT01540253 Phase I Buparlisib + Docetaxel PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic Completed USA 0
NCT01540526 Phase I Axitinib Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib Completed USA 0
NCT01548144 Phase I Crizotinib + Pazopanib Crizotinib + Pemetrexed Disodium Pazopanib + Pemetrexed Disodium Crizotinib + Pazopanib + Pemetrexed Disodium Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer Terminated USA 0
NCT01552356 Phase I Pazopanib Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors Active, not recruiting USA 0
NCT01552434 Phase I Bevacizumab + Cetuximab + Temsirolimus + Valproic acid Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab Active, not recruiting USA 0
NCT01553071 Phase I Safingol Fenretinide Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies Terminated USA 0
NCT01562275 Phase I Cobimetinib + Ipatasertib A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | ESP 0
NCT01562899 Phase II Binimetinib + Ganitumab A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 0
NCT01564251 Phase I GDC-0575 + Gemcitabine GDC-0575 A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma Completed USA | FRA 0
NCT01571024 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Buparlisib BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer Completed USA 0
NCT01576406 Phase I Crizotinib Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients Completed USA 0
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS 0
NCT01577745 Phase I MEDI0639 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors Completed USA 0
NCT01581541 Phase I PU-H71 PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment Terminated USA 0
NCT01582191 Phase I Everolimus + Vandetanib Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Active, not recruiting USA 0
NCT01587040 Phase Ib/II XL147 Voxtalisib Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen Completed USA | FRA | ESP | BEL 0
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA | NLD | GBR | FRA | ESP | AUS 1
NCT01588184 Phase III Bevacizumab An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study Completed NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT 13
NCT01588678 Phase I DS-3078a A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas Completed USA 0
NCT01588821 Phase II Cabozantinib Cabozantinib in Advanced Solid Malignancies Completed USA 0
NCT01591356 Phase I siRNA-EphA2-DOPC EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors Recruiting USA 0
NCT01593228 Phase III Carboplatin + Doxorubicin + Iniparib Iniparib + Paclitaxel Iniparib + Irinotecan Iniparib + Topotecan Carboplatin + Gemcitabine + Iniparib Iniparib Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial Completed USA | ITA | ESP | BEL 0
NCT01596140 Phase I Temsirolimus + Vemurafenib Everolimus + Vemurafenib Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer Completed USA 0
NCT01596270 Phase I Voxtalisib A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma Completed USA 0
NCT01606878 Phase I Dexamethasone + Doxorubicin + Vincristine Sulfate Cyclophosphamide + Topotecan Crizotinib Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed USA | CAN 0
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed USA | CAN 1
NCT01609556 Phase I Mirvetuximab Soravtansine First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors Completed USA | CAN 0
NCT01610570 Phase Ib/II Plicamycin Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma Terminated USA 0
NCT01624467 Phase II Necitumumab A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors Completed USA 0
NCT01624766 Phase I Denosumab + Everolimus Anakinra + Everolimus Anakinra or Denosumab and Everolimus in Advanced Cancer Completed USA 0
NCT01625156 Phase I Temsirolimus + Tivantinib Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed By Surgery Completed USA 0
NCT01625234 Phase Ib/II Ensartinib Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Completed USA 0
NCT01631279 Phase Ib/II TH-4000 A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors Terminated USA | NZL 0
NCT01633970 Phase I Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Capecitabine A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 0
NCT01634893 Phase I Hydroxychloroquine + Sorafenib Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors Completed USA 0
NCT01636479 Phase I SAR405838 Phase 1 Safety Testing of SAR405838 Completed USA | NLD | FRA 0
NCT01636622 Phase I Carboplatin + Paclitaxel + Vemurafenib Study of Vemurafenib, Carboplatin, and Paclitaxel Completed USA 0
NCT01638533 Phase I Romidepsin Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Active, not recruiting USA | CAN 0
NCT01639911 Phase I Alisertib + Pazopanib MLN8237 and Pazopanib in Combination for Solid Tumors Completed USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Terminated USA 0
NCT01653470 Phase I Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors Completed USA | CAN | BEL 0
NCT01654965 Phase I Pegfilgrastim + Tivantinib + Topotecan Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Completed USA 0
NCT01655225 Phase I LY3023414 + Midazolam Letrozole + LY3023414 LY3023414 A Study of LY3023414 in Participants With Advanced Cancer Completed USA | ITA 1
NCT01661400 Phase I Cyclophosphamide Thalidomide Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors Completed USA 0
NCT01661972 Phase Ib/II Aflibercept + Capecitabine Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer Completed USA 0
NCT01664000 Phase I thioureidobutyronitrile A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors Completed USA 0
NCT01670175 Phase I Cyclophosphamide + Sirolimus + Topotecan Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors Completed USA 0
NCT01673737 Phase I SAR260301 SAR260301 + Vemurafenib A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer Completed USA | CAN 0
NCT01677559 Phase I Alisertib + Nab-paclitaxel Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Completed USA 0
NCT01677741 Phase I Dabrafenib A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 2
NCT01683149 Phase I Sorafenib + Topotecan Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies Completed USA 0
NCT01693562 Phase Ib/II Durvalumab A Phase 1/2 Study to Evaluate MEDI4736 Completed USA | ITA | GBR | FRA | DEU | CAN | BEL 2
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed USA | GBR | FRA | ESP | DEU 1
NCT01697527 Phase II Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine + NY-ESO-1 peptide vaccine Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies Active, not recruiting USA 0
NCT01700270 Phase I Dovitinib + Fluvoxamine Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors. Completed USA | NLD 2
NCT01703481 Phase I Erdafitinib A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma Completed USA | FRA | ESP 0
NCT01708161 Phase I Alpelisib + Ganitumab A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors Terminated USA | ESP | CAN | BEL 0
NCT01709435 Phase I Cabozantinib Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors Completed USA | CAN 0
NCT01713972 Phase I Dabrafenib + Pazopanib Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors Completed USA 0
NCT01714739 Phase I Lirilumab + Nivolumab A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors Completed USA | ITA | FRA | ESP | CAN 1
NCT01723020 Phase I KRT-232 A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma Completed USA | NLD | FRA 0
NCT01725100 Phase I Trametinib A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies Completed USA 0
NCT01727869 Phase I Erlotinib + REGN1400 Cetuximab + REGN1400 REGN1400 Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer Completed USA 0
NCT01728311 Phase I BAY1082439 Open Label Study of BAY1082439 in Patients With Advanced Cancer Completed 3
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Completed USA 0
NCT01733004 Phase I Everolimus + MM-141 MM-141 Gemcitabine + MM-141 + Nab-paclitaxel A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors Completed USA | FRA 0
NCT01738139 Phase I Imatinib + Ipilimumab Ipilimumab and Imatinib Mesylate in Advanced Cancer Completed USA 0
NCT01738451 Phase I Dabrafenib A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors Completed USA | GBR | AUS 0
NCT01739764 Phase III Vemurafenib An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol Completed USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 15
NCT01741727 Phase II Depatuxizumab mafodotin A Study of ABT-414 in Subjects With Solid Tumors Completed USA | CAN 0
NCT01742286 Phase I Ceritinib Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 1
NCT01744652 Phase I Crizotinib + Dasatinib Dasatinib and Crizotinib in Advanced Cancer Completed USA 0
NCT01748825 Phase I Adavosertib MK-1775 for Advanced Solid Tumors Completed USA 0
NCT01749384 Phase I Bevacizumab + Tivantinib Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery Completed USA 0
NCT01750983 Phase I Ipilimumab + Lenalidomide Ipilimumab and Lenalidomide in Advanced Cancer Completed USA 0
NCT01752920 Phase I Derazantinib Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors Completed USA | ITA 0
NCT01760525 Phase I CGM097 A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors Completed USA | FRA | DEU 2
NCT01765543 Phase I Rifampin + Vemurafenib A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy Completed USA 4
NCT01767623 Phase I Vemurafenib A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients Completed USA | GBR | AUS 4
NCT01769768 Phase I Sonidegib Warfarin Bupropion Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Completed USA 0
NCT01772004 Phase I Avelumab Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) Completed USA | GBR | FRA | DEU | BEL 4
NCT01775423 Phase Ib/II Napabucasin A Study of BBI608 in Adult Patients With Advanced Malignancies Completed USA | CAN 0
NCT01778439 Phase I Brontictuzumab A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Completed USA 0
NCT01781429 Phase Ib/II Ulixertinib Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Completed USA 0
NCT01781455 Phase Ib/II Amcasertib A Study of BBI503 in Adult Patients With Advanced Solid Tumors Completed USA | CAN 0
NCT01784861 Phase Ib/II Everolimus + Vorolanib VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Terminated USA 0
NCT01787500 Phase I Cetuximab + Irinotecan + Vemurafenib Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT01789281 Phase III Everolimus + Octreotide acetate Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Completed USA | NLD | ITA | ESP 5
NCT01791088 Phase I Sirolimus Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery Completed USA 0
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed USA 0
NCT01804530 Phase I PLX7486 Gemcitabine + Nab-paclitaxel Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors Terminated USA 0
NCT01804634 Phase II Cyclophosphamide + Fludarabine + Melphalan + Sirolimus A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Recruiting USA 0
NCT01815294 Phase I Doxorubicin Pegylated liposomal doxorubicin A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer Completed USA | GBR | ESP | BEL 0
NCT01822522 Phase I Cabozantinib Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus Completed USA 0
NCT01822756 Phase I Ruxolitinib An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors Terminated USA 0
NCT01827384 Phase II Adavosertib + Carboplatin Temozolomide + Veliparib Everolimus Trametinib Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT01828554 Phase III Capecitabine Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight Completed USA 0
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated USA 1
NCT01831726 Phase II Dovitinib Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Completed USA 0
NCT01833169 Phase II Buparlisib BKM120 for Patients With PI3K-activated Tumors Completed USA 0
NCT01835184 Phase I Cabozantinib + Vemurafenib Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery Terminated USA 0
NCT01837667 Phase I Docetaxel + LB-100 Phase I Study of LB-100 With Docetaxel in Solid Tumors Completed USA 0
NCT01844583 Phase I Alisertib + Esomeprazole Alisertib + Rifampin Alisertib Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib Completed USA 0
NCT01844674 Phase I Tizanidine + Vemurafenib A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies Completed USA | CAN 3
NCT01849744 Phase I VS-4718 Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies Terminated USA 0
NCT01851369 Phase Ib/II Temozolomide + TRC102 TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas Completed USA 0
NCT01853046 Phase I Regorafenib Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Completed USA | CAN 0
NCT01858883 Phase I Nab-paclitaxel Filgrastim Itacitinib Gemcitabine Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors Completed USA 0
NCT01875705 Phase I Ravoxertinib A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA 0
NCT01876511 Phase II Pembrolizumab Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors Completed USA 0
NCT01877382 Phase I Milademetan A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas Completed USA 0
NCT01877811 Phase Ib/II RXDX-105 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Completed USA 0
NCT01884285 Phase I AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib AZD8186 First Time In Patient Ascending Dose Study Completed USA | GBR | ESP | CAN 0
NCT01885195 Phase II Binimetinib MEK162 for Patients With RAS/RAF/MEK Activated Tumors Completed USA 0
NCT01898078 Phase I Alisertib Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas Completed USA 0
NCT01898130 Phase II Bevacizumab Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy Completed USA 0
NCT01899053 Phase I Sapanisertib + Serabelisib Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies Completed USA | GBR | ESP 0
NCT01902173 Phase Ib/II Dabrafenib + Trametinib + Uprosertib Dabrafenib + Uprosertib Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Active, not recruiting USA 0
NCT01905228 Phase I CBL0137 A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas Completed USA 0
NCT01907802 Phase I Dabrafenib Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Terminated USA | CAN 0
NCT01908413 Phase I GDC-0917 Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma Terminated USA 0
NCT01910545 Phase I OTS167 Phase 1 Study of OTS167 in Patients With Solid Tumors Completed USA 0
NCT01915576 Phase I BAY1125976 Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients Completed USA | FRA | DEU 1
NCT01922752 Phase I CEP-37440 To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors Completed USA 0
NCT01923337 Phase I Alisertib + Irinotecan Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer Completed USA 0
NCT01924260 Phase I Alisertib + Gemcitabine Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer Completed USA 0
NCT01928459 Phase I Alpelisib + Infigratinib Phase 1b Trial of BGJ398/BYL719 in Solid Tumors Completed USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT01946074 Phase I ABT-165 ABT-165 + Budigalimab + Paclitaxel ABT-165 + Budigalimab ABT-165 + Paclitaxel ABT-165 + Fluorouracil + Irinotecan + Leucovorin A Study of ABT-165 in Subjects With Solid Tumors Completed USA 0
NCT01948297 Phase I Debio 1347 Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations Terminated USA | ESP 3
NCT01953926 Phase II Neratinib + Trastuzumab Fulvestrant + Neratinib + Trastuzumab Neratinib Neratinib + Paclitaxel Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations Terminated USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 5
NCT01954043 Phase I Dabrafenib + Rabeprazole + Rifampin A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors Completed USA | GBR | AUS 0
NCT01954316 Phase I CFI-400945 A Study of CFI-400945 Fumarate in Patients With Advanced Cancer Completed USA | CAN 0
NCT01967823 Phase II Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Completed USA 0
NCT01971489 Phase I Buparlisib + Cisplatin + Gemcitabine PI3K Inhibitor BKM120, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors Withdrawn USA 0
NCT01971515 Phase I M2698 First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies Completed USA 0
NCT01973868 Phase I Cetuximab + Regorafenib Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination Completed USA 0
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn USA 0
NCT01975831 Phase I Durvalumab + Tremelimumab A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab Completed USA 0
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Completed USA | FRA | ESP | DEU 3
NCT01981187 Phase II Encorafenib LGX818 for Patients With BRAFV600 Mutated Tumors Terminated USA 0
NCT01986166 Phase I Cobimetinib + Duligotuzumab A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS Completed USA | ESP 0
NCT01987362 Phase I TEN-010 A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously Completed USA 0
NCT01988896 Phase I Atezolizumab + Cobimetinib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | DEU | CAN | AUS 2
NCT01989546 Phase Ib/II Talazoparib Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Completed USA 0
NCT01989585 Phase Ib/II Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma Active, not recruiting USA 0
NCT01991938 Phase I VS-5584 Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma Terminated USA | GBR 0
NCT01992874 Phase I Pimasertib Relative Bioavailability of Pimasertib in Cancer Patients Completed USA 0
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed USA 0
NCT01999972 Phase I Axitinib + Crizotinib A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors Completed USA | GBR 0
NCT02000934 Phase I Mivavotinib A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Completed USA | ITA | GBR | ESP 0
NCT02002689 Phase II Sonidegib LDE225 for Patients With PTCH1 or SMO Mutated Tumors Terminated USA 0
NCT02004106 Phase I Cergutuzumab amunaleukin A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed USA | NLD | GBR | FRA | ESP 3
NCT02009631 Phase I Veliparib A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors Completed USA | NLD | ESP 0
NCT02012231 Phase Ib/II PLX8394 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated USA 0
NCT02014116 Phase I LY3009120 A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body Terminated USA | FRA | ESP | AUS 0
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed USA 0
NCT02015117 Phase I Trametinib Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases Active, not recruiting USA 0
NCT02022982 Phase Ib/II Palbociclib + PD-0325901 PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors Completed USA 0
NCT02025803 Phase I Capecitabine + TAS-114 A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors Completed USA 0
NCT02029001 Phase II Durvalumab + Tremelimumab Olaparib Pazopanib Nilotinib Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus) Recruiting FRA 0
NCT02033148 Phase I Icotinib Icotinib Hydrochloride in Treating Patients With Advanced Cancers Withdrawn 0
NCT02038673 Phase I ASP5878 An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors Completed USA 3
NCT02042989 Phase I Ixazomib + Vorinostat MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies Completed USA 0
NCT02048488 Phase Ib/II Belizatinib A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas Completed USA | GBR | ESP 2
NCT02048709 Phase I Navoximod IDO Inhibitor in Advanced Solid Tumors Completed USA 0
NCT02048943 Phase I Dovitinib + Gemcitabine + Nab-paclitaxel Nab-paclitaxel Dovitinib Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer Withdrawn USA 0
NCT02049593 Phase I Talazoparib + Temozolomide Irinotecan + Talazoparib PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 0
NCT02051751 Phase I Alpelisib + Paclitaxel A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Completed USA | ITA | FRA | ESP 0
NCT02052778 Phase Ib/II Futibatinib A Study of TAS-120 in Patients With Advanced Solid Tumors Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT02054806 Phase I Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) Completed 0
NCT02065063 Phase I Palbociclib + Trametinib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors Completed USA 0
NCT02069730 Phase I Selinexor A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes Active, not recruiting CAN 0
NCT02070406 Phase I Aldesleukin + Cyclophosphamide + Fludarabine NY-ESO-1 peptide vaccine Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies Terminated USA 0
NCT02070549 Phase I Trametinib Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Active, not recruiting USA | CAN 0
NCT02071862 Phase I Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Completed USA 0
NCT02073994 Phase I Ivosidenib Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation Completed USA | FRA 0
NCT02076997 Phase I Methotrexate Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate Completed USA 0
NCT02077933 Phase I Alpelisib + Everolimus Alpelisib + Everolimus + Exemestane Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors Completed USA | NLD | ITA | GBR | FRA | ESP | DEU 2
NCT02078752 Phase I PF-06647263 A Study Of PF-06647263 In Patients With Advanced Solid Tumors Terminated USA 0
NCT02079740 Phase Ib/II Navitoclax + Trametinib Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT02080078 Phase I Erlotinib + Theophylline A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline Terminated CAN 0
NCT02081495 Phase I Pegylated liposomal doxorubicin A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer Completed USA | ESP | CAN | BEL 0
NCT02082210 Phase Ib/II Emibetuzumab + Ramucirumab A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed USA 0
NCT02082665 Phase I Dabrafenib + Midazolam + Rosuvastatin Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam Completed USA | ESP 0
NCT02091141 Phase II Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Completed USA 0
NCT02095054 Phase I Cetuximab + Regorafenib Regorafenib and Cetuximab in Patients With Advanced Malignancy Completed USA 0
NCT02095132 Phase Ib/II Adavosertib + Irinotecan Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Completed USA | CAN 0
NCT02097225 Phase I Dabrafenib + Onalespib + Trametinib Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Unknown status USA 0
NCT02097810 Phase I Entrectinib Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1) Completed USA 1
NCT02098967 Phase I RO6839921 A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia. Completed USA | CAN 0
NCT02099058 Phase I Carboplatin + Telisotuzumab vedotin Erlotinib + Telisotuzumab vedotin Telisotuzumab vedotin Bevacizumab + Telisotuzumab vedotin Cetuximab + Telisotuzumab vedotin A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors Active, not recruiting USA | NLD | ITA | FRA | BEL 4
NCT02110563 Phase I DCR-MYC Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Terminated USA 0
NCT02111850 Phase Ib/II Aldesleukin + Anti-MAGE-A3-DP4 TCR T-cells + Cyclophosphamide + Fludarabine T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive Completed USA 0
NCT02112565 Phase I COH29 RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists Active, not recruiting USA 0
NCT02116777 Phase Ib/II Talazoparib + Temozolomide BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Completed USA 0
NCT02116803 Phase III Dovitinib An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective Completed USA | ITA | ESP | BEL | AUT 2
NCT02117648 Phase I Abemaciclib + Clarithromycin Abemaciclib A Study of LY2835219 in Participants With Cancer Completed USA 0
NCT02118337 Phase I Durvalumab + MEDI0680 A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies Completed USA | NLD | GBR | FRA | CAN | AUS 0
NCT02122770 Phase I Paclitaxel Docetaxel Itraconazole Carboplatin MLN4924 Fluconazole Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors Completed USA 0
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed 1
NCT02122913 Phase I Larotrectinib A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer Completed USA 0
NCT02124148 Phase I Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed Disodium + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Completed USA 0
NCT02124772 Phase I Trametinib Dabrafenib + Trametinib Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Completed USA | GBR | FRA | CAN | AUS 0
NCT02130466 Phase Ib/II Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) Completed 0
NCT02132754 Phase I Pembrolizumab MK-4166 Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) Completed 0
NCT02134067 Phase I VIC-1911 Paclitaxel Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors Terminated USA 0
NCT02138812 Phase I BAY1161909 + Paclitaxel Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel Terminated USA 0
NCT02142803 Phase I Bevacizumab + Sapanisertib MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Active, not recruiting USA 0
NCT02143401 Phase I Navitoclax + Sorafenib Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Active, not recruiting USA 0
NCT02143635 Phase I Siremadlin Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt Completed USA | NLD | FRA | ESP | DEU 3
NCT02145559 Phase I Metformin + Sirolimus Sirolimus A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors Completed USA 0
NCT02146222 Phase I Docetaxel + Vorolanib VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors Completed USA 0
NCT02150733 Phase I Tivantinib Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment Completed USA 0
NCT02152943 Phase I Everolimus + Letrozole + Trastuzumab Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Completed USA 0
NCT02155582 Phase I Copanlisib Copanlisib Pharmacodynamic Study Completed GBR | FRA | BEL 0
NCT02157792 Phase I Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine M6620 First in Human Study Completed USA | GBR 0
NCT02159989 Phase I Aflibercept + Sapanisertib MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery Completed USA 0
NCT02160041 Phase II Infigratinib BGJ398 for Patients With Tumors With FGFR Genetic Alterations Terminated USA 0
NCT02160106 Phase I Vactosertib First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors Completed USA 0
NCT02161770 Phase I Osimertinib Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment Completed USA | GBR | FRA | ESP | BEL 1
NCT02162888 Phase I Bendamustine A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients Completed USA 0
NCT02164838 Phase I Axitinib VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Completed USA | CAN 0
NCT02168777 Phase Ib/II Refametinib + Regorafenib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated USA 0
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-aATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Unknown status USA 0
NCT02174172 Phase I Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | NLD 0
NCT02179918 Phase I Utomilumab Pembrolizumab A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) Completed USA 0
NCT02186821 Phase II Ceritinib Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) Terminated USA 0
NCT02187783 Phase II Ribociclib LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Completed USA 0
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting USA | FRA | ESP | CAN 1
NCT02188264 Phase I Cyclosporine Selumetinib Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer Active, not recruiting USA | CAN 0
NCT02189174 Phase Ib/II CLR457 Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies Terminated USA | ESP | CAN 2
NCT02194049 Phase I Buparlisib + Cisplatin + Etoposide Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer Completed USA 0
NCT02197572 Phase I Sapanisertib Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors Completed USA 0
NCT02201212 Phase II Everolimus Everolimus for Cancer With TSC1 or TSC2 Mutation Completed USA 0
NCT02205333 Phase Ib/II Rituximab MEDI6469 Tremelimumab Durvalumab A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies Terminated USA 0
NCT02211755 Phase I Bortezomib + Clofarabine Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors Recruiting USA 0
NCT02214147 Phase I Alisertib Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function Completed USA 0
NCT02216409 Phase I Hu5F9-G4 Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody Completed USA 0
NCT02219711 Phase I Sitravatinib Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer Completed USA 1
NCT02219724 Phase I Vonlerolizumab A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | ESP | CAN | BEL | AUS 1
NCT02221882 Phase I LY3164530 A Study of LY3164530 in Participants With Cancer Completed USA 0
NCT02221960 Phase I Durvalumab Efizonerimod A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors Completed USA | AUS 0
NCT02222922 Phase I Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Completed USA | ESP 0
NCT02223247 Phase I TVB-2640 A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors Completed USA | GBR 0
NCT02224599 Phase Ib/II Autologous TAPA-pulsed dendritic cell vaccine + Cyclophosphamide Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies Terminated USA 0
NCT02227940 Phase I Ceritinib + Gemcitabine + Nab-paclitaxel Ceritinib + Cisplatin + Gemcitabine Ceritinib + Gemcitabine Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer Completed USA 0
NCT02228811 Phase I Altiratinib A Study of DCC-2701 in Participants With Advanced Solid Tumors Terminated USA 0
NCT02232243 Phase I Hydroxychloroquine HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors Completed USA 0
NCT02239900 Phase Ib/II Ipilimumab Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors Completed USA 0
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed USA | ITA 3
NCT02243917 Phase I CB-5083 A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors Terminated USA 0
NCT02250157 Phase I Oratecan A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Completed USA 0
NCT02250781 Phase I ONC201 Akt/ERK Inhibitor ONC201 in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT02253420 Phase I Copanlisib Itraconazole COPANLISIB (BAY80-6946) Drug-drug Interaction Study in Advanced Solid Tumor Patients Completed USA | CAN 0
NCT02253992 Phase Ib/II Nivolumab + Urelumab Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma Terminated USA | FRA | ESP | DEU 0
NCT02259010 Phase I Alisertib Itraconazole A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma Completed USA 0
NCT02260661 Phase I Fulvestrant AZD8835 Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours Completed USA | GBR 0
NCT02261220 Phase I Durvalumab + Tremelimumab A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors Completed USA | NLD | GBR | FRA | ESP | DEU | CAN 2
NCT02264613 Phase Ib/II ALRN-6924 Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors Completed USA 0
NCT02264678 Phase Ib/II Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA | GBR | FRA | ESP | CAN | BEL | AUS 2
NCT02265510 Phase I Gemcitabine Carfilzomib Dexamethasone Lenalidomide Nab-paclitaxel Azacitidine INCB052793 Bortezomib An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Terminated USA 0
NCT02266745 Phase I Imifoplatin A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors Active, not recruiting USA | FRA 0
NCT02272998 Phase II Ponatinib Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. Active, not recruiting USA 0
NCT02273739 Phase Ib/II Enasidenib Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed USA | FRA 0
NCT02278250 Phase I VX-803 Carboplatin + VX-803 An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors Completed USA | NLD | GBR | ESP 0
NCT02279433 Phase I Taletrectinib A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Completed USA 0
NCT02281409 Phase Ib/II Mogamulizumab Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Completed USA 0
NCT02285439 Phase Ib/II Binimetinib Study of MEK162 for Children With Low-Grade Gliomas Active, not recruiting USA 0
NCT02286687 Phase II Talazoparib Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Active, not recruiting USA 0
NCT02287311 Phase I LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) Recruiting USA 0
NCT02298387 Phase I Navicixizumab A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors Completed USA 0
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT02301117 Phase I Trifluridine-tipiracil hydrochloride A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment Completed USA 2
NCT02301130 Phase I Mogamulizumab Durvalumab Tremelimumab Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors Completed USA 0
NCT02303028 Phase Ib/II Pazopanib + Topotecan Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours Completed CAN 0
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Completed USA 0
NCT02304393 Phase I Selicrelumab Atezolizumab A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors Completed USA | NLD | FRA | ESP | CAN 1
NCT02304419 Phase I Galunisertib A Study of Galunisertib on the Immune System in Participants With Cancer Completed USA 0
NCT02304458 Phase Ib/II Ipilimumab + Nivolumab Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Completed USA | CAN 0
NCT02307240 Phase I CUDC-907 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Completed USA 0
NCT02312804 Phase I Paclitaxel Carboplatin Infigratinib Ph Ib/BGJ398/Cervix and Other Solid Tumors Withdrawn 0
NCT02313012 Phase I CC-90003 Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors Terminated USA | AUS 0
NCT02317874 Phase I Carboplatin + Paclitaxel + Talazoparib Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer Completed USA 0
NCT02318277 Phase Ib/II Durvalumab + Epacadostat A Study of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors Completed USA 0
NCT02318329 Phase I Bemarituzumab Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors Completed USA 2
NCT02318394 Phase I Tavolimab A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors Completed USA 1
NCT02318901 Phase Ib/II Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated USA 0
NCT02321501 Phase I Ceritinib + Everolimus Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT02323880 Phase I Selinexor Study of Selinexor in Pediatric Solid Tumors Active, not recruiting USA 0
NCT02324621 Phase I ONC201 Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT02325739 Phase Ib/II FGF401 Safety and Efficacy of FGF401 in Patients With Solid Malignancies Completed USA | ITA | FRA | ESP | DEU 6
NCT02327169 Phase I Sapanisertib + Tovorafenib Alisertib + Tovorafenib Paclitaxel + Tovorafenib A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies Completed USA | GBR | FRA | ESP 0
NCT02331251 Phase Ib/II Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) Terminated USA 0
NCT02332668 Phase Ib/II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Recruiting USA | NLD | ITA | GBR | FRA | DEU 4
NCT02341456 Phase I Adavosertib Carboplatin Paclitaxel Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours Completed AUS 2
NCT02343718 Phase I Temsirolimus + Vinblastine Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours Completed CAN 0
NCT02350673 Phase I Cergutuzumab amunaleukin Atezolizumab A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors Completed USA | NLD | ESP | CAN 2
NCT02352844 Phase II Everolimus Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations Completed USA 0
NCT02354547 Phase I Cyclophosphamide + SGT-53 + Topotecan A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors Suspended USA 0
NCT02354612 Phase Ib/II Axitinib + Carotuximab Carotuximab + Pazopanib Capecitabine + Carotuximab Carotuximab Bevacizumab + Carotuximab An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy No longer available USA 0
NCT02355535 Phase I PAC-1 Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies Completed USA 0
NCT02358200 Phase I Carboplatin + Paclitaxel + Talazoparib Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer Terminated USA 0
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated USA | ESP 0
NCT02366949 Phase I BAY1217389 + Paclitaxel Paclitaxel Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel Completed USA | NLD 0
NCT02367196 Phase I CC-90002 + Rituximab CC-90002 A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers Completed USA | ESP 0
NCT02368951 Phase I Aprutumab ixadotin Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2) Terminated USA 2
NCT02369029 Phase I BAY 1238097 BAY1238097, First in Man Terminated USA | GBR | FRA | DEU 2
NCT02376699 Phase I Pembrolizumab + SEA-CD40 SEA-CD40 Safety Study of SEA-CD40 in Cancer Patients Terminated USA 0
NCT02379416 Phase I Nab-paclitaxel + Nilotinib Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors Recruiting USA 0
NCT02379520 Phase I Cyclophosphamide + Fludarabine + HPVST cells + Nivolumab HPVST cells HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA) Active, not recruiting USA 0
NCT02381886 Phase I IDH305 A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations Active, not recruiting USA | NLD | ESP | DEU | CAN | BEL | AUS 1
NCT02383212 Phase I Carboplatin + Cemiplimab + Docetaxel Carboplatin + Cemiplimab + Pemetrexed Disodium Cemiplimab + Cyclophosphamide + Sargramostim Cemiplimab + Cyclophosphamide Cemiplimab Carboplatin + Cemiplimab + Paclitaxel Cemiplimab + Docetaxel Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies Completed USA | ESP | AUS 0
NCT02386501 Phase Ib/II ADXS31-164 Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors Completed USA 0
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Terminated USA 0
NCT02389309 Phase I Cyclophosphamide + Dasatinib + Temsirolimus A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT02390752 Phase Ib/II Pexidartinib PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting USA 0
NCT02390843 Phase I Cyclophosphamide + Filgrastim + Simvastatin + Topotecan Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors (AflacST1402) Completed USA 0
NCT02391480 Phase I Mivebresib A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Completed USA 0
NCT02391727 Phase I SYN004 Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors (SYN004_Ph_1) Completed USA 0
NCT02392611 Phase I Exemestane + GS-5829 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas Completed USA 0
NCT02392793 Phase I Irinotecan + Talazoparib Temozolomide Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies Completed USA 0
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Terminated USA 1
NCT02401815 Phase Ib/II PLX9486 + Sunitinib Pexidartinib + PLX9486 PLX9486 PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors Completed USA 0
NCT02404441 Phase Ib/II Spartalizumab Phase I/II Study of PDR001 in Patients With Advanced Malignancies Completed USA | NLD | ITA | FRA | ESP | DEU | CAN 7
NCT02404480 Phase I PTC596 PTC596 in Patients With Advanced Solid Tumors Completed USA | CAN 0
NCT02407509 Phase I RO5126766 Everolimus + RO5126766 Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK) Recruiting GBR 0
NCT02407990 Phase I Tislelizumab Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors Completed USA | NZL | AUS 2
NCT02408861 Phase I Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors Recruiting USA | AUS 0
NCT02410512 Phase I Vonlerolizumab Atezolizumab A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP | CAN | BEL | AUS 1
NCT02412462 Phase I AB-16B5 Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy Completed CAN 0
NCT02412722 Phase I Sapanisertib Paclitaxel Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies Completed USA 0
NCT02414516 Phase I OBP-801 A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors Unknown status USA 0
NCT02414724 Phase I Gemcitabine + Ribociclib Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma Terminated USA 0
NCT02419417 Phase Ib/II BMS986158 Paclitaxel Study of BMS-986158 in Subjects With Select Advanced Solid Tumors Completed USA | FRA | ESP | CAN | AUS 0
NCT02419495 Phase I Cyclophosphamide Pemetrexed Disodium Eribulin Selinexor Carboplatin Paclitaxel Topotecan Dexamethasone Doxorubicin Selinexor in Combination With Standard Chemotherapy Active, not recruiting USA 0
NCT02422589 Phase I Warfarin Midazolam Ceritinib A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors Completed USA | ITA | ESP 1
NCT02423057 Phase I TdCyd Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors Suspended USA 0
NCT02423343 Phase Ib/II Galunisertib Nivolumab A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma Completed USA | ESP 0
NCT02423954 Phase Ib/II Temsirolimus Nivolumab Capecitabine Irinotecan Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) Terminated USA 0
NCT02428712 Phase Ib/II PLX8394 A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors Active, not recruiting USA 0
NCT02431260 Phase I INCB054329 An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies Terminated USA 0
NCT02432274 Phase Ib/II Etoposide Lenvatinib Cyclophosphamide Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies Completed USA | ITA | GBR | FRA | ESP | DEU 0
NCT02432326 Phase I Amcasertib Napabucasin A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors Completed USA 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT02439723 Phase I Regorafenib Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients Withdrawn CAN 0
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated USA 1
NCT02442297 Phase I HER2 sensitized T-cells T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR) Active, not recruiting USA 0
NCT02442414 Phase I Pirotinib A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors Completed USA 0
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated USA 0
NCT02448589 Phase I VIC-1911 An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel Terminated USA | NLD | ITA | GBR | ESP 0
NCT02451553 Phase I Afatinib Capecitabine Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer Completed USA 0
NCT02452268 Phase I NIZ985 + Spartalizumab A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers Terminated USA 0
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated USA 0
NCT02453620 Phase I Entinostat + Ipilimumab + Nivolumab Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer Active, not recruiting USA 0
NCT02454010 Phase I FF-21101(90Y) A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer Completed USA 0
NCT02456883 Phase I Gilteritinib Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors Completed USA 0
NCT02457351 Phase I Roniciclib Itraconazole Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study Completed CAN 0
NCT02457793 Phase I Cobimetinib Ravoxertinib A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA 0
NCT02458638 Phase II Atezolizumab An Open Label Study of MPDL3280A in Advanced Solid Tumors Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT 9
NCT02460224 Phase Ib/II Ieramilimab Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT02465060 Phase II Nivolumab + Relatlimab Dabrafenib + Trametinib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Active, not recruiting USA 2
NCT02466802 Phase I Regorafenib Sildenafil Study of Regorafenib and Sildenafil for Advanced Solid Tumors Completed USA 0
NCT02467361 Phase Ib/II Nivolumab Pembrolizumab Ipilimumab Napabucasin A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers Completed USA 0
NCT02471846 Phase I Navoximod Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02473497 Expanded access Crizotinib Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients No longer available USA 0
NCT02476955 Phase I Miransertib Carboplatin + Paclitaxel Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel Terminated USA 0
NCT02478320 Phase II ABT-348 Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors Terminated USA 0
NCT02481154 Phase I Vorasidenib Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation Active, not recruiting USA 0
NCT02482168 Phase I Sotigalimab Study of the CD40 Agonistic Monoclonal Antibody APX005M Completed USA 0
NCT02482441 Phase I Rosmantuzumab Fluorouracil + Irinotecan + Leucovorin A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Completed USA 0
NCT02483247 Phase Ib/II Paclitaxel Doxorubicin Capecitabine Nivolumab Sunitinib Pembrolizumab Amcasertib A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer Completed USA | CAN 0
NCT02483858 Phase I PQR309 Study of Oral PQR309 in Patients With Advanced Solid Tumors Completed USA 0
NCT02484404 Phase Ib/II Cediranib + Durvalumab Durvalumab + Olaparib Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer Recruiting USA 0
NCT02490800 Phase Ib/II BAL101553 Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma Completed GBR | DEU | BEL 1
NCT02494258 Phase II Azacitidine A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders. Active, not recruiting USA | GBR 0
NCT02499328 Phase Ib/II Danvatirsen + Durvalumab AZD5069 + Durvalumab Durvalumab Danvatirsen Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck Active, not recruiting USA | ITA | GBR | ESP | DEU | BEL 0
NCT02499861 Phase Ib/II Decitabine + Genistein Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies Completed CAN 0
NCT02500199 Phase I Pyrotinib Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Unknown status USA 0
NCT02503423 Phase Ib/II ASTX-660 Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL 1
NCT02503709 Phase I AT7519 Onalespib Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT02503774 Phase I Durvalumab Oleclumab MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors Completed USA | AUS 1
NCT02506517 Phase II Afatinib A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene Completed CAN 0
NCT02508532 Phase I Avapritinib Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT02511795 Phase I Adavosertib Olaparib AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors Completed USA | CAN 0
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Completed USA | FRA | ESP | DEU | BEL 1
NCT02516813 Phase I Peposertib Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy Completed USA | NLD | DEU | BEL 4
NCT02517398 Phase I Bintrafusp alfa MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT02517918 Phase I Cyclophosphamide + Methotrexate + Sirolimus + Zoledronic acid Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma a (METZOLIMOS) Completed FRA 0
NCT02518958 Phase I Nivolumab A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab Completed USA 0
NCT02520752 Phase I Midazolam Capmatinib A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP 2
NCT02521844 Phase I ETC-159 A Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours Active, not recruiting USA 1
NCT02527434 Phase II Durvalumab + Tremelimumab Durvalumab Study of Tremelimumab in Patients With Advanced Solid Tumors Completed USA | NLD | BEL 2
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | NLD | FRA | CAN 0
NCT02529553 Phase I LY3076226 A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Completed USA | CAN 0
NCT02536183 Phase I ThermoDox A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Terminated USA 0
NCT02537418 Phase I Cisplatin + Etoposide Durvalumab Tremelimumab Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens Active, not recruiting CAN 0
NCT02537561 Phase I Talazoparib Cisplatin + Gemcitabine Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors Withdrawn 0
NCT02540876 Phase I ABT-348 Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery Completed USA 0
NCT02541604 Phase I Atezolizumab A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors Terminated USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN 3
NCT02546531 Phase I Defactinib + Gemcitabine + Pembrolizumab Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer Completed USA 0
NCT02549937 Phase I Surufatinib A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors Completed USA | ITA 0
NCT02551055 Phase I Docetaxel Paclitaxel Alisertib Mivavotinib Serabelisib MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma Terminated USA | ESP 0
NCT02551185 Phase I Citarinostat ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors Completed USA 0
NCT02552953 Phase I CYC065 A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers Completed USA 0
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Terminated USA | GBR | FRA | CAN | AUS 3
NCT02556463 Phase I MEDI9197 Durvalumab + MEDI9197 A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors Terminated USA | FRA | CAN 0
NCT02558140 Phase I RG7386 A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 0
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02561234 Phase I Pegzilarginase A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Completed USA 0
NCT02561455 Phase Ib/II Gilteritinib Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial Completed USA 0
NCT02564198 Phase I Ramucirumab A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Completed USA 0
NCT02564900 Phase I Trastuzumab deruxtecan Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors Completed USA 1
NCT02565758 Phase I Gemcitabine Nivolumab Nab-paclitaxel ABBV-085 ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors Completed USA | FRA | ESP 0
NCT02567396 Phase I Talazoparib Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Withdrawn 0
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 7
NCT02571036 Phase I Ripretinib A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Completed USA | NLD | ITA | GBR | DEU | CAN 0
NCT02574728 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting USA 0
NCT02575638 Phase I CZ48 Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48) Unknown status USA 0
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed FRA | ESP 1
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Active, not recruiting USA | FRA | ESP | DEU 14
NCT02576444 Phase II Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib OLAParib COmbinations (OLAPCO) Terminated USA 0
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Terminated USA 0
NCT02579226 Phase I Irinotecan AZD2811 A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors Completed USA 0
NCT02582827 Phase I ABI-011 QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas Withdrawn USA 0
NCT02584933 FDA approved Ceritinib Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUS 14
NCT02586987 Phase I Durvalumab + Selumetinib A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours Completed USA 0
NCT02587598 Phase Ib/II INCB053914 Study of INCB053914 in Subjects With Advanced Malignancies Terminated USA 0
NCT02587962 Phase Ib/II Birinapant + Pembrolizumab Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors Terminated USA 0
NCT02588105 Phase I Olaparib AZD0156 Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer Completed USA | GBR | ESP 1
NCT02593708 Phase I Neratinib + Paclitaxel + Pertuzumab + Trastuzumab Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ Terminated USA 0
NCT02595866 Phase I Pembrolizumab Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms Active, not recruiting USA 0
NCT02595931 Phase I Berzosertib + Irinotecan VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT02597036 Phase I LY3127804 Ramucirumab A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Completed USA | FRA | ESP | BEL 0
NCT02598960 Phase Ib/II Nivolumab BMS-986156 A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors Completed USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS 1
NCT02601950 Phase II Tazemetostat A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Active, not recruiting USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS 1
NCT02605083 Phase Ib/II Tomivosertib A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors Terminated USA 0
NCT02607813 Phase I LXH 254 + Spartalizumab LXH 254 Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations Terminated USA | NLD | ITA | FRA | ESP | DEU | CAN 3
NCT02608125 Phase I PRN1371 A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma Terminated USA | ESP 0
NCT02608268 Phase Ib/II Spartalizumab Sabatolimab Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Terminated USA | NLD | ITA | CAN 5
NCT02608385 Phase I Pembrolizumab Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors Active, not recruiting USA 0
NCT02609230 Phase I ONC201 A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma Completed USA 0
NCT02610075 Phase I Adavosertib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. Completed USA 0
NCT02610361 Phase I Lifirafenib Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors Completed NZL | AUS 0
NCT02612285 Phase II SNX-5422 Study of SNX-5422 in TP53 Null Cancers Terminated USA 0
NCT02614456 Phase I Nivolumab Interferon gamma Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors Completed USA 0
NCT02617277 Phase I Adavosertib + Durvalumab Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours Active, not recruiting USA 0
NCT02620839 Phase I Alpelisib + Cisplatin Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies Terminated USA 0
NCT02624388 Phase II Genistein Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Terminated USA 0
NCT02626234 Phase I Capmatinib A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors Completed USA | ITA | GBR | ESP | BEL | AUT 2
NCT02627274 Phase I RO6874281 A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors Completed USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL 1
NCT02627430 Phase I Onalespib + Talazoparib Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | AUS 15
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN | AUS 0
NCT02628574 Phase I TRX518 Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors Completed USA 0
NCT02630368 Phase Ib/II Avelumab + Cyclophosphamide + JX-594 Cyclophosphamide + JX-594 Cyclophosphamide A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX) Recruiting FRA 0
NCT02631733 Phase I Liposomal irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors Active, not recruiting USA 0
NCT02632448 Phase Ib/II Gemcitabine + LY2880070 LY2880070 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Recruiting USA | CAN 2
NCT02632994 Expanded access LY3023414 LY2503029 Master Rollover Protocol for Continued Safety Assessment of Study Drug Available USA 0
NCT02635672 Phase I VIP152 Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer Active, not recruiting USA | ESP 1
NCT02637687 Phase I Larotrectinib A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 12
NCT02642016 Phase I CDX-0158 A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors Completed USA 0
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Completed USA 0
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting CAN 0
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Completed USA 0
NCT02646319 Phase I Nab-rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed USA 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT02646852 Phase I PLX038 A Phase I Study of PLX038 in Patients With Advanced Solid Tumors Completed USA 0
NCT02648490 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers Completed USA 1
NCT02648711 Phase I NLG207 Bevacizumab Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors Terminated USA 0
NCT02648724 Phase Ib/II SYM015 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies Completed USA | ESP 4
NCT02650401 Phase I Entrectinib Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 4
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated USA 0
NCT02650713 Phase I Atezolizumab + RO6958688 A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors Completed USA | NLD | ITA | FRA | ESP | CAN 1
NCT02650986 Phase Ib/II Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + TGFbDNRII-transduced autologous TILs Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Active, not recruiting USA 0
NCT02651727 Phase I Gemcitabine + Nab-paclitaxel + VS-4718 Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects Terminated USA 0
NCT02653196 Phase II Thiotepa Etoposide Alemtuzumab Palifermin Fludarabine + Melphalan Cyclosporine + Mycophenolate mofetil + Tacrolimus A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors Terminated USA 0
NCT02656849 Phase II Roniciclib BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors Withdrawn USA 0
NCT02658890 Phase Ib/II Ipilimumab + Linrodostat + Nivolumab Linrodostat + Nivolumab An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread Completed USA | ITA | FRA | ESP | DEU | CAN | AUS 4
NCT02659631 Phase I PF-06671008 PF-06671008 Dose Escalation Study in Advanced Solid Tumors Terminated USA 0
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed USA | NZL | GBR | FRA | ESP | AUS 0
NCT02661542 Phase Ib/II FF-10502 Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas Completed USA 0
NCT02665416 Phase I RO5520985 + Selicrelumab Bevacizumab + Selicrelumab Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors Completed USA | NLD | ITA | ESP | CAN | BEL 1
NCT02667873 Phase I SL-801 A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors Completed USA 0
NCT02668770 Phase I Ipilimumab + Lefitolimod Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies Active, not recruiting USA 0
NCT02669914 Phase II Durvalumab MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Terminated USA 0
NCT02671955 Phase I Onvatilimab A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated USA 0
NCT02673736 Phase I AC708 A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor Terminated USA 0
NCT02674555 Phase I Naquotinib A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors Withdrawn 0
NCT02675439 Phase I Ipilimumab + MIW815 MIW815 Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas Terminated USA 0
NCT02675829 Phase II Ado-trastuzumab emtansine Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers Recruiting USA 0
NCT02675946 Phase I CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) Unknown status USA 1
NCT02677116 Phase I Doxorubicin Ifosfamide Irinotecan + Vincristine Sulfate Olaratumab A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer Completed USA 1
NCT02679131 Phase I Belinostat To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. Terminated USA 0
NCT02680795 Phase I Belinostat To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes Completed USA 0
NCT02683395 Phase I PLX51107 A Study of PLX51107 in Advanced Malignancies Terminated USA 0
NCT02686164 Phase I Lenvatinib + Midazolam Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors Completed USA 0
NCT02688088 Phase I Abemaciclib Caffeine + Dextromethorphan + Midazolam + Warfarin A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body Completed USA 0
NCT02689336 Phase II Erlotinib + Temozolomide Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors Withdrawn 0
NCT02693535 Phase II Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) Recruiting USA 0
NCT02694822 Phase I Zalifrelimab AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers Completed USA 0
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT02702492 Phase I KPT-9274 KPT-9274 + Niacin PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA) Terminated USA | CAN 0
NCT02703571 Phase Ib/II Ribociclib + Trametinib Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors Terminated USA | NLD | ESP | DEU | CAN | BEL | AUS 0
NCT02705105 Phase Ib/II Mogamulizumab + Nivolumab Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors Completed USA 0
NCT02705482 Phase I Tavolimab + Tremelimumab Durvalumab + Tavolimab A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors Completed USA | NLD | FRA 0
NCT02705963 Phase I Trametinib A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors Completed USA | NLD | GBR | ESP | BEL 0
NCT02709889 Phase Ib/II Rovalpituzumab Tesirine Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Terminated USA 0
NCT02711137 Phase Ib/II INCB057643 A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies Terminated USA | FRA | BEL 0
NCT02712905 Phase Ib/II INCB059872 An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies Terminated USA | NLD | BEL 0
NCT02715284 Phase I Dostarlimab-gxly A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET) Recruiting USA | ITA | GBR | FRA | ESP | CAN 7
NCT02716116 Phase Ib/II Mobocertinib A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer Active, not recruiting USA | ITA | GBR | ESP | DEU 5
NCT02718911 Phase I LY3022855 + Tremelimumab Durvalumab + LY3022855 A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors Completed USA | BEL 2
NCT02719691 Phase I Alisertib + Sapanisertib Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer Completed USA 0
NCT02720068 Phase I MK-4280 + Pembrolizumab MK-4280 Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001) Completed 0
NCT02722954 Phase I Demcizumab + Pembrolizumab A Study of Demcizumab Plus Pembrolizumab +/- Chemotherapy Completed USA | GBR 0
NCT02723864 Phase I Berzosertib + Cisplatin + Veliparib Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors Completed USA 0
NCT02729298 Phase I Dubermatinib First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors Completed USA 0
NCT02730481 Phase I Oraxol A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies Completed USA 0
NCT02731742 Phase I MK-1966 + SD-101 Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001) Terminated 0
NCT02737072 Phase I Durvalumab + LY2510924 A Study of LY2510924 and Durvalumab in Participants With Solid Tumors Terminated 0
NCT02737475 Phase Ib/II Ipilimumab BMS-986178 Nivolumab Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors Completed USA | NLD | ITA | ESP | CAN 1
NCT02740270 Phase I GWN 323 + Spartalizumab GWN 323 Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas Completed USA | ESP | CAN 3
NCT02740985 Phase I AZD4635 AZD4635 + Durvalumab A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies Completed USA 0
NCT02743637 Phase I SDX-7320 A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors (SDX-0101) Completed USA 0
NCT02746081 Phase I BAY1436032 Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors Active, not recruiting USA | DEU 2
NCT02747537 Phase II Irinotecan + Sorafenib Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan Withdrawn 0
NCT02747797 Phase II Lucitanib Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations Withdrawn USA 0
NCT02748837 Phase I ERY974 A Study of ERY974 in Patient With Advanced Solid Tumors Completed USA | NLD | FRA 0
NCT02754141 Phase Ib/II BMS-986179 + Nivolumab A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers Completed USA | NLD | ITA | FRA | DEU | CAN | AUS 0
NCT02756845 Phase I Talimogene laherparepvec Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors Completed USA | ITA | FRA | ESP | CAN | BEL 1
NCT02761694 Phase I ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations Terminated USA 0
NCT02762981 Phase Ib/II Nab-paclitaxel + Relacorilant Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors Completed USA 0
NCT02765165 Phase Ib/II Lomustine + USL311 USL311 Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM) Terminated USA | ESP 0
NCT02769962 Phase Ib/II NLG207 + Olaparib Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer Recruiting USA 0
NCT02771626 Phase Ib/II Nivolumab + Telaglenastat Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors Terminated USA 0
NCT02774291 Phase I Aldesleukin Cyclophosphamide + Fludarabine Filgrastim Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1 Terminated USA 0
NCT02775292 Phase I Aldesleukin + Cyclophosphamide + Fludarabine Nivolumab NY-ESO-1 peptide vaccine Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 Completed USA 0
NCT02780011 Phase I Alisertib + Brentuximab vedotin Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies Withdrawn USA 0
NCT02780804 Phase I Entinostat Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Completed USA 0
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Completed USA | NLD | FRA | CAN 0
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 1
NCT02791334 Phase I LY3300054 + Necitumumab LY3300054 + Ramucirumab LY3300054 A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT) Active, not recruiting USA | FRA | ESP | CAN | BEL 2
NCT02792465 Phase I CFI-402257 A Study of Investigational Drug CFI-402257 in Patients With Advanced Cancers Active, not recruiting CAN 0
NCT02793466 Phase I Durvalumab Durvalumab in Pediatric and Adolescent Patients Completed USA 0
NCT02794571 Phase I Atezolizumab + Tiragolumab Tiragolumab Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors Active, not recruiting USA | FRA | ESP | CAN | AUS 2
NCT02797795 Phase I NEV801 A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers Unknown status USA 0
NCT02799095 Phase I ALKS 4230 A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors Completed USA | ESP | CAN | BEL | AUS 2
NCT02801097 Phase I Irinotecan + RRx-001 A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) (PAYLOAD) Terminated USA 0
NCT02805660 Phase Ib/II Durvalumab + Mocetinostat Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC Terminated USA 0
NCT02808650 Phase I Prexasertib Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Completed USA 0
NCT02810418 Phase Ib/II LMB-100 LMB-100 + Nab-paclitaxel Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Completed USA 0
NCT02811497 Phase II Azacitidine + Durvalumab Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) Completed CAN 0
NCT02812875 Phase I CA-170 A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas Completed USA | GBR | ESP 1
NCT02813135 Phase Ib/II Ribociclib + Temozolomide + Topotecan Adavosertib + Carboplatin Enasidenib Lirilumab + Nivolumab Irinotecan + Olaparib European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART) Recruiting NLD | ITA | GBR | FRA | ESP | DEU 1
NCT02817633 Phase I Cobolimab Cobolimab + unspecified PD-1 antibody A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors Recruiting USA | ESP 0
NCT02819843 Phase II Talimogene laherparepvec A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Completed USA 0
NCT02827968 Phase I Envafolimab Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors Completed USA 0
NCT02829099 Phase I JNJ-64457107 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Completed ESP 1
NCT02829372 Phase I GBR1302 Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (GBR 1302-101) Terminated USA | DEU 0
NCT02829723 Phase Ib/II BLZ945 BLZ945 + Spartalizumab Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors Terminated USA | ITA | ESP 5
NCT02830724 Phase Ib/II Cyclophosphamide + Fludarabine Aldesleukin + Anti-hCD70 CAR T cells Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers Recruiting USA 0
NCT02832167 Phase II Nivolumab An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread (CheckMate 627) Completed USA | DEU 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT02834247 Phase I Mivavotinib + Nivolumab A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Terminated USA | ITA | GBR | ESP 0
NCT02840994 Phase Ib/II CV301 + Nivolumab Nivolumab A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer Completed USA 0
NCT02842125 Phase I Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer Terminated USA 0
NCT02843165 Phase II unspecified PD-L1 antibody unspecified CTLA4 antibody unspecified PD-1 antibody Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease Active, not recruiting USA 0
NCT02846766 Phase II Lenvatinib Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling Withdrawn USA 0
NCT02856425 Phase I Nintedanib + Pembrolizumab Trial Of Pembrolizumab And Nintedanib (PEMBIB) Recruiting FRA 0
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Completed USA | FRA | AUS 1
NCT02858310 Phase I Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers Recruiting USA 0
NCT02859857 Phase I BXQ-350 Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors Completed USA 0
NCT02860780 Phase I Prexasertib + Ralimetinib A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Completed USA | DEU 0
NCT02861300 Phase Ib/II Capecitabine + Telaglenastat CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer Active, not recruiting USA 0
NCT02862275 Phase 0 Atezolizumab Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer Active, not recruiting USA | CAN 0
NCT02864316 Phase II Nivolumab Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure Terminated USA 0
NCT02867007 Phase I KHK2455 + Mogamulizumab KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA 0
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT02869217 Phase I Cyclophosphamide + Fludarabine TBI-1301 Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Active, not recruiting CAN 0
NCT02869295 Phase I NKTR-214 A Phase 1 Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors Completed USA 0
NCT02873975 Phase II Prexasertib A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency Completed USA 0
NCT02875223 Phase I CC-90011 A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas Terminated ITA | GBR | FRA | ESP 1
NCT02875548 Phase II Tazemetostat Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study Enrolling by invitation USA | GBR | FRA | BEL | AUS 2
NCT02876510 Phase I Aldesleukin + Cyclophosphamide + Fludarabine + IMA101 T cells ACTolog in Patients With Solid Cancers Completed USA 0
NCT02886585 Phase II Pembrolizumab Pembrolizumab In Central Nervous System Metastases Active, not recruiting USA 0
NCT02889445 Expanded access DM-CHOC-PEN A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers No longer available USA 0
NCT02890368 Phase I TTI-621 Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Terminated USA 0
NCT02892123 Phase I Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers Active, not recruiting USA | CAN 1
NCT02896335 Phase II Palbociclib Palbociclib In Progressive Brain Metastases Recruiting USA 0
NCT02897778 Phase I Entinostat Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed USA 0
NCT02898207 Phase I Olaparib + Onalespib Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Completed USA 0
NCT02900157 Phase I Durvalumab + MEDI9090 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors Completed USA 1
NCT02900651 Phase Ib/II MAK683 Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 4
NCT02903914 Phase I INCB001158 INCB001158 + Nivolumab Arginase Inhibitor CB-1158 in Patients With Solid Tumors Completed USA | NLD | ITA | ESP 0
NCT02904226 Phase Ib/II Nivolumab + Vopratelimab Vopratelimab Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC) Completed USA 0
NCT02906670 Phase Ib/II Pan-HER Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies Terminated USA 0
NCT02908906 Phase I Cetrelimab A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers Active, not recruiting USA | GBR | ESP 4
NCT02909452 Phase I Entinostat + Pembrolizumab Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Completed USA 0
NCT02909777 Phase I CUDC-907 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Active, not recruiting USA 0
NCT02912949 Phase Ib/II Zenocutuzumab A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 8
NCT02913313 Phase Ib/II BMS-986207 + Nivolumab BMS-986207 A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers Completed USA | CAN | AUS 5
NCT02915172 Phase I Capecitabine + Lenvatinib Lenvatinib and Capecitabine in Patients With Advanced Malignancies Withdrawn 0
NCT02920996 Phase II Merestinib Merestinib In Non-Small Cell Lung Cancer And Solid Tumors Terminated USA 0
NCT02921919 Phase II Talazoparib Open-Label Extension and Safety Study of Talazoparib Completed USA | GBR | FRA | DEU | CAN 4
NCT02922764 Phase I RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting USA 0
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP 1
NCT02923466 Phase Ib/II Avelumab + VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS Trial of Intratumoral Administration of Recombinant Vesicular Stomatitis Virus Monotherapy and in Combination With Avelumab in Patients With Refractory Solid Tumors Completed USA 0
NCT02925104 Phase I Capmatinib A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. Completed USA | NLD | GBR | ESP | DEU | AUT 2
NCT02925234 Phase II Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab The Drug Rediscovery Protocol (DRUP Trial) (DRUP) Recruiting NLD 0
NCT02926768 Phase Ib/II CK-101 Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Completed USA | NZL | AUS 2
NCT02929862 Phase Ib/II LYC-55716 Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer Completed USA 0
NCT02932280 Phase Ib/II Neratinib Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment Active, not recruiting USA | CAN 0
NCT02932956 Phase I Cyclophosphamide + Fludarabine Anti-GPC3-scFvGC33-CAR autologous T Lymphocytes Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP) Active, not recruiting USA 0
NCT02934568 Phase II Ribociclib Ribociclib (LEE011) Rollover Study for Continued Access Recruiting USA | FRA | ESP 2
NCT02935907 Phase I APG-115 APG-115 in Patients With Advanced Solid Tumors or Lymphomas Completed USA 0
NCT02936102 Phase I FAZ053 FAZ053 + Spartalizumab A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Active, not recruiting USA | ITA | FRA | ESP | CAN 4
NCT02937272 Phase I LY3200882 A Study of LY3200882 in Participants With Solid Tumors Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 1
NCT02938793 Phase II Durvalumab + Tremelimumab Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors Recruiting USA 0
NCT02942095 Phase I Erlotinib + Ixazomib Study of Ixazomib and Erlotinib in Solid Tumors Completed USA 0
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Completed USA | ITA | DEU | CAN | AUT 4
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Unknown status USA 0
NCT02952248 Phase I Ezabenlimab A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Completed USA | GBR | CAN 0
NCT02952989 Phase I SGN-2FF A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors Terminated USA 0
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Completed USA 0
NCT02955251 Phase I ABBV-428 + Nivolumab ABBV-428 A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors Completed USA | FRA | AUS 1
NCT02955446 Expanded access Nirogacestat Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies No longer available USA 0
NCT02955940 Phase II Ruxolitinib Capecitabine + Regorafenib Capecitabine + Regorafenib + Ruxolitinib An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib Active, not recruiting USA 0
NCT02959437 Phase Ib/II Azacitidine + Epacadostat + Pembrolizumab Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Terminated USA | GBR | ESP 0
NCT02961283 Phase I ASN003 Study of ASN003 in Subjects With Advanced Solid Tumors Terminated USA 0
NCT02963610 Phase Ib/II Lenalidomide + Pembrolizumab Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Terminated USA 0
NCT02964013 Phase I Vibostolimab Pembrolizumab + Vibostolimab Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) Active, not recruiting 0
NCT02972034 Phase I MK-8353 + Pembrolizumab Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) Completed USA | CAN 0
NCT02974738 Phase I Belzutifan A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors Active, not recruiting 0
NCT02975882 Phase I Irinotecan + Nab-rapamycin + Temozolomide Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Active, not recruiting USA 0
NCT02977156 Phase I Ipilimumab + JX-594 Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) Completed FRA 0
NCT02982941 Phase I MGA271 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Completed USA 0
NCT02987166 Phase I Pembrolizumab HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001) Completed USA 0
NCT02987504 Phase I Samalizumab Study of Samalizumab in Patients With Advanced Cancer Terminated USA 0
NCT02988817 Phase Ib/II Enapotamab vedotin HuMax-AXL-ADC Safety Study in Patients With Solid Tumors Completed USA | NLD | GBR | ESP | BEL 1
NCT02988960 Phase I ABBV-927 + Nivolumab ABBV-927 A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors Active, not recruiting USA | FRA | ESP | CAN | AUS 2
NCT02990481 Phase I TRK-950 A Study of TRK-950 in Patients With Advanced Solid Tumors Completed USA | FRA 0
NCT02992964 Phase Ib/II Nivolumab Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers Terminated USA | FRA | CAN | AUS 1
NCT02994953 Phase I Avelumab + NHS-IL12 A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) Terminated USA | NLD | ITA | FRA | ESP | BEL 1
NCT02997163 Phase I Talazoparib An Open-Label Pharmacokinetics and Safety Study of Talazoparib Completed USA | CAN 0
NCT02997176 Phase I Talazoparib An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Completed USA 0
NCT02998567 Phase I Guadecitabine + Pembrolizumab Decitabine and Cedazuridine + Pembrolizumab Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (HyPeR) Recruiting GBR 0
NCT03000257 Phase I Budigalimab A Study of ABBV-181 in Participants With Advanced Solid Tumors Completed USA | FRA | ESP | CAN | BEL | AUT | AUS 3
NCT03005782 Phase I Cemiplimab + Fianlimab Fianlimab Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers Active, not recruiting USA | GBR | AUS 2
NCT03006172 Phase I Inavolisib + Letrozole + Palbociclib Inavolisib Fulvestrant + Inavolisib Inavolisib + Letrozole To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer Active, not recruiting USA | GBR | FRA | ESP | CAN 0
NCT03008018 Phase I KA2507 Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours Completed USA 0
NCT03010176 Phase I Pembrolizumab + Ulevostinag Ulevostinag Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) Completed USA | GBR | FRA 2
NCT03013218 Phase I Evorpacept Atezolizumab + Evorpacept Evorpacept + Trastuzumab A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma Active, not recruiting USA 1
NCT03013491 Phase II CX-072 + Ipilimumab CX-072 + Vemurafenib CX-072 A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas Completed USA | NLD | GBR | ESP 2
NCT03017833 Phase I Metformin + Sapanisertib Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers Completed USA 0
NCT03030378 Phase I Interleukin-12 + Pembrolizumab Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors Active, not recruiting USA 0
NCT03030417 Phase I LMP744 Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas Completed USA 0
NCT03035253 Phase I Fluorouracil + Irinotecan + Leucovorin + Navicixizumab A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer Terminated USA 0
NCT03037385 Phase Ib/II Pralsetinib Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL 5
NCT03040973 Phase II Capmatinib + Nazartinib Capmatinib Capmatinib + Gefitinib Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments. Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 3
NCT03042910 Phase I Talazoparib A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors Completed USA 0
NCT03051035 Phase I KO-947 First-in-Human Study of KO-947 in Non-Hematological Malignancies Terminated USA | ESP 0
NCT03052205 Phase I IMO-2125 A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors Completed USA 1
NCT03052569 Expanded access RXDX-105 Expanded Access to RXDX-105 for Cancers With RET Alterations No longer available USA 0
NCT03057145 Phase I Olaparib + Prexasertib Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors Completed USA 0
NCT03058289 Phase Ib/II INT230-6 INT230-6 + unspecified PD-1 antibody A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01) Completed USA | CAN 0
NCT03059823 Phase I Retifanlimab A Phase 1 Study of MGA012 in Patients With Advanced Solid Tumors Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | BEL | AUS 7
NCT03061188 Phase I Nivolumab + Veliparib Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes Unknown status USA 0
NCT03065062 Phase I Gedatolisib + Palbociclib Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Recruiting USA 0
NCT03065387 Phase I Everolimus + Neratinib Neratinib + Palbociclib Neratinib + Trametinib Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Active, not recruiting USA 0
NCT03066661 Expanded access Entrectinib Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions No longer available USA 0
NCT03069469 Phase I Vimseltinib Study of DCC-3014 in Patients With Advanced Malignancies Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | AUS 1
NCT03071757 Phase I ABBV-368 ABBV-368 + Nivolumab A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP 3
NCT03080311 Phase I APG-1252 A Study of APG-1252 in Patients With SCLC or Other Solid Tumors Completed USA 0
NCT03082209 Phase I ABBV-621 A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies Completed USA | NLD | ESP 1
NCT03085914 Phase Ib/II Epacadostat + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Epacadostat + Gemcitabine + Nab-paclitaxel + Nivolumab Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cyclophosphamide + Epacadostat + Pembrolizumab A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207) Completed USA 0
NCT03087591 Phase I APN401 APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Completed USA 0
NCT03089645 Phase I MEDI5083 Durvalumab + MEDI5083 MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors Completed USA | AUS 0
NCT03091478 Phase II Pembrolizumab Pembrolizumab in Patients With Leptomeningeal Disease Terminated USA 0
NCT03092934 Phase Ib/II LY3295668 A Study of AK-01 (LY3295668) in Solid Tumors Completed CAN 0
NCT03093116 Phase Ib/II Repotrectinib A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT03096054 Phase I LY3143921 A CR-UK Phase I Trial of LY3143921 Active, not recruiting GBR 0
NCT03096340 Phase I IT-141 Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer Terminated USA 0
NCT03098550 Phase Ib/II Daratumumab + Nivolumab A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread Completed USA | ITA | FRA | ESP | DEU | CAN | AUS 2
NCT03099109 Phase I LY3321367 LY3300054 + LY3321367 A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors Completed USA | ESP 2
NCT03099161 Phase I Preladenant Pembrolizumab + Preladenant Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) Terminated USA | CAN 1
NCT03099174 Phase I Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. Active, not recruiting USA | FRA | ESP 4
NCT03101839 Phase I AZD4785 Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Completed USA | GBR 0
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Completed USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUS 3
NCT03104699 Phase Ib/II Balstilimab Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer Completed USA | FRA | ESP | BEL | AUS 4
NCT03108131 Phase II Atezolizumab + Cobimetinib Cobimetinib and Atezolizumab in Advanced Rare Tumors Completed USA 0
NCT03110107 Phase Ib/II Ipilimumab BMS-986218 + Nivolumab BMS-986218 First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS 8
NCT03113188 Phase I CBP501 + Cisplatin + Nivolumab CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors Completed USA 0
NCT03114319 Phase I TNO155 Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors Recruiting USA | NLD | ITA | ESP | CAN 4
NCT03118349 Phase I MVT-1075 + MVT-5873 Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy Terminated USA 0
NCT03119428 Phase I Etigilimab A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT03123744 Phase II Palbociclib Histology-Independent Study of Palbociclib in Patients With Advanced Cancer Withdrawn USA 0
NCT03125200 Phase I ADCT-502 Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression Terminated USA | BEL 0
NCT03126110 Phase Ib/II INCAGN01876 + Ipilimumab + Nivolumab INCAGN01876 + Nivolumab INCAGN01876 + Ipilimumab Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Completed USA | ESP | BEL | AUS 0
NCT03127098 Phase Ib/II ETBX-011 + Nogapendekin alfa inbakicept QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer Completed USA 0
NCT03127215 Phase II Olaparib + Trabectedin Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors (NCT-PMO-1603) Active, not recruiting DEU 0
NCT03132155 Phase II AMG 337 QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma Terminated USA 0
NCT03132792 Phase I AFPc332T AFPc332T in Advanced HCC Active, not recruiting USA | GBR | FRA | ESP 0
NCT03134638 Phase I Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 A Study of SY-1365 in Adult Patients With Advanced Solid Tumors Terminated USA | FRA | CAN 0
NCT03138083 Phase Ib/II OMO-1 OMO-1 + unspecified EGFR tyrosine kinase inhibitor OMO-1 in Solid Malignancies Terminated USA | NLD | GBR | FRA | BEL 0
NCT03138538 Phase I M8891 M8891 First in Human in Solid Tumors Terminated USA 0
NCT03138889 Phase Ib/II NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors Terminated USA | FRA | ESP | DEU | AUS 0
NCT03139370 Phase I Cyclophosphamide + Fludarabine KITE-718 Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers Terminated USA 0
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Terminated USA | BEL 0
NCT03147976 Phase II AMG 337 QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors Withdrawn USA 0
NCT03148418 Phase II Atezolizumab A Study in Participants Previously Enrolled in a Genentech? and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 20
NCT03149549 Phase Ib/II CX-2009 PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors Terminated USA | NLD | GBR | ESP 0
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP | AUS 0
NCT03154294 Phase I Paclitaxel + Sapanisertib + Serabelisib Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors Unknown status USA 0
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA | CAN | AUS 1
NCT03156114 Phase I Ezabenlimab Miptenalimab This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. Completed USA | GBR | ESP | CAN 1
NCT03157128 Phase Ib/II Selpercatinib A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Active, not recruiting USA 0
NCT03164603 Phase I NLG802 NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors Completed USA 0
NCT03166631 Phase I BI 891065 + Ezabenlimab BI 891065 A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Terminated USA 0
NCT03168061 Phase Ib/II NC-6300 Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma Unknown status USA 0
NCT03172936 Phase I MIW815 + Spartalizumab Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas Terminated USA | NLD | ESP | DEU | CAN | AUS 2
NCT03175224 Phase Ib/II Vebreltinib APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 6
NCT03179436 Phase Ib/II MK-1308 + Pembrolizumab MK-1308 Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) Completed USA | NZL | ITA | FRA | ESP | CAN | AUS 9
NCT03188965 Phase I Elimusertib First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Completed USA | GBR | CAN 4
NCT03190941 Phase Ib/II Cyclophosphamide anti-KRAS G12V mTCR cells Fludarabine Aldesleukin Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Recruiting USA 0
NCT03192345 Phase I Cemiplimab + SAR439459 SAR439459 A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors Terminated USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT03194893 Phase III Crizotinib Alectinib A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer Recruiting USA | ITA | FRA | ESP 6
NCT03195699 Phase I C188-9 Phase I Study of Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers Active, not recruiting USA 0
NCT03203525 Phase I Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Doxorubicin + Temsirolimus Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer Recruiting USA 0
NCT03205176 Phase I AZD5153 Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas Completed USA | CAN 0
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed USA 0
NCT03209401 Phase I Carboplatin + Niraparib Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies Terminated USA 0
NCT03210714 Phase II Erdafitinib Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03212274 Phase II Olaparib Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting USA 0
NCT03213652 Phase II Ensartinib Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Recruiting USA | AUS 1
NCT03213665 Phase II Tazemetostat Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213678 Phase II LY3023414 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213691 Phase II Selumetinib Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03215511 Phase Ib/II Selitrectinib A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer Completed USA | ITA | FRA | ESP | DEU | BEL | AUS 3
NCT03217253 Phase I Tazemetostat Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction Withdrawn USA 0
NCT03217669 Phase I Epacadostat + Sirolimus Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy Active, not recruiting USA 0
NCT03217747 Phase Ib/II Avelumab + PF-04518600 + Utomilumab Avelumab + Utomilumab Avelumab + PF-04518600 Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Active, not recruiting USA 0
NCT03218826 Phase I AZD8186 + Docetaxel PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Active, not recruiting USA 0
NCT03219268 Phase I MGD013 A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms Completed USA | ESP | AUS 5
NCT03220035 Phase II Vemurafenib Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03220347 Phase I CC-90010 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas Active, not recruiting ITA | FRA | ESP 1
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Unknown status USA 0
NCT03225105 Phase I M3541 M3541 in Combination With Radiotherapy in Subjects With Solid Tumors Terminated USA 0
NCT03229200 FDA approved Ibrutinib Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Enrolling by invitation USA | NZL | ITA | GBR | FRA | ESP | CAN | AUS 9
NCT03229278 Phase I Nivolumab + Pembrolizumab + Trigriluzole Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Completed USA 0
NCT03233204 Phase II Olaparib Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03236857 Phase I Venetoclax A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies Completed USA | NLD | GBR | FRA | DEU | CAN | AUS 1
NCT03236935 Phase I L-NMMA + Pembrolizumab Phase Ib of L-NMMA and Pembrolizumab Active, not recruiting USA 0
NCT03237390 Phase I Gemcitabine + Ribociclib Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Completed USA 0
NCT03238027 Phase I SNDX-6352 Durvalumab + SNDX-6352 A Phase 1, Open-label, Dose Escalation Trial to Investigate SNDX-6352 in Patients With Solid Tumors Completed USA 0
NCT03239145 Phase I Pembrolizumab + Trebananib Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Active, not recruiting USA 0
NCT03240861 Phase I Busulfan + Fludarabine Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC Filgrastim + Plerixafor Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT) Terminated USA 0
NCT03241173 Phase Ib/II INCAGN01949 + Ipilimumab INCAGN01949 + Nivolumab INCAGN01949 + Ipilimumab + Nivolumab A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Completed USA 0
NCT03245151 Phase Ib/II Everolimus + Lenvatinib Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors Completed USA | CAN 0
NCT03245736 Phase II Tisotumab vedotin-tftv Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed USA | GBR 0
NCT03249792 Phase I MK-2118 + Pembrolizumab MK-2118 Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001) Completed USA 1
NCT03250832 Phase I TSR-033 TSR-033 + unspecified PD-1 antibody Study of TSR-033 With an Anti-PD-1 Completed USA | FRA 0
NCT03251378 Phase I Fruquintinib The Evaluation of Safety, Tolerability, and Pharmacokinetics for Fruquintinib in Solid Tumors Active, not recruiting USA 0
NCT03251924 Phase Ib/II BMS-986226 + Nivolumab BMS-986226 + Ipilimumab BMS-986226 A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors Terminated USA | ESP | CAN 1
NCT03252938 Phase I Eftilagimod alpha Avelumab + Eftilagimod alpha Feasibility and Safety of IMP321 for Advanced Stage Solid Tumors Recruiting DEU 0
NCT03253679 Phase II Adavosertib WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification Completed USA 0
NCT03255070 Phase I ARX-788 A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01) Completed USA | AUS 0
NCT03260322 Phase Ib/II ASP8374 ASP8374 + Pembrolizumab A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | ITA | GBR | ESP | CAN 4
NCT03270176 Phase I Avelumab + Xevinapant A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy Completed CAN 2
NCT03272464 Phase I Dabrafenib + Itacitinib + Trametinib INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. Terminated USA 0
NCT03274661 Phase II Pembrolizumab Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors Completed USA 0
NCT03277352 Phase Ib/II Epacadostat + INCAGN01876 + Pembrolizumab INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Terminated USA 0
NCT03284385 Phase II Adavosertib Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 Active, not recruiting USA 0
NCT03286296 Phase I LZM009 LZM009 to Treat Patients With Advanced Solid Tumors Completed USA 0
NCT03289962 Phase I Autogene cevumeran Atezolizumab + Autogene cevumeran A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Active, not recruiting USA | NLD | GBR | ESP | DEU | CAN | BEL 1
NCT03291938 Phase I IACS-010759 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma Completed USA 0
NCT03295942 Phase I OMP-336B11 A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors Terminated USA 0
NCT03297424 Phase Ib/II PLX2853 A Study of PLX2853 in Advanced Malignancies. Completed USA 0
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting CAN 0
NCT03301896 Phase I LHC165 + Spartalizumab LHC165 Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Terminated USA | ITA | ESP | DEU | BEL 2
NCT03306420 Phase I MS201408-0005A + MS201408-0005B MS201408-0005A + MS201408-0005C MS201408-0005A First-in-Human Study of MS201408-0005A as Single Agent and in Combinations Terminated USA 0
NCT03307785 Phase I Carboplatin + Dostarlimab-gxly + Paclitaxel Dostarlimab-gxly + Niraparib Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042 Active, not recruiting USA 0
NCT03310541 Phase I Capivasertib Capivasertib + Enzalutamide Capivasertib + Fulvestrant AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations Completed USA 0
NCT03310879 Phase II Abemaciclib Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 Recruiting USA 0
NCT03311412 Phase I Sym021 Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas Completed USA | CAN 0
NCT03313557 Phase I Adavosertib AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies Completed USA | NLD | GBR | FRA 0
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) Recruiting USA 0
NCT03314935 Phase Ib/II INCB001158 + Paclitaxel Cisplatin + Gemcitabine + INCB001158 Fluorouracil + INCB001158 + Leucovorin + Oxaliplatin A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors Completed USA | GBR | BEL 0
NCT03317496 Phase II Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies Terminated USA | ITA | GBR | ESP | CAN | AUS 2
NCT03318445 Phase I Rucaparib Irinotecan + Rucaparib Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Completed USA 0
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Completed USA 0
NCT03320330 Phase Ib/II Pepinemab VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Active, not recruiting USA 0
NCT03322384 Phase Ib/II Epacadostat + SD-101 Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma Completed USA 0
NCT03323034 Phase I Irinotecan + MLN4924 + Temozolomide Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Active, not recruiting USA 0
NCT03323398 Phase I mRNA-2416 Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies Terminated USA 0
NCT03329001 Phase I Niraparib Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Compared to Niraparib Capsule Active, not recruiting USA 0
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Terminated USA | GBR | CAN | BEL | AUS 4
NCT03330561 Phase I PRS-343 PRS-343 in HER2-Positive Solid Tumors Completed USA 0
NCT03330990 Phase I Entrectinib Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients Completed USA 0
NCT03332355 Phase I PAC-1 + Temozolomide Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 Terminated USA 0
NCT03333824 Phase I Adavosertib Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer Completed USA 0
NCT03335540 Phase I Linrodostat + Nivolumab Nivolumab + Relatlimab Cabiralizumab + Nivolumab Lirilumab + Nivolumab BMS-986156 + Nivolumab Ipilimumab + Nivolumab Nivolumab An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment Completed USA 0
NCT03340506 FDA approved Trametinib Dabrafenib Dabrafenib + Trametinib Dabrafenib and/or Trametinib Rollover Study Recruiting USA | NLD | FRA | ESP | DEU | AUT 6
NCT03343613 Phase I LY3300054 + LY3381916 LY3381916 A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors Terminated USA | ITA | FRA | ESP | BEL 1
NCT03345485 Phase Ib/II Tinostamustine Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors Completed USA | CAN 0
NCT03347123 Phase Ib/II Epacadostat + Ipilimumab + Nivolumab Epacadostat + Lirilumab + Nivolumab A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208) Terminated USA 0
NCT03348514 Phase I CPX-POM Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors Completed USA 0
NCT03351231 Phase Ib/II BMS-986242 + Nivolumab An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer Terminated USA 0
NCT03355066 Phase I SM08502 A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT03359733 Phase I Mivavotinib A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor Withdrawn USA 0
NCT03359850 Phase I Niraparib Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients Completed USA 0
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated USA 0
NCT03362723 Phase I Idasanutlin A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors Completed USA | CAN 0
NCT03363893 Phase Ib/II Samuraciclib Fulvestrant + Samuraciclib Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Completed USA | GBR 0
NCT03364049 Phase I MK-7162 + Pembrolizumab Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) Completed USA | CAN 2
NCT03364400 Phase I VT1021 Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT03365791 Phase II Ieramilimab Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03366103 Phase Ib/II Navitoclax + Vistusertib Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors Terminated USA 0
NCT03366116 Phase I Aza-TdCyd 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors Recruiting USA 0
NCT03369223 Phase Ib/II BMS-986242 BMS-986249 + Nivolumab An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread Active, not recruiting USA | ITA | ESP | DEU | CAN | AUS 5
NCT03373097 Phase Ib/II GD2-CART01 Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors Recruiting ITA 0
NCT03375086 Phase I APX3330 A Study of APX3330 in Patients With Advanced Solid Tumors (APX3330) Completed USA 0
NCT03382340 Phase Ib/II IMX-110 IMX-110 in Patients With Advanced Solid Tumors Active, not recruiting USA | AUS 0
NCT03384316 Phase I ETBX-011 + ETBX-051 + ETBX-061 Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer Completed USA 0
NCT03386526 Phase Ib/II APG-1387 APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed USA 0
NCT03386721 Phase II Atezolizumab + RO6874281 Study to Evaluate the Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors Terminated USA | NZL | GBR | FRA | ESP | DEU | BEL 8
NCT03388632 Phase I Ipilimumab + rhIL-15 Nivolumab + rhIL-15 Ipilimumab + Nivolumab + rhIL-15 Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers Recruiting USA 0
NCT03396211 Phase I Nivolumab + Rivoceranib Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Completed USA 0
NCT03396445 Phase I MK-5890 MK-5890 + Pembrolizumab Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) Active, not recruiting USA | NLD | ESP 4
NCT03398720 Phase I HTI-1066 Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors Unknown status USA 0
NCT03400332 Phase Ib/II BMS-986253 + Nivolumab An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT03406949 Phase I Obrindatamab + Retifanlimab MGD009/MGA012 Combination in Relapsed/Refractory Cancer Completed USA 0
NCT03407976 Phase Ib/II Pembrolizumab + Rivoceranib Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Terminated USA 0
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Terminated USA | GBR | FRA | ESP 0
NCT03412877 Phase II Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer Recruiting USA 0
NCT03415126 Phase I ERAS-007 A Study of ASN007 in Patients With Advanced Solid Tumors Completed USA 0
NCT03416335 Phase Ib/II DSP-0509 DSP-0509 + Pembrolizumab A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Completed USA 0
NCT03416816 Phase I DSP-0337 A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile Terminated USA 0
NCT03420430 Expanded access GL-ONC1 Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care Temporarily not available USA 0
NCT03421353 Phase Ib/II Cisplatin + Danvatirsen + Durvalumab + Gemcitabine Carboplatin + Danvatirsen + Durvalumab + Gemcitabine Cisplatin + Danvatirsen + Durvalumab + Fluorouracil Danvatirsen + Durvalumab Carboplatin + Danvatirsen + Durvalumab + Nab-paclitaxel AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer Active, not recruiting USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Terminated USA | FRA | ESP | DEU 2
NCT03423628 Phase I AZD1390 A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Recruiting USA | GBR 0
NCT03425279 Phase Ib/II Mecbotamab Vedotin CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting USA 2
NCT03428802 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Recruiting USA 0
NCT03429218 Phase I TP-0184 First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors Completed USA 0
NCT03429803 Phase I Tovorafenib DAY101 In Gliomas and Other Tumors Active, not recruiting USA 0
NCT03430882 Phase I Carboplatin + Paclitaxel + Sapanisertib TAK228 With Carbo and Taxol in Advanced Malignancies Completed USA 0
NCT03431948 Phase I Nivolumab + Urelumab Cabiralizumab + Nivolumab Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer (C4 MOSART) Completed USA 0
NCT03435250 Phase I AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss Terminated USA | FRA | ESP 0
NCT03435952 Phase I Clostridium novyi-NT spores + Doxycycline + Pembrolizumab Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Active, not recruiting USA 0
NCT03440437 Phase I FS118 FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy Active, not recruiting USA | FRA 0
NCT03444714 Phase I RiMO-301 Phase I Study of RiMO-301 With Radiation in Advanced Tumors Recruiting USA 0
NCT03444753 Phase I BMS-986299 + Ipilimumab + Nivolumab BMS-986299 An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed Terminated USA 0
NCT03445858 Phase I Decitabine + Pembrolizumab Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Active, not recruiting USA 0
NCT03446040 Phase Ib/II BMS-986258 + Nivolumab BMS-986258 An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread Active, not recruiting USA | CAN | AUS 1
NCT03447314 Phase I GSK1795091 + GSK3174998 GSK3174998 Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors Completed USA | NLD | ESP | CAN 0
NCT03447470 Phase I Nivolumab + RXC004 RXC004 Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies Active, not recruiting GBR 0
NCT03448042 Phase I BTRC 4017A A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUS 5
NCT03449381 Phase I BI 907828 This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) Recruiting USA | ESP | DEU | CAN | BEL 6
NCT03451825 Phase Ib/II Avelumab Phase I/II Study of Avelumab in Pediatric Cancer Subjects Completed USA | CAN | BEL 2
NCT03454035 Phase I Palbociclib + Ulixertinib Phase I Trial of Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors Recruiting USA 0
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Terminated USA 0
NCT03459222 Phase Ib/II Linrodostat + Nivolumab + Relatlimab Ipilimumab + Nivolumab + Relatlimab An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Active, not recruiting USA | ITA | GBR | FRA | ESP | AUS 1
NCT03461952 Phase II Nivolumab Ipilimumab + Nivolumab Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (NIMBLe) Terminated USA | CAN 0
NCT03463473 Phase I MSB2311 A Phase I Study of MSB2311 in Advanced Solid Tumors Completed USA 0
NCT03468426 Phase I BI 836880 + Ezabenlimab A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours Active, not recruiting USA | GBR | FRA | ESP | DEU | AUS 6
NCT03471286 Phase I Epacadostat A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies Terminated USA 0
NCT03474640 Phase I Toripalimab-tpzi Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies Unknown status USA 0
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03477175 Phase II Lenvatinib Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials Completed USA | NLD | ITA | DEU | BEL | AUS 5
NCT03478462 Phase I CLR 131 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Active, not recruiting USA | CAN | AUS 0
NCT03486301 Phase I BDB001 BDB001 + Pembrolizumab Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab Active, not recruiting USA 0
NCT03486314 Phase I Carboplatin + Docetaxel + MLN4924 + Paclitaxel MLN4924 + Rifampin A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors Completed USA 0
NCT03486730 Phase Ib/II BT1718 BT1718 in Patients With Advanced Solid Tumours. Completed GBR 0
NCT03486873 Phase III Pembrolizumab Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 37
NCT03489343 Phase I Sym023 Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas Completed USA | CAN 0
NCT03489369 Phase I Sym022 Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas Completed USA | CAN 0
NCT03493945 Phase Ib/II Bintrafusp alfa + Epacadostat + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept Bintrafusp alfa + Nogapendekin alfa inbakicept Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1). Active, not recruiting USA 0
NCT03495323 Phase I LY3300054 + Prexasertib A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors Completed USA 0
NCT03495882 Phase Ib/II Balstilimab + Zalifrelimab Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) Completed USA | ESP | AUS 6
NCT03496519 Phase I Durvalumab + Trabectedin Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors Withdrawn 0
NCT03498521 Phase II Atezolizumab + Paclitaxel Carboplatin Carboplatin + Paclitaxel Olaparib Vismodegib Alectinib Bevacizumab + Erlotinib Cisplatin + Gemcitabine Cobimetinib + Vemurafenib Ipatasertib + Paclitaxel Cisplatin + Paclitaxel Gemcitabine Atezolizumab Entrectinib Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Ipatasertib Carboplatin + Gemcitabine A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO) Active, not recruiting NLD | ITA | GBR | FRA | ESP | DEU | AUT | AUS 25
NCT03502733 Phase I Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Patients With Metastatic Solid Tumors or Lymphoma Active, not recruiting USA 0
NCT03504488 Phase Ib/II BA3021 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting USA | ITA | ESP | DEU 4
NCT03507491 Phase I Gemcitabine + Nab-paclitaxel Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors Active, not recruiting USA 0
NCT03510104 Phase I MRX-2843 Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors Active, not recruiting USA 0
NCT03511222 Phase I Pembrolizumab + Vorolanib Nivolumab + Vorolanib Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors Terminated USA 0
NCT03512340 Phase I SRF231 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers Completed USA | CAN 0
NCT03514121 Phase I FPA150 FPA150 in Patients With Advanced Solid Tumors Completed USA 1
NCT03515551 Phase Ib/II IMCnyeso Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers Terminated USA | GBR | CAN 0
NCT03517956 Phase I Copanlisib + Rogaratinib Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO) Completed USA | ESP | DEU | BEL 2
NCT03518554 Phase I JAB-3068 A First in Human, Dose Escalation Study of JAB-3068 in Adult Patients With Advanced Solid Tumors Unknown status USA 0
NCT03518606 Phase Ib/II Durvalumab + Tremelimumab + Vinorelbine Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE) Active, not recruiting FRA 0
NCT03520075 Phase Ib/II ASTX029 Study of ASTX029 in Subjects With Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT03522142 Phase I INCB081776 INCB081776 + Nivolumab A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors Active, not recruiting USA | NLD 3
NCT03525795 Phase Ib/II CPI-1205 + Ipilimumab ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors Completed USA 0
NCT03525925 Phase I Ibrutinib + Nivolumab Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors Completed USA 0
NCT03526250 Phase II Palbociclib Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03526835 Phase I MCLA-158 A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Recruiting USA | NLD | GBR | FRA | ESP | BEL 0
NCT03530397 Phase I Carboplatin + Pembrolizumab + Pemetrexed Disodium Durvalumab Carboplatin + MEDI5752 + Pemetrexed Disodium MEDI5752 A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors Active, not recruiting USA | NLD | ITA | FRA | ESP | AUS 3
NCT03536728 Phase I AMXT1501 + Eflornithine Oral AMXT 1501 Dicaprate in Combination With DFMO Completed USA 0
NCT03539484 Phase I RO7172508 A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors Terminated ESP | CAN | BEL 1
NCT03543813 Phase Ib/II CX-2029 PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL Completed USA | GBR | ESP 1
NCT03549000 Phase I NZV930 + Spartalizumab + Taminadenant NZV930 + Spartalizumab NZV930 + Taminadenant NZV930 A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. Terminated USA | GBR | ESP | CAN | AUS 2
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 1
NCT03558139 Phase I Avelumab + Hu5F9-G4 A Trial of Hu5F9-G4 With Avelumab in Ovarian Cancer Completed USA 0
NCT03560882 Phase I Atorvastatin A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies Active, not recruiting USA 0
NCT03564691 Phase I MK-4830 + Pembrolizumab MK-4830 Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) Active, not recruiting USA | FRA | ESP | CAN | AUS 7
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Completed USA | ITA | GBR | ESP | CAN 4
NCT03565991 Phase II Avelumab + Talazoparib Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors Terminated USA | NLD | ITA | GBR | FRA | ESP | BEL 2
NCT03568058 Phase I Pembrolizumab Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers Active, not recruiting USA 0
NCT03568656 Phase Ib/II CCS1477 Abiraterone + CCS1477 CCS1477 + Enzalutamide Study to Evaluate CCS1477 in Advanced Tumours Recruiting USA | NLD | GBR | FRA | ESP 1
NCT03573310 Phase I JNJ-64619178 A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS Active, not recruiting USA | ESP | DEU | CAN 1
NCT03573544 Phase Ib/II OBI-888 This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. Terminated USA 1
NCT03576131 Phase Ib/II GEN1029 GEN1029 (HexaBody-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors Terminated USA | GBR | ESP 0
NCT03579628 Phase I AsiDNA + Carboplatin AsiDNA + Carboplatin + Paclitaxel AsiDNA AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors (DRIIV-1) Completed FRA | BEL 0
NCT03588039 Phase I Oraxol + Pembrolizumab Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT03589339 Phase I NBTXR3 NBTXR3 + unspecified PD-1 antibody NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy Recruiting USA 0
NCT03589651 Phase I Parsaclisib + Retifanlimab Epacadostat + Retifanlimab INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Completed USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Completed USA 0
NCT03592264 Phase Ib/II OBI-3424 This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer Terminated USA 0
NCT03593226 Phase Ib/II AGI-134 Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour Completed USA | GBR 1
NCT03595059 Phase I Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors Active, not recruiting USA | NLD | ESP | CAN | AUS 5
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03600883 Phase Ib/II Midazolam + Sotorasib Sotorasib + unspecified PD-1 antibody Sotorasib + unspecified PD-L1 antibody Sotorasib A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) Active, not recruiting USA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 8
NCT03601897 Phase I Paclitaxel + Rebastinib A Safety, Tolerability and PK Study of Rebastinib in Patients With Advanced Solid Tumors Completed USA 0
NCT03602079 Phase Ib/II A166 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Completed USA 0
NCT03603964 Phase II Guadecitabine Guadecitabine Extension Study Terminated USA | ITA | ESP | CAN | AUT 4
NCT03604445 Phase I BI 905677 This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) Terminated USA | NLD | ESP 1
NCT03604783 Phase I TP-1287 Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors Terminated USA 0
NCT03607890 Phase II Nivolumab + Relatlimab Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor Recruiting USA 0
NCT03611595 Phase I Cabozantinib + Isotretinoin Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors Recruiting USA 0
NCT03611868 Phase Ib/II APG-115 + Pembrolizumab A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Recruiting USA | AUS 0
NCT03616574 Phase I CA102N CA102N + Trifluridine-tipiracil hydrochloride First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors Completed USA 0
NCT03616834 Phase II Tomivosertib eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy Completed USA 0
NCT03618381 Phase I EGFR806CAR(2G)-EGFRt CD19CAR(2G)-T2A-HER2tG + EGFR806CAR(2G)-EGFRt EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting USA 0
NCT03620318 Expanded access Crenolanib Individual Patient Compassionate Use of Crenolanib Available ITA 0
NCT03620643 Phase II Crizotinib Crizotinib + Fulvestrant Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo) Active, not recruiting GBR 0
NCT03621982 Phase I Camidanlumab tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Terminated USA | GBR | BEL 0
NCT03634982 Phase I RMC-4630 Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors Unknown status USA 0
NCT03635632 Phase I C7R-GD2.CART cells Cyclophosphamide + Fludarabine C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Active, not recruiting USA 0
NCT03637491 Phase II Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors Terminated USA | BEL 1
NCT03647163 Phase I Pembrolizumab + VSV-hIFNbeta-NIS Combination Therapy With Intravenous VSV-IFNbeta-NIS and Pembrolizumab in Refractory NSCLC and HCC Recruiting USA 0
NCT03648372 Phase I Subasumstat A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Metastatic Solid Tumors or Lymphomas Terminated USA 0
NCT03650348 Phase I Atezolizumab + PRS-343 PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors Completed USA 0
NCT03651271 Phase II Ipilimumab + Nivolumab Nivolumab Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer Completed USA 0
NCT03652077 Phase I INCAGN02390 A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Completed USA 0
NCT03654547 Phase I Tinengotinib Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer Active, not recruiting USA 1
NCT03654716 Phase I ALRN-6924 + Cytarabine ALRN-6924 Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer Completed USA 0
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA | CAN | BEL 0
NCT03665129 Phase I Avdoralimab + Durvalumab IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) Terminated USA | FRA 0
NCT03665285 Phase Ib/II NC318 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT03666273 Phase I BAY1905254 BAY1905254 + Pembrolizumab A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 Active, not recruiting USA 0
NCT03666988 Phase I GSK3368715 First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) Terminated USA | ESP | CAN | AUS 0
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT03668119 Phase II Ipilimumab + Nivolumab Nivolumab A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT03669601 Phase I Ceralasertib + Gemcitabine AZD6738 & Gemcitabine as Combination Therapy (ATRiUM) Recruiting GBR 0
NCT03673787 Phase Ib/II Atezolizumab + Ipatasertib A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP) Unknown status GBR 0
NCT03678883 Phase Ib/II Carboplatin + Elraglusib + Paclitaxel Elraglusib + Irinotecan Doxorubicin + Elraglusib Elraglusib + Lomustine Carboplatin + Elraglusib Elraglusib + Gemcitabine + Nab-paclitaxel Elraglusib Elraglusib + Gemcitabine 9-ING-41 in Patients With Advanced Cancers Active, not recruiting USA | NLD | FRA | ESP | CAN | BEL 1
NCT03680560 Phase I ACTR707 + Trastuzumab ACTR087 + Trastuzumab Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers Terminated USA 0
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Terminated USA 0
NCT03682289 Phase II Ceralasertib + Olaparib Olaparib Phase II Trial of AZD6738 Alone and in Combination With Olaparib Recruiting USA 0
NCT03684785 Phase Ib/II AST-008 + Pembrolizumab Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors Terminated USA 0
NCT03684811 Phase Ib/II Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Completed USA | GBR | FRA | ESP | AUS 1
NCT03685591 Phase I PF-06952229 Enzalutamide + PF-06952229 Letrozole + Palbociclib + PF-06952229 PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Terminated USA 0
NCT03686124 Phase I IMA-203 TCR-engineered T Cells in Solid Tumors Recruiting USA | DEU 0
NCT03690154 Phase I FN-1501 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors Terminated USA | AUS 0
NCT03690869 Phase Ib/II Cemiplimab REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Terminated USA 0
NCT03693014 Phase II A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors Recruiting USA 0
NCT03696030 Phase I HER2 CAR-T cells HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases Recruiting USA 0
NCT03696771 Phase I NJH395 Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer Completed USA | ITA 2
NCT03697304 Phase II Ezabenlimab Miptenalimab Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. Active, not recruiting USA | GBR | CAN 0
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03706274 Phase I CX-188 PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors Withdrawn USA 0
NCT03707093 Phase I ADG106 Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma Completed USA 0
NCT03708328 Phase I RO7121661 A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors Active, not recruiting USA | NZL | FRA | ESP 2
NCT03709680 Phase I Irinotecan + Palbociclib + Temozolomide Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 12
NCT03711058 Phase Ib/II Copanlisib + Nivolumab Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer Active, not recruiting USA 0
NCT03715504 Phase I TP-3654 Phase I Study of TP-3654 in Patients With Advanced Solid Tumors Completed USA 0
NCT03715933 Phase I INBRX-109 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Recruiting USA 0
NCT03717415 Phase Ib/II Carboplatin + Rebastinib A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Completed USA 0
NCT03718091 Phase II Berzosertib M6620 (VX-970) in Selected Solid Tumors Completed USA 0
NCT03721679 Phase Ib/II Cemiplimab + Poly ICLC Atezolizumab + Poly ICLC Pembrolizumab + Poly ICLC Durvalumab + Poly ICLC Nivolumab + Poly ICLC Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 Terminated USA 0
NCT03724890 Phase I Avelumab + Peposertib Study of Avelumab-M3814 Combinations Completed USA 0
NCT03725436 Phase I ALRN-6924 + Paclitaxel ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors Active, not recruiting USA 0
NCT03726294 Phase I NBM-BMX A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer Completed USA 0
NCT03729596 Phase Ib/II MGC018 MGC018 + Retifanlimab MGC018 With or Without MGA012 in Advanced Solid Tumors Terminated USA | ESP | AUS 1
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA | CAN 0
NCT03739931 Phase I mRNA-2752 mRNA-2752 + Tremelimumab Durvalumab + mRNA-2752 Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies Active, not recruiting USA | AUS 1
NCT03742895 Phase II Olaparib Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 14
NCT03744403 Phase I Sugemalimab A Phase I Study of CS1001 in Advanced Solid Tumors Completed USA 0
NCT03744468 Phase Ib/II BGB-A425 + Tislelizumab Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors Recruiting USA | ITA | FRA | ESP | AUS 2
NCT03744715 Phase II Poziotinib A Study to Allow Continued Treatment of Patients Who Have Participated in a Spectrum-Sponsored Poziotinib Study Terminated USA 0
NCT03745326 Phase Ib/II Aldesleukin + anti-KRAS G12D mTCR cells + Cyclophosphamide + Fludarabine Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients Recruiting USA 0
NCT03745989 Phase I MK-8353 + Selumetinib Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) Completed USA | CAN 1
NCT03746431 Phase Ib/II 225Ac-FPI-1434 A Phase 1/2 Study of [225Ac]-FPI-1434 Injection Recruiting USA | CAN | AUS 0
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Active, not recruiting USA 0
NCT03756818 Phase I Mivavotinib + Paclitaxel TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT03761017 Phase I MGD019 MGD019 DART Protein in Unresectable/Metastatic Cancer Active, not recruiting USA | ESP 3
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Active, not recruiting USA 0
NCT03762447 Phase I INCB086550 A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors Completed USA | ITA | GBR | FRA | BEL 0
NCT03763149 Phase I IBI188 A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas Completed USA 0
NCT03767075 Phase II Atezolizumab A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB) Recruiting NLD | ITA | GBR | FRA | ESP | DEU 1
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Recruiting USA | GBR | FRA | ESP | DEU 0
NCT03770494 Phase I LY3405105 A Study of LY3405105 in Participants With Advanced Cancer Terminated USA | FRA | ESP | CAN 1
NCT03775525 Phase I Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma (GEN602) Active, not recruiting USA 0
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Completed USA | CAN 0
NCT03780517 Phase I DS-5010 Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors Completed USA | FRA | ESP | BEL 3
NCT03781362 Phase I CPI-100 Capecitabine + CPI-100 Study of CPI-100 in Patients With Advanced Tumors Completed USA 0
NCT03783403 Phase I CC-95251 CC-95251 + Cetuximab A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, With Cetuximab in Subjects With Advanced Solid Cancers Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 1
NCT03784677 Phase I SOR-C13 SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Completed USA 0
NCT03785249 Phase Ib/II Adagrasib Adagrasib + Afatinib Adagrasib + Cetuximab Adagrasib + Pembrolizumab Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 Recruiting USA 1
NCT03786484 Phase I PBF 999 Study of PBF-999 in Solid Tumour Advanced Cancer Completed ESP 0
NCT03790488 Phase I Pimivalimab Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies Completed USA 0
NCT03792724 Phase Ib/II Nivolumab + Urelumab Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) Unknown status ESP 0
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT03797391 Phase Ib/II EMB-01 A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors Recruiting USA 1
NCT03799003 Phase I ASP1951 A Study of ASP1951 in Subjects With Advanced Solid Tumors Completed USA | CAN 2
NCT03804515 Phase I Poziotinib A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib Terminated USA 0
NCT03809624 Phase II INBRX-105 INBRX-105 + Pembrolizumab Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) Recruiting USA 0
NCT03810872 Phase II Afatinib + Paclitaxel An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation Unknown status BEL 0
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed USA | CAN 0
NCT03815643 Phase III Avelumab Avelumab Program Rollover Study Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 14
NCT03815682 Phase I Pembrolizumab + RPTR-147 RPTR-147 RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Terminated USA 0
NCT03816332 Phase I Ipilimumab + Nivolumab + Prednisone + Tacrolimus Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Active, not recruiting USA 0
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Recruiting USA | CAN 0
NCT03821233 Phase I ZW49 A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers Active, not recruiting USA | CAN | AUS 1
NCT03821935 Phase I ABBV-151 ABBV-151 + Budigalimab Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | CAN | BEL | AUS 5
NCT03822117 Phase II Pemigatinib Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Terminated USA | ITA | GBR | FRA | ESP | DEU 5
NCT03829254 Phase Ib/II NUC-7738 NUC-7738 + Pembrolizumab A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma Recruiting GBR 0
NCT03829436 Phase I TPST-1120 Nivolumab + TPST-1120 Docetaxel + TPST-1120 Cetuximab + TPST-1120 TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers Completed USA 0
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Active, not recruiting USA | ITA | GBR 3
NCT03830918 Phase Ib/II Niraparib + Temozolomide Niraparib and Temozolomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy Recruiting USA 0
NCT03831295 Phase I BMS-986178 + SD-101 SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies Completed USA 0
NCT03832569 Phase II Pembrolizumab Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors Active, not recruiting USA 0
NCT03833427 Phase I Pembrolizumab + Selumetinib Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) Completed USA | CAN 0
NCT03834220 Phase II Debio 1347 Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) Terminated USA | NLD | GBR | FRA | ESP | AUT | AUS 16
NCT03834662 Phase I BMS-986416 A Trial of AVID200, a Transforming Growth Factor beta (TGFbeta) Inhibitor, in Patients Malignancies Unknown status USA | CAN 0
NCT03834948 Phase I AO-176 AO-176 in Multiple Solid Tumor Malignancies Completed USA 0
NCT03834961 Phase II Larotrectinib Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia Active, not recruiting USA | CAN 0
NCT03835949 Phase I Atezolizumab + Uliledlimab Study of TJ004309 in Combination With Atezolizumab (Tecentriq) in Patients With Advanced or Metastatic Cancer Unknown status USA 0
NCT03836352 Phase II Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors Active, not recruiting USA | CAN 0
NCT03837899 Phase Ib/II Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab for Pediatric Malignancies Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU 0
NCT03839342 Phase II Binimetinib + Encorafenib Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) Active, not recruiting CAN 0
NCT03841110 Phase I FT500 + Pembrolizumab Atezolizumab + FT500 FT500 + Nivolumab FT500 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors Completed USA 0
NCT03842228 Phase I Copanlisib + Durvalumab + Olaparib Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations Active, not recruiting USA 0
NCT03842865 Expanded access FANG vaccine Expanded Access of Vigil in Solid Tumors Temporarily not available USA 0
NCT03843359 Phase I GSK3745417 GSK3745417 + Pembrolizumab Phase 1 First Time in Humans (FTIH), Open Label Study of GSK3745417 Administered to Subjects With Advanced Solid Tumors Active, not recruiting USA | NLD | FRA | ESP | CAN | AUS 2
NCT03843775 Phase Ib/II Binimetinib + Encorafenib A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers Completed USA 0
NCT03845166 Phase I XL092 A Study of XL092 in Subjects With Solid Tumors Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 1
NCT03847649 Phase II Durvalumab Durvalumab + Prednisone Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Toxicity Recruiting CAN 0
NCT03853109 Phase I AMG 404 AMG 404 in Patients With Advanced Solid Tumors. Completed USA | GBR | ESP | CAN | BEL | AUS 7
NCT03854227 Phase I PF-06939999 A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors Terminated USA 0
NCT03859752 Phase I TR1801-ADC TR1801-ADC in Patients With Tumors That Express c-Met Suspended USA 0
NCT03860272 Phase I Botensilimab Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Recruiting USA | GBR 0
NCT03861403 Phase Ib/II Avelumab + Cyclophosphamide + TRX518 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Terminated USA 0
NCT03861793 Phase I ALKS 4230 + Pembrolizumab ALKS 4230 A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) Completed USA | NLD | ESP | CAN 2
NCT03864042 Phase I Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors Active, not recruiting USA | NLD | ESP | CAN | BEL 0
NCT03868423 Phase II Brigatinib Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Withdrawn USA 0
NCT03871348 Phase I SAR441000 Cemiplimab + SAR441000 A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Terminated USA | NLD | FRA | ESP | DEU | BEL 0
NCT03872427 Phase II Telaglenastat Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study Active, not recruiting USA 0
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Recruiting USA | FRA 0
NCT03873883 Phase I EOS100850 + Pembrolizumab EOS100850 First-in-Human Study of EOS100850 in Patients With Cancer Active, not recruiting USA | GBR | FRA | ESP | BEL 1
NCT03875820 Phase I Defactinib + RO5126766 Phase I Trial of Defactinib and VS-6766. (FRAME) Active, not recruiting GBR 0
NCT03878095 Phase II Ceralasertib + Olaparib Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors Suspended USA 0
NCT03881488 Phase I CTX-471 Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies Recruiting USA 0
NCT03884556 Phase I Gemcitabine + Nab-paclitaxel + TTX-030 Docetaxel + TTX-030 Pembrolizumab + TTX-030 TTX-030 TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers Completed USA 0
NCT03886831 Phase I PRT543 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Completed USA 0
NCT03889275 Phase I Durvalumab Durvalumab + MEDI5395 MEDI5395 A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors Completed USA | GBR 0
NCT03889795 Phase I Digoxin + Metformin + Simvastatin Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors Recruiting USA 0
NCT03891953 Phase I DKY709 DKY709 + Spartalizumab Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Active, not recruiting USA | ESP | DEU 3
NCT03893955 Phase I ABBV-368 + ABBV-927 + Nab-paclitaxel ABBV-368 + ABBV-927 ABBV-368 + ABBV-927 + Budigalimab ABBV-927 + Budigalimab + Carboplatin ABBV-927 + Carboplatin ABBV-368 + ABBV-927 + Carboplatin A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting USA | FRA | ESP | AUS 2
NCT03894540 Phase I IACS-6274 IACS-6274 + Pembrolizumab IACS-6274 + Paclitaxel A Phase I, Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours Terminated USA 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Active, not recruiting USA | ESP | CAN | BEL 0
NCT03895684 Phase I Seclidemstat Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors Completed USA 0
NCT03899792 Phase Ib/II Selpercatinib A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT03905148 Phase Ib/II Lifirafenib + PD-0325901 Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors Recruiting USA | AUS 0
NCT03906331 Expanded access Selpercatinib Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation Available USA | NZL | ITA | FRA | ESP | DEU | AUS 5
NCT03906643 Phase I HS-201 HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies Withdrawn USA 0
NCT03907475 Phase II Durvalumab Durvalumab + Nab-paclitaxel Capecitabine + Durvalumab Durvalumab + Pegylated liposomal doxorubicin Durvalumab + Gemcitabine Durvalumab + Paclitaxel Carboplatin + Durvalumab Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) Recruiting USA 0
NCT03907969 Phase Ib/II AZD7648 + Pegylated liposomal doxorubicin AZD7648 + Olaparib AZD7648 A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers Completed USA | GBR 0
NCT03911557 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors Active, not recruiting USA 0
NCT03917381 Phase Ib/II GEN1046 GEN1046 Safety Trial in Patients With Malignant Solid Tumors Active, not recruiting USA | ITA | ESP 7
NCT03918278 Phase I MK-0482 MK-0482 + Pembrolizumab A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001) Active, not recruiting USA | ITA | ESP | CAN | AUS 3
NCT03919292 Phase Ib/II Divalproex sodium + Neratinib Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca Recruiting USA 0
NCT03920839 Phase I Carboplatin + Paclitaxel + Retifanlimab Cisplatin + Gemcitabine + Retifanlimab Cisplatin + Pemetrexed Disodium + Retifanlimab Carboplatin + Pemetrexed Disodium + Retifanlimab INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) Withdrawn 0
NCT03922204 Phase I MCLA-145 A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies Recruiting USA | NLD | ESP | BEL 0
NCT03928314 Phase I Nab-paclitaxel + ORIC-101 Study of ORIC-101 in Combination With Anticancer Therapy Terminated USA 0
NCT03931681 Phase I OKI-179 A Study of OKI-179 in Patients With Solid Tumors Completed USA 0
NCT03934359 Phase I DN1508052 A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors Completed USA 0
NCT03934372 Phase Ib/II Ponatinib Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Recruiting NLD | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT03934814 Phase I Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma Completed USA 1
NCT03936465 Phase I BMS986158 CC-90010 Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Active, not recruiting USA | CAN 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03941262 Phase I Avelumab + SNK01 SNK01 Pembrolizumab + SNK01 Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Completed USA 0
NCT03943004 Phase I DFP-14927 Trial of DFP-14927 in Advanced Solid Tumors Recruiting USA 0
NCT03946800 Phase I MEDI1191 Durvalumab + MEDI1191 A Study of MEDI1191 Alone and in Combination With Durvalumab in Subjects With Advanced Solid Tumors Completed USA | ESP 0
NCT03947385 Phase Ib/II IDE196 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Recruiting USA | CAN | AUS 0
NCT03948763 Phase I mRNA 5671 mRNA 5671 + Pembrolizumab A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) Completed USA | NZL | AUS 4
NCT03950297 Phase I 609A Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A Unknown status USA 0
NCT03950570 Phase I ORIN1001 + Paclitaxel ORIN1001 ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer Active, not recruiting USA 0
NCT03951116 Phase I FCN-437 Study of FCN-437c in Patients With Advanced Solid Tumors (FCN-437c) Completed USA 0
NCT03953235 Phase Ib/II GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens Completed USA 0
NCT03953742 Phase I CPI-200 Study of CPI-200 in Patients With Advanced Tumors Completed USA 0
NCT03954067 Phase I ASP9801 A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors Active, not recruiting USA 0
NCT03954704 Phase I Fluorouracil + GS-1423 + Leucovorin + Oxaliplatin GS-1423 Study of GS-1423 in Participants With Advanced Solid Tumors Terminated USA 0
NCT03956680 Phase I Ipilimumab + Nivolumab BMS-986301 An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers Active, not recruiting USA | CAN 0
NCT03964233 Phase I BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) Recruiting USA | NLD | GBR | FRA | ESP | DEU | BEL | AUS 3
NCT03964727 Phase II Sacituzumab govitecan-hziy A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03) Active, not recruiting USA | FRA | ESP | CAN | BEL | AUS 2
NCT03965845 Phase Ib/II Palbociclib + Telaglenastat A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Completed USA 0
NCT03967093 Phase I BXQ-350 A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors Terminated USA 0
NCT03967938 Phase II Olaparib Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes (1-2018 BSMO) Recruiting BEL 0
NCT03968653 Phase I Carboplatin + Debio 0123 Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors Recruiting NLD | ESP 0
NCT03975387 Phase Ib/II ASTX295 Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 Active, not recruiting USA 0
NCT03976050 Phase I Tunlametinib Phase I Study of HL-085 in Patients With Advanced Solid Tumors Terminated USA 0
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Tiragolumab Atezolizumab + Cisplatin Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Active, not recruiting USA 0
NCT03986606 Phase I PSB205 A Study of PSB205 in Subjects With Advanced Solid Tumors Unknown status USA 0
NCT03987685 Phase I HM30181A + Topotecan Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies Completed USA | GBR 0
NCT03989115 Phase Ib/II Cobimetinib + RMC-4630 Osimertinib + RMC-4630 Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC Completed USA 1
NCT03990233 Phase I Effi-DEM Effi-DEM + Ezabenlimab A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours Active, not recruiting FRA | BEL 0
NCT03990454 Phase I SLC-391 Safety Study of SLC-391 in Subjects With Solid Tumors Completed CAN 0
NCT03992131 Phase Ib/II Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) Terminated USA 0
NCT03993379 Phase II CX-072 PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors Terminated USA | NLD | ESP | AUS 1
NCT03993873 Phase Ib/II TPX-0022 Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1) Active, not recruiting USA | FRA | ESP 2
NCT03994601 Phase Ib/II BMS-986288 BMS-986288 + Nivolumab An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Active, not recruiting USA | ITA | FRA | ESP | CAN 2
NCT03994796 Phase II Abemaciclib GDC-0084 Entrectinib Genetic Testing in Guiding Treatment for Patients With Brain Metastases Recruiting USA 0
NCT03995472 Phase I SHR-1316 + SHR1501 A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors Completed AUS 1
NCT04001101 Phase II unspecified PD-1 antibody Anti-PD-1 +/- RT for MSI-H Solid Tumors Withdrawn USA 0
NCT04003623 Phase II Pemigatinib Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) Terminated USA 0
NCT04006301 Phase I JNJ-74699157 First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation Completed USA | FRA 0
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting USA 0
NCT04008797 Phase I Lenvatinib E7386 + Lenvatinib A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor Recruiting USA | FRA 3
NCT04009681 Phase Ib/II THOR-707 + unspecified PD-L1 antibody THOR-707 + unspecified PD-1 antibody THOR-707 THOR-707 + unspecified CTLA4 antibody A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) Recruiting USA | ESP | AUS 3
NCT04020185 Phase Ib/II IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 Safety and Efficacy Study of IMSA101 in Refractory Malignancies Completed USA 0
NCT04021043 Phase Ib/II BMS-986156 + Ipilimumab + Nivolumab BMS-986156 + Nivolumab BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers Active, not recruiting USA 0
NCT04029688 Phase Ib/II Idasanutlin + Venetoclax Cyclophosphamide + Idasanutlin + Topotecan Cytarabine + Fludarabine + Idasanutlin Cytarabine + Hydrocortisone + Methotrexate Cytarabine Methotrexate Idasanutlin Cyclophosphamide + Idasanutlin A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Active, not recruiting USA | NLD | GBR | FRA | ESP | CAN 0
NCT04029922 Phase I MT-5111 Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) Terminated USA | NZL | AUS 0
NCT04034238 Phase I LMB-100 + Tofacitinib Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Completed USA 0
NCT04036682 Phase Ib/II Zipalertinib A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1) Recruiting USA | NLD 6
NCT04042116 Phase Ib/II Lucitanib + Nivolumab A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor Suspended USA | ITA | ESP | DEU | BEL | AUT 0
NCT04045496 Phase I A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors Unknown status USA 0
NCT04047290 Phase I Ivonescimab A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors Recruiting AUS 0
NCT04047862 Phase I BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors Active, not recruiting USA | AUS 2
NCT04049617 Phase Ib/II Evixapodlin Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors Terminated USA | NZL 0
NCT04050709 Phase I PD-L1.t-haNK cells QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers Active, not recruiting USA 0
NCT04053673 Phase I RBN-2397 RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study Recruiting USA | ESP 0
NCT04056910 Phase II Ivosidenib + Nivolumab Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors Completed USA 0
NCT04058756 Phase I Spartalizumab Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL 9
NCT04059588 Phase I 2141 V-11 A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin Completed USA 0
NCT04064359 Phase I MEN1309 Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors Recruiting USA | FRA | ESP | BEL 1
NCT04068194 Phase Ib/II Avelumab Avelumab + Peposertib Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Recruiting USA 0
NCT04069026 Phase I BAY2416964 A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer Completed USA | GBR | ESP | DEU | CAN 0
NCT04074967 Phase Ib/II Ipilimumab + Pexmetinib Nivolumab + Pexmetinib Study of ARRY-614 Plus Either Nivolumab or Ipilimumab Active, not recruiting USA 0
NCT04078152 FDA approved Durvalumab Durvalumab Long-Term Safety and Efficacy Study (WAVE) Active, not recruiting USA | NLD | GBR | FRA | ESP | DEU | CAN | BEL | AUS 22
NCT04082572 Phase II Pembrolizumab Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers Active, not recruiting USA 0
NCT04083599 Phase Ib/II GEN1042 GEN1042 Safety Trial in Subjects With Malignant Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU 6
NCT04083976 Phase II Erdafitinib A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 7
NCT04084366 Phase Ib/II OBI-999 Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors Terminated USA 0
NCT04084951 Phase I SQZ-PBMC-HPV Atezolizumab + SQZ-PBMC-HPV Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors Completed USA | DEU | CAN 0
NCT04087018 Phase I Zimberelimab Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT04089449 Phase I PRT811 A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis Completed USA 0
NCT04089527 Phase I FT-1101 Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma Completed FRA | ESP 0
NCT04094610 Phase Ib/II Repotrectinib A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 4
NCT04095273 Phase I Elimusertib + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Completed USA | GBR | ESP | DEU 1
NCT04096638 Phase I Nivolumab + SB 11285 SB 11285 Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04098068 Phase II Pembrolizumab Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) Active, not recruiting USA 0
NCT04099277 Phase I LY3435151 + Pembrolizumab LY3435151 A Study of LY3435151 in Participants With Solid Tumors Terminated USA 1
NCT04101357 Phase Ib/II BNT411 Atezolizumab + BNT411 + Carboplatin + Etoposide Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 Active, not recruiting USA | GBR | ESP | DEU 0
NCT04104776 Phase Ib/II Tulmimetostat Irinotecan + Tulmimetostat A Study of CPI-0209 in Patients With Advanced Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT04105335 Phase I CEBPA-51 + Pembrolizumab A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (TIMEPOINT) Active, not recruiting GBR 0
NCT04111107 Phase II Precision Medicine for Patients With Identified Actionable Mutations Terminated USA 0
NCT04111445 Phase I ADG116 Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors Terminated USA 0
NCT04111458 Phase I BI 1701963 BI 1701963 + Trametinib A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) Active, not recruiting USA | NLD | DEU 0
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Completed USA 0
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Recruiting USA 0
NCT04116320 Phase I unspecified PD-1 antibody Imiquimod Imiquimod + unspecified PD-1 antibody Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (AM-003) Active, not recruiting USA 0
NCT04116541 Phase II Alectinib Cabozantinib Ribociclib + Siremadlin A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) Recruiting FRA 0
NCT04116710 Phase I HS-110 + HS-130 A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors Completed USA 0
NCT04121442 Phase Ib/II Isunakinra + unspecified PD-1 antibody Isunakinra Isunakinra + unspecified PD-L1 antibody Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Recruiting USA 0
NCT04121676 Phase I AGEN2373 A Study in Subjects With Advanced Cancer Active, not recruiting USA 0
NCT04122339 Phase I MAX-10181 MAX-10181 Given Orally to Patients With Advanced Solid Tumor Unknown status AUS 0
NCT04122625 Phase Ib/II Nivolumab + Xevinapant Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) Completed USA | FRA | ESP 0
NCT04123366 Phase II Olaparib + Pembrolizumab Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 16
NCT04128423 Phase I AMV-564 Study of AMV564 in Subjects With Advanced Solid Tumors Unknown status USA 0
NCT04130516 Phase Ib/II LNS8801 LNS8801 + Pembrolizumab Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab Recruiting USA 0
NCT04130542 Phase I LVGN6051 Phase 1 Trial of LVGN6051 as Single Agent and in Combination Therapy in Advanced or Metastatic Malignancy Recruiting USA 0
NCT04135352 Phase I Pembrolizumab + V938 A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) Terminated USA | CAN 1
NCT04136834 Phase I Pegtomarginase A Phase I Open-label Study for Subjects With Advanced Malignancies (PT01) Unknown status USA 0
NCT04137900 Phase I Icatolimab Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies Recruiting USA 0
NCT04140500 Phase I RO7247669 Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors Recruiting USA | GBR | ESP 10
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting USA | AUS 0
NCT04143711 Phase Ib/II DF1001 DF1001 + Pembrolizumab Study of DF1001 in Patients With Advanced Solid Tumors Recruiting USA | NLD | FRA | BEL 1
NCT04143789 Phase Ib/II AP-002 Evaluation of AP-002 in Patients With Solid Tumors Unknown status USA 0
NCT04144140 Phase I E7766 Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 Terminated USA | GBR | FRA | ESP 1
NCT04147234 Phase I BI 1387446 BI 1387446 + Ezabenlimab A Study to Find the Best Dose of BI 1387446 Alone or in Combination With BI 754091 in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) Completed USA | GBR | ESP 0
NCT04147247 Phase I BI 905681 A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread Completed USA 0
NCT04156100 Phase I AGEN1223 A Study in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04157517 Phase I TAK-573 A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study Completed USA | AUS 0
NCT04157985 Phase III Nivolumab Ipilimumab Pembrolizumab Atezolizumab Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04158336 Phase Ib/II ZN-c3 Talazoparib + ZN-c3 Pembrolizumab + ZN-c3 A Study of ZN-c3 in Participants With Solid Tumors Recruiting USA 0
NCT04158583 Phase I RO7296682 A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors. Terminated ESP | CAN | BEL | AUS 1
NCT04161391 Phase Ib/II TPX-0046 Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations Terminated USA 1
NCT04164199 Phase III Pamiparib + Tislelizumab Pemetrexed Disodium + Tislelizumab Tislelizumab Capecitabine + Tislelizumab Pamiparib Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies Enrolling by invitation 4
NCT04165031 Phase Ib/II Cetuximab + LY3499446 Erlotinib + LY3499446 LY3499446 Abemaciclib + LY3499446 Docetaxel A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation Terminated USA | AUS 0
NCT04165330 Phase Ib/II Anlotinib + Nivolumab Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors Active, not recruiting USA 0
NCT04165772 Phase II Dostarlimab-gxly + Fluorouracil Dostarlimab-gxly Capecitabine + Dostarlimab-gxly Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors Recruiting USA 0
NCT04167137 Phase I SYNB1891 Atezolizumab + SYNB1891 Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects Unknown status USA 0
NCT04170153 Phase I M1774 M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors Active, not recruiting USA | GBR | ESP 2
NCT04171219 Phase II Pembrolizumab + Talabostat mesylate Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers Active, not recruiting USA 0
NCT04171700 Phase II Rucaparib A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR) Terminated USA 0
NCT04172597 Phase II Poziotinib A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies Terminated USA 0
NCT04180215 Phase Ib/II HB-201 + HB-202 HB-201 + Nivolumab HB-201 HB-201 + HB-202 + Nivolumab A Study of TheraT Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers Recruiting USA | NLD | ESP 0
NCT04180371 Phase Ib/II BT5528 + Nivolumab BT5528 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression Recruiting USA | GBR | ESP | BEL 1
NCT04184869 Phase I Belinostat Atazanavir + Belinostat Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials Completed USA 0
NCT04185883 Phase Ib/II Fluorouracil + Irinotecan + Panitumumab + Sotorasib AMG 404 + Sotorasib Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sotorasib Sotorasib + TNO155 Atezolizumab + Sotorasib Pembrolizumab + Sotorasib Sotorasib Everolimus + Sotorasib Bevacizumab-awwb + Fluorouracil + Oxaliplatin + Sotorasib Bevacizumab-awwb + Fluorouracil + Irinotecan + Sotorasib BI 1701963 + Sotorasib Palbociclib + Sotorasib Afatinib + Sotorasib RMC-4630 + Sotorasib Panitumumab + Sotorasib + Trametinib Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) Recruiting USA | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS 3
NCT04186637 Phase I ALPN-202 An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1) Terminated USA | AUS 0
NCT04189445 Phase II Futibatinib Futibatinib in Patients With Specific FGFR Aberrations Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL 7
NCT04190628 Phase I ABM-1310 ABM-1310 + Cobimetinib Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT04192344 Phase I ABSK021 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK021 in Patients With Advanced Solid Tumor Recruiting USA 0
NCT04192981 Phase I GDC-0084 GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases Active, not recruiting USA 0
NCT04195555 Phase II Ivosidenib Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA | AUS 1
NCT04196530 Phase I Atezolizumab + BDB001 BDB001-102 Open Label Dose Escalation Combination w Atezolizumab Active, not recruiting USA 0
NCT04197713 Phase I Adavosertib + Olaparib Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study Active, not recruiting USA 0
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting USA 0
NCT04198818 Phase Ib/II HH2710 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Terminated USA 1
NCT04200404 Phase Ib/II Regorafenib + Sugemalimab A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors Completed AUS 0
NCT04200963 Phase I KYN-175 KYN-175 in Patients With Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Completed USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04208958 Phase Ib/II Nivolumab + Vancomycin + VE800 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer (Consortium-IO) Completed USA 0
NCT04209465 Phase I BDTX-189 A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. Terminated USA | FRA | ESP 1
NCT04209595 Phase Ib/II PLX038 + Rucaparib PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers Active, not recruiting USA 0
NCT04214093 Phase I AZD0466 A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors Terminated USA 0
NCT04214418 Phase Ib/II Atezolizumab + Cobimetinib + Hydroxychloroquine Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO) Active, not recruiting USA 0
NCT04215978 Phase I BGB-A445 + Tislelizumab BGB-A445 Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors Active, not recruiting USA | NZL | CAN | AUS 3
NCT04219254 Phase Ib/II BI-1206 + Pembrolizumab A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting USA 1
NCT04222413 Phase I Metarrestin Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Recruiting USA 0
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting USA | CAN 1
NCT04233567 Phase II Infigratinib Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Active, not recruiting USA 0
NCT04234113 Phase I SOT101 Pembrolizumab + SOT101 Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors Active, not recruiting USA | FRA | ESP 1
NCT04235101 Phase I Niraparib + Trastuzumab Duocarmazine Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors Completed NLD | GBR | BEL 0
NCT04236414 Phase I Olaparib Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 8
NCT04237649 Phase I KAZ954 + Spartalizumab KAZ954 + Taminadenant KAZ954 KAZ954 + NZV930 KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors Terminated USA | ITA | ESP | CAN 4
NCT04238819 Phase I Abemaciclib + Temozolomide Abemaciclib + Irinotecan + Temozolomide A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 0
NCT04239092 Phase I Elraglusib + Irinotecan Elraglusib 9-ING-41 in Pediatric Patients With Refractory Malignancies. Active, not recruiting USA 0
NCT04241835 Phase I Tazemetostat A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies Recruiting USA | FRA | BEL 2
NCT04242147 Phase I KD033 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors. Terminated USA 0
NCT04242199 Phase I INCB099280 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Recruiting USA | FRA | BEL | AUS 1
NCT04246671 Phase Ib/II TAEK-VAC-HerBy Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer Active, not recruiting USA 0
NCT04247126 Phase I SY-5609 A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors Completed USA 0
NCT04249843 Phase I BGB3245 Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors Recruiting USA | AUS 0
NCT04250155 Phase I RO7310729 Atezolizumab + RO7310729 An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | NLD | ITA | ESP | CAN | BEL | AUS 2
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Terminated USA 1
NCT04252339 Phase I GDC-1971 RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors Completed USA 0
NCT04257110 Phase I BB-1701 A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors Active, not recruiting USA 1
NCT04257617 Phase I ZL1201 A Trial of ZL-1201 in Subjects With Advanced Cancer Completed USA 1
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Active, not recruiting USA | GBR | ESP | DEU 1
NCT04260529 Phase Ib/II Cypep-1 Cypep-1 + Pembrolizumab CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (CICILIA) Active, not recruiting NLD | FRA | ESP 0
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04261075 Phase I Durvalumab + IPH5201 + Oleclumab Durvalumab + IPH5201 IPH5201 IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors Completed USA | FRA | ESP 1
NCT04261439 Phase I NIZ985 NIZ985 + Spartalizumab A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab Terminated USA | ITA | ESP | DEU | BEL 2
NCT04262466 Phase Ib/II IMC-F106C IMC-F106C + unspecified PD-1 antibody IMC-F106C + unspecified PD-L1 antibody Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors Recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 4
NCT04266912 Phase Ib/II Avelumab + Berzosertib Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors Active, not recruiting USA 0
NCT04267939 Phase I Elimusertib + Niraparib ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer Terminated USA 0
NCT04270864 Phase I IMO-2125 + Ipilimumab + Nivolumab Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO) Active, not recruiting FRA 0
NCT04272034 Phase I INCB099318 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors Active, not recruiting USA | GBR | BEL 4
NCT04273061 Phase II Atezolizumab Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) Recruiting CAN 0
NCT04276376 Phase II Atezolizumab + Rucaparib Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) Suspended FRA 0
NCT04278144 Phase I BDC-1001 + Pembrolizumab BDC-1001 A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors Recruiting USA | ITA | FRA | ESP 1
NCT04282018 Phase Ib/II BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Recruiting AUS 1
NCT04284774 Phase II Tipifarnib Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Active, not recruiting USA 1
NCT04287868 Phase Ib/II Bintrafusp alfa + NHS-IL12 + PDS0101 Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Active, not recruiting USA 0
NCT04291079 Phase I SRK-181 + unspecified PD-L1 antibody SRK-181 SRK-181 + unspecified PD-1 antibody SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors Active, not recruiting USA 1
NCT04293094 Phase I AMG 650 Study of AMG 650 in Adult Participants With Advanced Solid Tumors Completed USA | ITA | ESP | CAN | BEL | AUS 1
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Active, not recruiting USA 0
NCT04294628 Phase I Trastuzumab deruxtecan Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer Active, not recruiting USA 0
NCT04295863 Phase I Nivolumab Pembrolizumab Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers Recruiting USA 0
NCT04299880 Phase I Gemcitabine + Nab-paclitaxel + Napabucasin Napabucasin Bevacizumab Napabucasin + Paclitaxel Napabucasin + Nivolumab Fluorouracil + Irinotecan + Leucovorin + Napabucasin Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols Completed USA | FRA 2
NCT04301011 Phase Ib/II TBio-6517 Pembrolizumab + TBio-6517 Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) Terminated USA | CAN 1
NCT04303858 Phase I Atezolizumab + RO7284755 RO7284755 A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors Recruiting NLD | ESP | CAN | BEL 2
NCT04306224 Phase I IMC-002 A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas Completed USA 1
NCT04308330 Phase I Cefixime + Irinotecan + Temozolomide + Vincristine Sulfate Cefixime + Irinotecan + Temozolomide + Vincristine Sulfate + Vorinostat Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies (NYMC195) Recruiting USA 0
NCT04316169 Phase I Abemaciclib + Anastrozole + Hydroxychloroquine Abemaciclib + Fulvestrant + Hydroxychloroquine Abemaciclib + Hydroxychloroquine Abemaciclib + Hydroxychloroquine + Letrozole Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer Withdrawn USA 0
NCT04317105 Phase Ib/II Copanlisib + Ipilimumab + Nivolumab Copanlisib + Nivolumab Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Active, not recruiting USA | CAN 0
NCT04319224 Phase Ib/II Vopratelimab Nivolumab + Vopratelimab Ipilimumab + Vopratelimab Vopratelimab (JTX-2011) Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors Completed USA 0
NCT04319757 Phase I ACE1702 + Cyclophosphamide + Fludarabine ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Recruiting USA 1
NCT04320888 Phase II Selpercatinib Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Active, not recruiting USA | AUS 1
NCT04324814 Phase I SHR-1701 A Trial of SHR-1701 in Subjects With Advanced Solid Tumors Completed AUS 0
NCT04328740 Phase I Ipilimumab + Nivolumab + TP-1454 TP-1454 Phase 1 Study of Oral TP-1454 Recruiting USA 0
NCT04330664 Phase Ib/II Adagrasib + TNO155 Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) Active, not recruiting USA 0
NCT04332653 Phase Ib/II NT-I7 + Pembrolizumab NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT04336098 Phase I SRF617 Study of SRF617 in Patients With Advanced Solid Tumors Completed USA | CAN 0
NCT04336241 Phase I Nivolumab + RP2 RP2 Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors Recruiting GBR | ESP 0
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Completed USA | ESP 4
NCT04344795 Phase I TPST-1495 Pembrolizumab + TPST-1495 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors Active, not recruiting USA 0
NCT04347226 Phase II BMS-986253 Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19 Terminated USA 0
NCT04348916 Phase I ONCR-177 + Pembrolizumab ONCR-177 Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors Terminated USA | CAN 0
NCT04349969 Phase I AK117 Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47-targeting Antibody Completed AUS 0
NCT04353102 Phase I YH002 A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies Completed AUS 0
NCT04354246 Phase I COM902 COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies Recruiting USA 0
NCT04357756 Phase I Toripalimab-tpzi + YH001 A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors Completed AUS 0
NCT04362748 Phase I AMG 256 Study of AMG 256 in Adult Subjects With Advanced Solid Tumors Completed USA | ESP | BEL | AUS 0
NCT04363242 Phase I SYN125 SYN004 + SYN125 A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions Active, not recruiting USA 0
NCT04370704 Phase Ib/II INCAGN02385 + INCAGN02390 + Retifanlimab INCAGN02385 + INCAGN02390 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies Active, not recruiting USA | AUS 0
NCT04372706 Phase Ib/II RTX-240 RTX-240 Monotherapy Terminated USA 0
NCT04374877 Phase I SRF388 Study of SRF388 in Patients With Advanced Solid Tumors Recruiting USA 2
NCT04377932 Phase I Cyclophosphamide + Fludarabine AGAR T cells Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors Recruiting USA 0
NCT04383210 Phase II Seribantumab Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Active, not recruiting USA | CAN | AUS 1
NCT04383938 Phase Ib/II APR-246 + Pembrolizumab Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies Completed USA 0
NCT04387071 Phase Ib/II INCAGN01949 + Vidutolimod CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma Terminated USA 0
NCT04387084 Phase I Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy Recruiting USA 0
NCT04390737 Phase I HH2853 A Phase I Study to Evaluate the Safety and Clinical Activity of HH2853. Recruiting USA 1
NCT04393454 Phase II Sirolimus Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy Terminated USA 0
NCT04396821 Phase I TST001 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT04404569 Phase I BXQ-350 Continued Treatment for Participants Enrolled in Studies of BXQ-350 Enrolling by invitation USA 0
NCT04408599 Phase Ib/II NC410 A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors Terminated USA 0
NCT04410224 Phase I ASN004 Study of ASN004 in Patients With Advanced Solid Tumors (ASN004) Active, not recruiting USA 0
NCT04410653 Phase II Afatinib Afatinib in Advanced NRG1-Rearranged Malignancies Completed DEU 0
NCT04416568 Phase II Ipilimumab + Nivolumab Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Recruiting USA 0
NCT04417465 Phase I ABBV-CLS-579 ABBV-CLS-579 + unspecified PD-1 antibody First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors Recruiting USA | FRA | ESP 4
NCT04418167 Phase I JSI-1187 Dabrafenib + JSI-1187 JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations Suspended USA 0
NCT04418661 Phase Ib/II Pembrolizumab + RMC-4630 Adagrasib + RMC-4630 Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies Active, not recruiting USA | NLD | ESP | AUS 4
NCT04420884 Phase I Pembrolizumab + TAK-676 TAK-676 TAK-676 as Single Agent (SA) and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Recruiting USA | GBR | FRA | CAN | BEL | AUT 6
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04424641 Phase Ib/II GEN1044 A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors Terminated USA | ESP 2
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04430348 Phase I PTX-35 PTX-35 in Patients With Advanced Solid Tumors Terminated USA 0
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04432597 Phase Ib/II PRGN-2009 Bintrafusp alfa + PRGN-2009 HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers Active, not recruiting USA 0
NCT04434482 Phase I Senaparib + Temozolomide IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer Recruiting USA | AUS 3
NCT04434560 Phase II Ipilimumab + Nivolumab Neoadjuvant Immunotherapy in Brain Metastases Terminated USA 0
NCT04440735 Phase Ib/II Atezolizumab + DSP107 DSP107 A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors Recruiting USA 0
NCT04440943 Phase I CDX-527 A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies Completed USA 0
NCT04442126 Phase Ib/II NM21-1480 A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Terminated USA | ESP 1
NCT04443088 Phase I INV-1120 A Phase 1, Multi-Center, Safety, Dose Escalation, Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors Recruiting USA 0
NCT04444427 Phase Ib/II GLR2007 Evaluation of GLR2007 for Advanced Solid Tumors Completed USA 0
NCT04446260 Phase I Trastuzumab rezetecan A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Recruiting USA | AUS 3
NCT04446351 Phase I Dostarlimab-gxly + GSK6097608 GSK6097608 Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors Recruiting USA | CAN 2
NCT04447755 Phase II Lenvatinib A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231) Active, not recruiting USA | NZL | ITA | FRA | ESP | BEL | AUS 13
NCT04449549 Phase II Nilotinib + Paclitaxel Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel Recruiting USA 0
NCT04449874 Phase I Atezolizumab + Divarasib Bevacizumab + Divarasib Cetuximab + Divarasib Divarasib + Erlotinib Divarasib A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Recruiting USA | NZL | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS 9
NCT04450732 Phase I GQ1001 Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors Recruiting USA | AUS 1
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Active, not recruiting AUS 2
NCT04455620 Phase Ib/II BNT151 BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors Active, not recruiting USA | ESP 0
NCT04457778 Phase I M6223 Bintrafusp alfa + M6223 First in Human Study of M6223 in Participants With Metastatic or Locally Advanced Solid Unresectable Tumors Completed USA | CAN 0
NCT04458259 Phase I PF-07265807 A Study of PF-07265807 In Participants With Advanced or Metastatic Solid Tumors Active, not recruiting USA | ITA | ESP | CAN | AUS 3
NCT04460456 Phase I SBT6050 Pembrolizumab + SBT6050 Cemiplimab + SBT6050 A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors Active, not recruiting USA | AUS 1
NCT04465487 Phase I Cemiplimab + REGN6569 Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies Recruiting USA | ESP 0
NCT04469530 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) Recruiting USA 0
NCT04471415 Phase Ib/II DRP-104 Atezolizumab + DRP-104 Study to Investigate DRP-104 in Adults With Advanced Solid Tumors Terminated USA | ESP | DEU 2
NCT04471727 Phase Ib/II Atezolizumab + HPN328 HPN328 Study in Patients With Advanced Cancers Associated With Expression of DLL3 Recruiting USA 0
NCT04474470 Phase Ib/II Cetuximab + NT219 NT219 A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Active, not recruiting USA 1
NCT04475523 Phase I Onvatilimab Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies Completed USA | AUS 0
NCT04482309 Phase II Trastuzumab deruxtecan A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) Active, not recruiting USA | NLD | ITA | GBR | ESP | CAN | BEL | AUS 7
NCT04485013 Phase I TTX-080 TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers Active, not recruiting USA 0
NCT04488003 Phase II Ulixertinib Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Terminated USA 0
NCT04491942 Phase I Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Active, not recruiting USA | CAN 0
NCT04492488 Phase Ib/II MRG002 A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer Unknown status USA 0
NCT04497116 Phase Ib/II RP-3500 + Talazoparib RP-3500 Study of RP-3500 in Advanced Solid Tumors Active, not recruiting USA | GBR | CAN 1
NCT04500548 Phase I Nivolumab Ipilimumab + Nivolumab Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Withdrawn USA | CAN 0
NCT04501276 Phase I ADG116 ADG106 + ADG116 ADG116 + unspecified PD-1 antibody A Phase 1b Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients Active, not recruiting USA | AUS 0
NCT04502602 Phase I Neratinib + Niraparib Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE) Recruiting USA 0
NCT04503265 Phase Ib/II AMXI-5001 A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies Active, not recruiting USA 0
NCT04504669 Phase I AZD8701 + Durvalumab AZD8701 First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours Active, not recruiting USA | FRA | ESP | CAN 0
NCT04504916 Phase II VLS-101 A Study of VLS-101 in Patients With Solid Tumors Completed USA | CAN 0
NCT04504942 Phase II Leronlimab Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors Unknown status USA 0
NCT04511845 Phase I SPYK04 A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Recruiting USA 1
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04514497 Phase I Elimusertib + Irinotecan Elimusertib + Topotecan Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Active, not recruiting USA 0
NCT04518046 Phase I Ipilimumab + Nivolumab + Sitravatinib Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies Active, not recruiting USA 0
NCT04520711 Phase I CDX-1140 + Pembrolizumab + TSA/TAA-specific TCR engineered T cells Study of Adoptively Transferred, Gene-engineered T Cells With CD40 Activation and PD-1 Blockade in Incurable Cancers Active, not recruiting USA 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04521621 Phase Ib/II Coxsackievirus A21 + Pembrolizumab A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) Terminated USA | ITA | FRA | ESP | DEU | CAN 8
NCT04521686 Phase I LY3410738 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting USA | FRA | ESP | AUS 5
NCT04525014 Phase I Irinotecan + RRx-001 + Temozolomide RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors (PIRATE) Active, not recruiting USA 0
NCT04526106 Phase I RLY-4008 REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS 5
NCT04528836 Phase I BBP-398 First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT04534283 Phase II Abemaciclib + LY3214996 A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. Terminated USA 0
NCT04537715 Phase I Itraconazole + Tazemetostat Rifampin + Tazemetostat Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer Completed USA | ESP 0
NCT04543188 Phase I Binimetinib + Midazolam + PF-07284890 Binimetinib + PF-07284890 PF-07284890 A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement Terminated USA | CAN 1
NCT04544995 Phase I Dostarlimab-gxly + Niraparib Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors Suspended GBR | FRA | ESP | DEU 2
NCT04551521 Phase II Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib CRAFT: The NCT-PMO-1602 Phase II Trial Recruiting DEU 0
NCT04551885 Phase I Cyclophosphamide + Fludarabine Avelumab + FT516 Aldesleukin FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT04553692 Phase I Bevacizumab + Fluorouracil + IGM-8444 + Irinotecan + Leucovorin Fluorouracil + IGM-8444 + Irinotecan + Leucovorin IGM-8444 Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers Recruiting USA | FRA | ESP | AUS 1
NCT04555837 Phase Ib/II Alisertib + Pembrolizumab Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Active, not recruiting USA 0
NCT04557384 Phase I Ramucirumab A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer Terminated USA 1
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) Recruiting USA | GBR 6
NCT04561362 Phase Ib/II BT8009 BT8009 + Pembrolizumab Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies Recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT04564027 Phase II Ceralasertib A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer Active, not recruiting USA | FRA | ESP 0
NCT04564417 Phase I W0180 Pembrolizumab + W0180 First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors Terminated FRA | ESP 0
NCT04565275 Phase Ib/II ICP-192 A Study of ICP-192 in Patients With Advanced Solid Tumors Recruiting USA | AUS 0
NCT04566393 Expanded access Ulixertinib Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies Available USA 0
NCT04570839 Phase Ib/II BMS-986207 + COM701 + Nivolumab Nivolumab COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. Active, not recruiting USA 0
NCT04572152 Phase I AK119 + Cadonilimab A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors Active, not recruiting AUS 0
NCT04572451 Phase I BMS-986253 + Nivolumab Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors Recruiting USA 0
NCT04574583 Phase Ib/II Bintrafusp alfa + FPV-CV301 + MVA-BN-CV301 + SX-682 Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) Active, not recruiting USA 0
NCT04579380 Phase II Trastuzumab + Tucatinib Fulvestrant + Trastuzumab + Tucatinib Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations Active, not recruiting USA | NLD | ITA | GBR | ESP | DEU | BEL 3
NCT04579757 Phase Ib/II Surufatinib + Tislelizumab Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04585035 Phase Ib/II D-1553 Study to Evaluate D-1553 in Subjects With Solid Tumors Active, not recruiting USA | AUS 2
NCT04585750 Phase Ib/II PC14586 + Pembrolizumab PC14586 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Recruiting USA | ITA | GBR | FRA | ESP | DEU | AUS 2
NCT04585958 Phase I Olaparib + Trastuzumab deruxtecan Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer Suspended USA 0
NCT04586270 Phase I TAS0612 A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer Recruiting USA | FRA 0
NCT04586335 Phase I CYH33 + Olaparib Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Terminated USA | AUS 1
NCT04587479 Phase I JAB-8263 A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors Unknown status USA 0
NCT04588545 Phase Ib/II Pertuzumab + Trastuzumab Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease Recruiting USA 0
NCT04589845 Phase II Alectinib Ado-trastuzumab emtansine Ipatasertib Inavolisib Entrectinib Atezolizumab Idasanutlin Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 14
NCT04591431 Phase II Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) Active, not recruiting ITA 0
NCT04592484 Phase Ib/II CDK-002 A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors Completed USA | GBR 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Recruiting USA | ESP 0
NCT04601402 Phase I Avelumab + GEN-001 GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy Completed USA 0
NCT04605614 Phase I Pembrolizumab 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression Withdrawn 0
NCT04606381 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) Recruiting USA | GBR | CAN 1
NCT04609579 Phase I SNX281 Pembrolizumab + SNX281 Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma Terminated USA 0
NCT04613492 Phase I Durvalumab + MEDI9253 A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors Active, not recruiting USA | FRA 0
NCT04616534 Phase I Elimusertib + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Active, not recruiting USA 0
NCT04617522 Phase I Sacituzumab govitecan-hziy Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan-hziy in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment Recruiting USA | FRA 0
NCT04618393 Phase Ib/II EMB-02 A Study of EMB-02 in Participants With Advanced Solid Tumors Recruiting USA | AUS 1
NCT04626635 Phase Ib/II Cemiplimab + REGN7075 REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors Recruiting USA 1
NCT04628780 Phase I PF-07209960 Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors Terminated USA 0
NCT04631029 Phase I Atezolizumab + Carboplatin + Entinostat + Etoposide Atezolizumab + Entinostat Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread Completed USA 0
NCT04632992 Phase II Ipatasertib Atezolizumab + Capecitabine Entrectinib Atezolizumab + Docetaxel Ado-trastuzumab emtansine + Atezolizumab Capecitabine + Pertuzumab/trastuzumab/hyaluronidase-zzxf Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Alectinib Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab + Paclitaxel Ado-trastuzumab emtansine + Tucatinib A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC) Completed USA 0
NCT04635995 Phase I LVGN7409 Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy Recruiting USA 0
NCT04639219 Phase II Trastuzumab deruxtecan A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (DPT01) Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL 3
NCT04640246 Phase Ib/II TBX-3400 Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies Unknown status USA 1
NCT04642365 Phase I Atezolizumab + RO7296682 A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors. Completed USA | ESP | CAN | BEL | AUS 1
NCT04644068 Phase I AZD5305 + Carboplatin + Paclitaxel AZD5305 + Paclitaxel AZD5305 + Carboplatin AZD5305 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA) Recruiting USA | ITA | GBR | ESP | CAN | AUS 7
NCT04644315 Phase II Alectinib A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T) Terminated USA 0
NCT04645069 Phase I ADG126 ADG106 + ADG126 ADG126 + unspecified PD-1 antibody ADG126, ADG126 in Combination With Toripalimab, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors Recruiting USA | AUS 1
NCT04648202 Phase I FS120 FS120 First in Human Study in Patients With Advanced Malignancies Recruiting USA | ESP 0
NCT04648254 Phase I Q702 Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor Recruiting USA 0
NCT04649385 Phase I BGB-15025 BGB-15025 + Tislelizumab BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors Recruiting USA | NZL | AUS 2
NCT04655183 Phase Ib/II Niraparib + VX-803 Niraparib Study of M4344 in Combination With Niraparib Withdrawn 0
NCT04657068 Phase Ib/II ART0380 + Gemcitabine ART0380 Gemcitabine A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT04659096 Phase I ION537 A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors Completed USA 0
NCT04659629 Phase I NL-201 NL-201 in Patients With Relapsed or Refractory Cancer Active, not recruiting USA | CAN | AUS 0
NCT04660929 Phase I CT-0508 CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Active, not recruiting USA 0
NCT04662580 Phase I ARX517 ARX517 in Subjects With Advanced Solid Tumor (ARX517) Recruiting USA 0
NCT04665206 Phase I VT3989 Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations Recruiting USA | AUS 0
NCT04666688 Phase Ib/II LYT-200 LYT-200 + unspecified PD-1 antibody Gemcitabine + LYT-200 + Nab-paclitaxel LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors Recruiting USA 0
NCT04669899 Phase I JTX 8064 JTX 8064 + Pimivalimab JTX 8064 + Pembrolizumab Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors Completed USA 0
NCT04670679 Phase I ERAS-601 FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting USA | AUS 0
NCT04672460 Phase I Talazoparib A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors Completed USA | AUS 0
NCT04675996 Phase I INT-1B3 First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors Terminated NLD | BEL 0
NCT04676334 Phase III Rucaparib CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R) Completed ITA | GBR | CAN 3
NCT04676633 Phase I Cotsiranib Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy Completed USA 0
NCT04678648 Phase I RSC-1255 A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies Recruiting USA 0
NCT04678908 Phase I HB0025 A Study of Injection HB0025 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04678921 Phase I MOR210 Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors Completed USA 0
NCT04681248 Expanded access DKN-01 Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors Available USA 0
NCT04683250 Phase Ib/II Vepafestinib Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET)) Recruiting USA 1
NCT04683354 Phase I Tunlametinib Phase I Study of HL-085 in Patients With Advanced Solid Tumor Tumors Completed USA 0
NCT04686383 Phase I CAL056 mesylate Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors Completed USA 1
NCT04690699 Phase Ib/II PVSRIPO + unspecified PD-1 antibody LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04693468 Phase I Axitinib + Talazoparib Crizotinib + Talazoparib Palbociclib + Talazoparib Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial Recruiting USA 0
NCT04695847 Phase I M1231 M1231 in Participants With Solid Tumors Completed USA | CAN 0
NCT04699188 Phase Ib/II JDQ443 JDQ443 + TNO155 JDQ443 + Tislelizumab + TNO155 JDQ443 + Tislelizumab Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01) Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT04704661 Phase I Ceralasertib + Trastuzumab deruxtecan Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Recruiting USA 0
NCT04705818 Phase II Durvalumab + Tazemetostat Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) Recruiting FRA 0
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Recruiting USA | CAN 0
NCT04708470 Phase Ib/II Bintrafusp alfa + Entinostat + NHS-IL12 Entinostat + NHS-IL12 A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Recruiting USA 0
NCT04710043 Phase I BNT152 BNT153 Dose Escalation Trial of BNT152+153 in Patients With Cancer Recruiting USA 1
NCT04713371 Phase II Cyclophosphamide + Ipilimumab + Pembrolizumab + Sargramostim A Phase 2 Trial for Patients With Metastatic Solid Cancer Recruiting USA 0
NCT04713891 Phase I KF-0210 Atezolizumab + KF-0210 A Study of KF-0210 in Advanced Solid Tumors Patients Unknown status AUS 0
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04718675 Phase I KB-0742 A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma Recruiting USA | GBR | ESP 0
NCT04720976 Phase Ib/II JAB-3312 + Pembrolizumab Binimetinib + JAB-3312 JAB-3312 Activity in Adult Patients With Advanced Solid Tumors Recruiting USA 0
NCT04721015 Phase I ABBV-637 + Docetaxel ABBV-637 + Osimertinib ABBV-637 Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors Active, not recruiting USA | FRA | ESP | AUS 4
NCT04725331 Phase Ib/II BT-001 BT-001 + Pembrolizumab A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Recruiting FRA | BEL 0
NCT04725474 Phase I CTL-002 First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER) (GDFATHER) Recruiting ESP | DEU 1
NCT04726332 Phase I Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) Active, not recruiting USA 0
NCT04727151 Phase Ib/II Cyclophosphamide + Fludarabine + TAC01-HER2 TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2) Active, not recruiting USA | CAN 0
NCT04727554 Phase I AMG 404 + AMG 994 Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors Completed USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 2
NCT04729348 Phase II Lenvatinib + Pembrolizumab Pembrolizumab And Lenvatinib In Leptomeningeal Metastases Terminated USA 0
NCT04729725 Phase I Cemiplimab + SAR439459 Strategic Alliance: Phase 1b Trial Assessing Combination of TGF-beta Inhibitor and PD-1 Inhibitor Cemiplimab Terminated USA 0
NCT04730349 Phase Ib/II Nivolumab + NKTR-214 A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020) Terminated USA | ITA | FRA | ESP | DEU | AUS 0
NCT04735796 Phase I LM-102 Study of LM-102 in Subjects in Advanced Tumors Terminated USA 0
NCT04735978 Phase I RP3 Nivolumab + RP3 Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours Active, not recruiting USA | GBR | FRA | ESP 1
NCT04737122 Phase I LM-061 LM-061 + Toripalimab-tpzi Study of LM-061 in Subjects in Advanced Tumors Terminated AUS 0
NCT04739293 Phase I Narazaciclib Study of ON 123300 in Patients With Advanced Cancer Recruiting USA 0
NCT04739618 Phase II Ipilimumab + Pembrolizumab + Sargramostim Metastatic Solid Cancer Clinical Trial Unknown status USA 0
NCT04740424 Phase I FS222 FS222 First in Human Study in Patients With Advanced Malignancies Recruiting ESP 1
NCT04742959 Phase Ib/II Tinengotinib Nab-paclitaxel + Tinengotinib Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT04746612 Phase I HH30134 A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH30134 in Patients With Advanced Solid Tumours Terminated AUS 1
NCT04761198 Phase Ib/II Etigilimab + Nivolumab A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors. Completed USA | GBR 0
NCT04761601 Phase I Gemcitabine + Paclitaxel + UCT-01-097 UCT-01-097 First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors Terminated USA 0
NCT04762602 Phase I HMPL-306 A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations Active, not recruiting USA | ESP 0
NCT04762641 Phase I ABL503 This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT04768296 Phase II Berzosertib + Topotecan Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) Completed USA | ITA | FRA | ESP | BEL 2
NCT04768868 Phase I IMP7068 The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors (WEE1) Recruiting USA 2
NCT04770246 Phase II TAS-117 TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations Terminated USA | GBR | FRA | AUT 0
NCT04771520 Phase II Avapritinib Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors Recruiting USA 0
NCT04772989 Phase I AB308 + Zimberelimab A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12) Active, not recruiting USA | ESP 1
NCT04773782 Phase Ib/II Avapritinib A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling Recruiting USA | ITA | GBR | FRA | DEU | CAN | AUT | AUS 1
NCT04774718 Phase Ib/II Alectinib A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT04774952 Phase I RMC-5552 Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors Active, not recruiting USA 0
NCT04775485 Phase II Tovorafenib A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1) Recruiting USA | NLD | GBR | DEU | CAN | AUS 5
NCT04777994 Phase I ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484 A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors Recruiting USA | FRA | ESP 3
NCT04779151 Phase II Dostarlimab-gxly + Niraparib Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) Suspended FRA 0
NCT04780217 Phase Ib/II T3011 Pembrolizumab + T3011 A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT04785287 Phase Ib/II BMS-986218 BMS-986218 + Nivolumab Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies Active, not recruiting USA 0
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Recruiting USA 0
NCT04789668 Phase Ib/II Bintrafusp alfa + Pimasertib Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases Completed USA 0
NCT04794699 Phase I IDE397 Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion Recruiting USA | FRA | ESP | AUS 2
NCT04795661 Phase II Pembrolizumab Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) Active, not recruiting FRA 0
NCT04795713 Phase I MT-6402 Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 Recruiting USA 0
NCT04796012 Phase Ib/II Atezolizumab + Irinotecan + Temozolomide + Vincristine Sulfate VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors Recruiting USA 0
NCT04799054 Phase Ib/II Pembrolizumab + TransCon TLR7/8 Agonist TransCon TLR7/8 Agonist A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors Recruiting USA | NLD | ESP | AUS 2
NCT04800627 Phase Ib/II MLN4924 + Pembrolizumab Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor Terminated USA 0
NCT04800822 Phase I PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 PF-07284892 in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT04801095 Phase I WM-S1-030 A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors Recruiting AUS 1
NCT04801966 Phase 0 Palbociclib Alpelisib Atezolizumab Vemurafenib Ribociclib Talazoparib Cobimetinib Trametinib Abemaciclib Dabrafenib Nivolumab Binimetinib Pembrolizumab Encorafenib Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (TAILOR) Terminated AUS 0
NCT04802174 Phase Ib/II Berzosertib + Lurbinectedin A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers Recruiting USA 0
NCT04802876 Phase II Tislelizumab Spartalizumab Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI) Recruiting ESP 0
NCT04808362 Phase Ib/II OMO-103 Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure) Terminated ESP 0
NCT04826341 Phase Ib/II Berzosertib + Sacituzumab govitecan-hziy A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Recruiting USA 0
NCT04827576 Phase II Docetaxel + Hu5F9-G4 Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) Active, not recruiting USA | GBR | FRA | ESP 1
NCT04827810 Phase I G-TPP A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer Suspended USA 0
NCT04837196 Phase Ib/II ASP7517 + Pembrolizumab ASP7517 Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen Active, not recruiting USA 0
NCT04837677 Phase I PRT1419 A Study of PRT1419 in Patients With Advanced Solid Tumors Completed USA 0
NCT04839991 Phase I CB307 Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA) Recruiting USA | NLD | GBR | ESP 0
NCT04840394 Phase I BDB018 BDB018 + Pembrolizumab Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04840589 Phase I Ipilimumab + Nivolumab + ZEN-3694 Nivolumab + ZEN-3694 Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors Recruiting USA 0
NCT04843709 Phase Ib/II MRG004A A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT04844073 Phase Ib/II MVC-101 A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer Recruiting USA | AUS 1
NCT04851119 Phase Ib/II BC2059 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Recruiting USA 0
NCT04851834 Phase Ib/II Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301 NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma Terminated AUS 0
NCT04853017 Phase Ib/II ELI-002 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) Active, not recruiting USA 0
NCT04855656 Phase I RP-6306 Study of RP-6306 in Advanced Solid Tumors Recruiting USA | CAN 1
NCT04855929 Phase Ib/II ANV419 A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma. (ANV419-001) Recruiting GBR | ESP 1
NCT04857138 Phase I RO7300490 Atezolizumab + RO7300490 A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors Completed GBR | FRA | ESP 2
NCT04857372 Phase I IAG933 A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 2
NCT04859777 Phase I MPT-0118 + Pembrolizumab MPT-0118 A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors Unknown status USA 0
NCT04866134 Phase Ib/II ERAS-007 A Study of ERAS-007 in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1) (HERKULES-1) Active, not recruiting USA 0
NCT04868877 Phase Ib/II MCLA-129 A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Recruiting USA | NLD | ITA | FRA | ESP | DEU | BEL 2
NCT04870944 Phase Ib/II CBL0137 CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Recruiting USA 0
NCT04872166 Phase I BTX-A51 A Study of BTX-A51 in People With Advanced Solid Tumor or Non-Hodgkin Lymphoma Recruiting USA 0
NCT04875806 Phase Ib/II NC762 A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors Terminated USA 0
NCT04879121 Phase II Larotrectinib Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT04881045 Phase I PF-07257876 Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. Completed USA | ESP 0
NCT04882917 Phase I M4076 First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) Completed USA | CAN 0
NCT04886622 Phase I DT2216 A Study of DT2216 in Relapsed/Refractory Malignancies Completed USA 0
NCT04886804 Phase I BI 1810631 A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 8
NCT04887870 Phase II Ipilimumab + Sitravatinib Nivolumab + Sitravatinib Enfortumab vedotin-ejfv + Sitravatinib Pembrolizumab + Sitravatinib Sitravatinib Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study Enrolling by invitation USA 0
NCT04890093 Phase Ib/II STA-8666 + Temozolomide + Vincristine Sulfate Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors Not yet recruiting USA 0
NCT04890613 Phase I CX-5461 Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Recruiting USA | CAN 0
NCT04891718 Phase I MVC-101 + Nivolumab CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia Withdrawn AUS 0
NCT04892017 Phase Ib/II DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Recruiting USA 0
NCT04892043 Phase I Ipilimumab + SQZ-AAC-HPV SQZ-AAC-HPV Ipilimumab + Nivolumab + SQZ-AAC-HPV Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT04895709 Phase Ib/II BMS-986340 + Docetaxel BMS-986340 BMS-986340 + Nivolumab A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors Recruiting USA | ITA | ESP | DEU | CAN | AUS 2
NCT04896697 Phase Ib/II XTX101 Pembrolizumab + XTX101 XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04897321 Phase I Cyclophosphamide + Fludarabine + Mesna + Retroviral vector transduced B7-H3 CAR T cells B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Recruiting USA 0
NCT04898543 Phase I m-ceNK cells + Nogapendekin alfa inbakicept QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT04900519 Phase I STI-6643 Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04900818 Phase I TJ033721 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT04901702 Phase Ib/II Irinotecan + Temozolomide Irinotecan + Talazoparib Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Recruiting USA | CAN 0
NCT04901806 Phase Ib/II PBI-200 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | DEU | AUS 4
NCT04902040 Phase Ib/II Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Recruiting USA 0
NCT04902443 Phase I Nivolumab + Pomalidomide Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Recruiting USA 0
NCT04903873 Phase Ib/II EU101 A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04905914 Phase Ib/II ATRN-119 Study Of ATRN-119 In Patients With Advanced Solid Tumors Recruiting USA 0
NCT04908176 Phase I Avapritinib + Midazolam A Drug-drug Interaction Study of Avapritinib and Midazolam Completed USA 0
NCT04913025 Phase II Pembrolizumab Nivolumab REduced Frequency ImmuNE Checkpoint Inhibition in Cancers (REFINE) Recruiting GBR 0
NCT04913285 Phase I Binimetinib + Exarafenib Exarafenib A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors Recruiting USA | NLD | FRA | ESP | AUS 3
NCT04913337 Phase Ib/II NGM707 + Pembrolizumab NGM707 Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies Recruiting USA 2
NCT04914117 Phase I RC118 A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours Completed AUS 0
NCT04914286 Phase Ib/II GFH018 + Toripalimab-tpzi A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors Completed AUS 1
NCT04919811 Phase II Taletrectinib Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) Recruiting USA | ITA | FRA | ESP | CAN 4
NCT04920383 Phase I ALPN-202 + unspecified PD-1 antibody ALPN-202 With PD-1 Inhibition in Advanced Malignancies (NEON-2) Terminated USA 0
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Recruiting USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS 1
NCT04925609 Phase Ib/II Brigatinib Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED) Recruiting NLD | FRA 0
NCT04928677 Phase I Codrituzumab A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment Recruiting USA 0
NCT04936178 Phase I NB003 A Study of NB003 in Patients With Advanced Malignancies Recruiting USA | GBR | FRA | ESP 2
NCT04939701 Phase Ib/II ASP0739 + Pembrolizumab ASP0739 Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants Completed USA 0
NCT04946864 Phase Ib/II APG-2575 + Palbociclib APG-2575 A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer Recruiting USA 0
NCT04949191 Phase II Pemigatinib Pembrolizumab + Pemigatinib Pemigatinib + Retifanlimab The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. Terminated USA | ITA 2
NCT04949425 Phase I Adavosertib A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours Terminated USA | GBR 0
NCT04954599 Phase Ib/II CP-506 CP-506 + Ipilimumab Carboplatin + CP-506 Cemiplimab + CP-506 CP-506 + Durvalumab CP-506 + Pembrolizumab CP-506 + Nivolumab Avelumab + CP-506 Atezolizumab + CP-506 Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI Recruiting NLD | BEL 0
NCT04956640 Phase I LY3214996 + LY3537982 LY3537982 + Sintilimab Erlotinib + LY3537982 Abemaciclib + LY3537982 LY3537982 Cetuximab + LY3537982 LY3295668 + LY3537982 Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) Recruiting USA | FRA | CAN | AUS 2
NCT04957290 Phase Ib/II NOX66 A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors Terminated USA 0
NCT04957615 Phase II Nivolumab Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression Recruiting USA 0
NCT04958226 Phase I Capivasertib + Midazolam A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours Completed USA 0
NCT04958434 Phase I TST005 Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT04959266 Phase I Adavosertib + Omeprazole Adavosertib + Rifampin Adavosertib + Itraconazole A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib Terminated USA | ESP 0
NCT04964375 Phase I ABSK043 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor Unknown status AUS 0
NCT04965818 Phase Ib/II Binimetinib + Futibatinib Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer Terminated USA 0
NCT04969887 Phase II Ipilimumab + Nivolumab Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) Active, not recruiting NZL | AUS 0
NCT04970992 Phase I DZ-002 A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma Recruiting USA 0
NCT04972110 Phase Ib/II Niraparib + RP-3500 Olaparib + RP-3500 Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors (ATTACC) Recruiting USA 0
NCT04973163 Phase I BI 1823911 + Midazolam BI 1701963 + BI 1823911 A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Active, not recruiting USA | GBR | ESP | BEL 0
NCT04975256 Phase I Adagrasib + BI 1701963 Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) Completed USA 0
NCT04975958 Phase I Atezolizumab + Buparlisib Atezolizumab + Buparlisib + E7046 Atezolizumab + E7046 Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors Recruiting USA 0
NCT04977453 Phase Ib/II GI-101 GI-101 + Pembrolizumab GI-101 + Lenvatinib GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors Recruiting USA 1
NCT04982926 Phase I TAS2940 A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer Recruiting USA | FRA 0
NCT04983745 Phase II Dostarlimab-gxly + Niraparib Niraparib and Dostarlimab in HRD Solid Tumors (DIDO) Recruiting USA 0
NCT04983810 Phase Ib/II CYC065 A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT04985604 Phase Ib/II Pimasertib + Tovorafenib Tovorafenib Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors Recruiting USA | FRA | ESP | CAN | BEL | AUS 1
NCT04985721 Phase II Pamiparib + Tislelizumab A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD) Recruiting AUS 0
NCT04986865 Phase I ATG-101 A Study of Evaluating the Safety and Efficacy of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (PROBE) Recruiting USA | AUS 0
NCT04987112 Phase I CAN1012 Intratumoral CAN1012 in Subjects With Solid Tumors Recruiting USA 0
NCT04990739 Phase I MTB-9655 Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors Unknown status USA 1
NCT04991480 Phase Ib/II ART4215 + Talazoparib ART4215 A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors Active, not recruiting USA | GBR 0
NCT04992013 Phase II Niraparib Niraparib in Tumors Metastatic to the CNS Recruiting USA 0
NCT04999202 Phase I BAY2416964 + Pembrolizumab BAY2416964 A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults Active, not recruiting USA | ITA | GBR 1
NCT05001516 Phase Ib/II TPX-4589 Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors Completed USA 0
NCT05002140 Phase I XRD-0394 Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients Completed USA 0
NCT05002270 Phase Ib/II Cetuximab + Glecirasib Glecirasib JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Recruiting USA 0
NCT05004116 Phase Ib/II Irinotecan + Repotrectinib + Temozolomide A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer Recruiting USA 0
NCT05007782 Phase I GS-1811 GS-1811 + Pembrolizumab Study to Evaluate the Safety and Tolerability of GS-1811 as Monotherapy and in Combination With Pembrolizumab in Adults With Advanced Solid Tumors Recruiting USA | ESP | CAN | AUS 1
NCT05010096 Phase I Copanlisib + Elimusertib BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors Withdrawn 0
NCT05012397 Phase II Milademetan Milademetan in Advanced/Metastatic Solid Tumors Terminated USA 0
NCT05012618 Phase I LUNA18 A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). Recruiting USA 1
NCT05013554 Phase I SAR443216 Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors Terminated USA | FRA | ESP | BEL 2
NCT05017012 Phase I MK-3475A + Pembrolizumab MK-3475A + Pembrolizumab + Pemetrexed Disodium Carboplatin + MK-3475A + Pembrolizumab MK-3475A + Paclitaxel + Pembrolizumab MK-3475A + Nab-paclitaxel + Pembrolizumab Axitinib + MK-3475A + Pembrolizumab Cisplatin + MK-3475A + Pembrolizumab A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18) Active, not recruiting ESP 5
NCT05018273 Phase I Atezolizumab + VB10.NEO Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors Recruiting USA | ESP | DEU 0
NCT05021120 Phase I AK127 + Cadonilimab A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours Recruiting AUS 0
NCT05023486 Phase Ib/II NP-G2-044 NP-G2-044 + unspecified PD-L1 antibody NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies Recruiting USA 0
NCT05023655 Phase II Tazemetostat Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation Recruiting USA 0
NCT05024968 Phase II Sintilimab Sintilimab in Cancer of Unknown Primary Active, not recruiting USA 0
NCT05025085 Phase I AGEN1777 AGEN1777 + unspecified PD-1 antibody A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT05027139 Phase Ib/II Evorpacept + ZW25 A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer Recruiting USA 0
NCT05029882 Phase I ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab Recruiting USA | FRA | ESP | AUS 6
NCT05036291 Phase I NB004 A Study of NB004 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05037149 Phase I STP707 Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors Active, not recruiting USA 0
NCT05038150 Phase I SGN1 Study of SGN1 in Patients With Advanced Solid Tumor Recruiting USA 1
NCT05038839 Phase I Cabozantinib + Pamiparib Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors Recruiting USA 0
NCT05039632 Phase Ib/II Ipilimumab + NBTXR3 + Nivolumab NBTXR3, Radiation Therapy, Ipilimumab, and Nivolumab for the Treatment of Lung and/or Liver Metastases From Solid Malignancy Recruiting USA 0
NCT05039801 Phase I Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Recruiting USA 0
NCT05040932 Phase I YH004 Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy Completed AUS 0
NCT05041309 Phase II KITE-585 KITE-222 Brexucabtagene autoleucel KITE-718 axicabtagene ciloleucel KITE-439 Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Enrolling by invitation USA | NLD | GBR | FRA | DEU | CAN | AUS 2
NCT05041972 Phase II ARX-788 ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) Withdrawn USA 0
NCT05047536 Phase I KZR-261 KZR-261 in Subjects With Advanced Solid Malignancies Recruiting USA 0
NCT05052255 Phase Ib/II RVU120 RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors Recruiting ESP 1
NCT05052268 Phase Ib/II XTX202 XTX202 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT05053971 Phase Ib/II Entinostat + ZEN-3694 Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas Recruiting USA 0
NCT05054348 Phase I IO-108 + Pembrolizumab IO-108 Dose Escalation Study of IO-108 and IO-108+Pembrolizumab in Solid Tumors Active, not recruiting USA 0
NCT05055609 Phase I TRE-515 Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Recruiting USA 0
NCT05060432 Phase Ib/II EOS-448 + Pembrolizumab EOS-448 + EOS100850 Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006) Recruiting USA | ITA | GBR | FRA | ESP | BEL 0
NCT05061537 Phase I PF-06801591 + PF-07263689 PF-07263689 Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Terminated USA 0
NCT05064280 Phase II Lenvatinib Pembrolizumab Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases Recruiting USA 0
NCT05065710 Phase Ib/II ZL-1211 A Study of ZL-1211 in Patients With Advanced Solid Tumor Recruiting USA 1
NCT05067283 Phase I MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Advanced Solid Tumors (MK-1084-001) Recruiting USA | NZL | ESP | CAN | AUS 10
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05071183 Phase Ib/II Repotrectinib + Trametinib A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors Terminated USA 0
NCT05071209 Phase Ib/II Elimusertib Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Active, not recruiting USA | CAN 0
NCT05073484 Phase I BAT6021 BAT1308 + BAT6021 Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients Terminated AUS 0
NCT05074472 Phase Ib/II ZB131 A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors Completed USA 0
NCT05075564 Phase I ES002023 A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT05075993 Phase I Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 + LVGN7409 LVGN3616 + LVGN6051 + LVGN7409 + Nab-paclitaxel Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 LVGN3616 + LVGN6501 + Nab-paclitaxel Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors Recruiting USA 0
NCT05076552 Phase I TACH101 A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer Recruiting USA 0
NCT05076591 Phase I IMM2902 IMM2902, a HER2/SIRPalpha Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors Recruiting USA 0
NCT05078671 FDA approved Olaparib Cobicistat + Olaparib Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness (PROACTIVE) Recruiting NLD 0
NCT05081609 Phase Ib/II TransCon IL-2 beta/gamma Pembrolizumab + TransCon IL-2 beta/gamma IL Believe: A Study of TransCon IL-2 beta/gamma Alone or in Combination With Pembrolizumab or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (IL Believe) Recruiting USA | AUS 1
NCT05082025 Phase II Copanlisib + Fulvestrant Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations Active, not recruiting USA 0
NCT05082259 Phase I ASTX-660 + Pembrolizumab ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (ASTEROID) Recruiting GBR 0
NCT05082545 Phase I SHR-1316 + SHR-2002 Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors Active, not recruiting AUS 0
NCT05082610 Phase I HMBD-002 HMBD-002 + Pembrolizumab A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab Recruiting USA 0
NCT05083481 Phase Ib/II ASP1570 A Study of ASP1570 in Adults With Locally Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05091528 Phase Ib/II SBT6050 + Trastuzumab deruxtecan SBT6050 + Trastuzumab + Tucatinib Capecitabine + SBT6050 + Trastuzumab + Tucatinib A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers Terminated USA 0
NCT05093322 Phase Ib/II Gemcitabine + Surufatinib A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Completed USA 0
NCT05094336 Phase Ib/II AMG193 AMG193 + Docetaxel AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP) Recruiting USA | GBR | FRA | DEU | CAN | BEL | AUT | AUS 5
NCT05094804 Phase Ib/II Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor Recruiting USA 0
NCT05097599 Phase II Binimetinib + Encorafenib Trastuzumab deruxtecan Enfortumab vedotin-ejfv Talazoparib Lorlatinib Strata PATH (Precision Indications for Approved Therapies) (Strata PATH) Recruiting USA 0
NCT05098132 Phase I STK012 Pembrolizumab + STK012 Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors Recruiting USA 0
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Terminated NLD | FRA 0
NCT05099549 Phase Ib/II AFM24 + SNK01 Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers Terminated USA 0
NCT05101070 Phase Ib/II Pembrolizumab + S-531011 Pembrolizumab S-531011 S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) Recruiting USA 1
NCT05102214 Phase Ib/II HLX301 HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors Recruiting AUS 0
NCT05103046 Phase I UCT-03-008 First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT05103345 Phase I SGN1 Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor Recruiting 2
NCT05103358 Phase II Nab-rapamycin Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) Recruiting USA 2
NCT05103683 Phase I TORL-1-23 First in Human Study of TORL-1-23 in Participants With Advanced Cancer Recruiting USA 0
NCT05108623 Phase I AgenT-797 AgenT-797 + Nivolumab AgenT-797 + Pembrolizumab A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors Completed USA 0
NCT05109975 Phase I Debio 0123 A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors Recruiting USA | ESP 1
NCT05111561 Phase I Binimetinib + ZEN-3694 Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer Recruiting USA 0
NCT05112549 Phase I Nivolumab Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26) (IT-PD1) Recruiting DEU 0
NCT05114668 Phase I EVT801 Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours Recruiting FRA 0
NCT05115292 Phase I BJ-005 A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma Active, not recruiting USA 0
NCT05116891 Phase Ib/II Cisplatin + Gemcitabine + Nidanilimab Docetaxel + Nidanilimab Fluorouracil + Leucovorin + Nidanilimab + Oxaliplatin A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Completed FRA | ESP 0
NCT05117177 Phase I EOS100850 New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer Recruiting GBR | BEL 0
NCT05117476 Phase I CLN-619 CLN-619 + Pembrolizumab A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors Recruiting USA | ESP | AUS 1
NCT05118789 Phase Ib/II NUV-520 A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) Recruiting USA | NLD | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT05119933 Phase Ib/II YL-15293 A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation Unknown status USA 0
NCT05120596 Phase Ib/II Pembrolizumab + T3P-Y058-739 T3P-Y058-739 First in Human Study of T3P-Y058-739 (T3P) Recruiting GBR 1
NCT05120960 Phase I Tepotinib Osimertinib + Tepotinib A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors Withdrawn 0
NCT05121948 Phase I HC-7366 A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) Terminated USA 0
NCT05123482 Phase Ib/II AZD8205 First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies Recruiting USA | NLD | GBR | ESP | CAN | BEL | AUS 7
NCT05128487 Phase Ib/II NDI-101150 NDI-101150 + Pembrolizumab A Study of NDI 1150-101 in Patients With Solid Tumors Recruiting USA 0
NCT05128825 Phase II ZN-c3 A Study of ZN-c3 in Subjects With Malignant Tumors Recruiting USA | FRA | AUS 0
NCT05129280 Phase I RO7444973 + Tocilizumab RO7444973 A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors Terminated USA | GBR | ESP | BEL | AUS 1
NCT05135975 Phase II Cabozantinib A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Recruiting USA 0
NCT05142241 Phase II Talazoparib + Temozolomide Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients >= 18 Years Old With Advanced Stage Rare Cancers, RARE 2 Study Recruiting USA 0
NCT05142592 Phase I IPG7236 IPG7236 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05143970 Phase I IPH5301 IPH5301 + Paclitaxel + Trastuzumab A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) Recruiting FRA 0
NCT05144334 Phase I BTX-1188 A Study of BTX-1188 in Subjects With Advanced Malignancies Terminated USA 0
NCT05144698 Phase II RAPA-201 RAPA-201 Therapy of Solid Tumors Recruiting USA 0
NCT05147272 Phase I Gemcitabine + RP-6306 Study of RP-6306 With Gemcitabine in Advanced Solid Tumors Active, not recruiting USA | GBR | CAN 0
NCT05147350 Phase I Fluorouracil + Irinotecan + Leucovorin + RP-6306 Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (MINOTAUR) Active, not recruiting USA | GBR | ESP | CAN 0
NCT05150457 Phase I BNA035 Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors Recruiting AUS 0
NCT05150691 Phase Ib/II DB-1303 A Study of DB-1303 in Advanced/Metastatic Solid Tumors Recruiting USA | AUS 2
NCT05155332 Phase I BI 1831169 + Ezabenlimab BI 1831169 A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors). Recruiting USA | FRA | ESP | DEU | BEL | AUT 0
NCT05156866 Phase I TORL-2-307-ADC First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer Recruiting USA 1
NCT05159388 Phase Ib/II PRS-344/S095012 A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Recruiting USA | ESP | BEL | AUS 0
NCT05159440 Phase I TORL-2-307-MAB First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer Recruiting USA 1
NCT05159518 Phase I PRT2527 A Study of PRT2527 in Participants With Advanced Solid Tumors Completed USA 0
NCT05159700 Phase I PRJ1-3024 A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT05162443 Expanded access Adagrasib Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation Approved for marketing USA 0
NCT05162755 Phase I S095029 S095029 + Sym021 Futuximab + S095029 + Sym021 Modotuximab + S095029 + Sym021 S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers Active, not recruiting USA | CAN 0
NCT05163028 Phase I HBI-2376 A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations Recruiting USA 1
NCT05163041 Phase Ib/II BT7480 BT7480 + Nivolumab Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression Recruiting USA | GBR 0
NCT05169437 Phase II Niraparib Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO) Active, not recruiting USA 0
NCT05169697 Phase I YH001 + YH002 A Study to Assess YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors Recruiting AUS 1
NCT05176483 Phase I Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002) Recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 3
NCT05176509 Phase I Pembrolizumab + YH001 + YH003 A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting AUS 0
NCT05178888 Phase I Adagrasib + Palbociclib Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) Active, not recruiting USA 0
NCT05180474 Phase Ib/II GEN1047 GEN1047 for Solid Tumors - First in Human (FIH) Trial Recruiting USA | NLD | ITA | GBR | FRA | ESP | BEL 2
NCT05180799 Phase Ib/II BA3071 + Nivolumab BA3071 A Phase 1/2 Study of BA3071 Recruiting USA | AUS 0
NCT05188664 Phase Ib/II Toripalimab-tpzi + TPX-4589 TPX-4589 Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors Terminated AUS 0
NCT05198349 Phase I M1069 First in Human Study of M1069 in Advanced Solid Tumors Terminated USA | CAN 0
NCT05199272 Phase Ib/II 23ME-00610 A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies Active, not recruiting USA | CAN 0
NCT05199285 Phase II Ipilimumab + Nivolumab Nivolumab and Ipilimumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Liver Cancer Recruiting USA 0
NCT05199584 Phase II Taladegib A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations Active, not recruiting USA 0
NCT05199753 Phase Ib/II LM-108 LM-108 + unspecified PD-1 antibody Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours Recruiting AUS 0
NCT05200013 Phase I BAT7104 BAT7104 in Patients With Advanced Solid Tumours Active, not recruiting AUS 0
NCT05200273 Phase I AK114 A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 Unknown status AUS 0
NCT05200559 Phase Ib/II E7777 + Pembrolizumab T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Recruiting USA 0
NCT05203172 FDA approved Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT05204290 Phase I Pembrolizumab A Pilot Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab Recruiting USA 0
NCT05204862 Phase Ib/II TU2218 TU2218 + unspecified PD-1 antibody Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05205109 Phase I ATG-037 A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients Recruiting AUS 1
NCT05210413 Phase Ib/II Pazopanib + Spartalizumab Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Young Adults (SPARTO) Recruiting FRA 0
NCT05215574 Phase I NGM831 NGM831 + Pembrolizumab Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05216432 Phase I RLY-2608 Fulvestrant + RLY-2608 First-in-Human Study of Mutant-selective PI3Kalpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer Recruiting USA | ITA | FRA | ESP 0
NCT05220098 Phase Ib/II TAK-280 First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer Recruiting USA | AUS 0
NCT05222165 Phase Ib/II Infigratinib Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations (NEWEL) Withdrawn USA | DEU | CAN 0
NCT05225584 Phase I KT-333 Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors Recruiting USA 0
NCT05226507 Phase I NXP800 A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers Recruiting USA | GBR 0
NCT05226871 Phase II Letrozole + Palbociclib Cetuximab + Palbociclib Cetuximab Fulvestrant + Palbociclib Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies Recruiting USA 3
NCT05227326 Phase I AOH1996 AOH1996 for the Treatment of Refractory Solid Tumors Active, not recruiting USA 0
NCT05228015 Phase I IK-930 Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors Recruiting USA | GBR 0
NCT05228600 Phase I YL-13027 YL-13027 in Patients With Advanced Solid Tumors Unknown status USA 0
NCT05231746 Phase I hSTC810 A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001) Completed USA 1
NCT05233436 Phase I PF-07265028 PF-06801591 + PF-07265028 PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors Terminated USA 1
NCT05234853 Phase I PUR001 Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05238831 Phase II Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole SMMART Adaptive Clinical Treatment (ACT) Trial Withdrawn 0
NCT05238922 Phase I INCB123667 Study of INCB123667 in Subjects With Advanced Solid Tumors Recruiting USA | NLD | ITA | GBR | FRA 2
NCT05240898 Phase I KSQ-4279 A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05241834 Phase I LOXO-260 A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment Active, not recruiting USA 0
NCT05242822 Phase I KIN-3248 A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations Active, not recruiting USA | ESP 4
NCT05244551 Phase I ABSK061 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05245500 Phase Ib/II MRTX1719 Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion Recruiting USA 0
NCT05251714 Phase Ib/II CFI-402257 CFI-402257 + Fulvestrant CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer Recruiting USA 0
NCT05252390 Phase Ib/II NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Recruiting USA | AUS 0
NCT05252416 Phase Ib/II BLU-222 + Carboplatin BLU-222 + Fulvestrant + Ribociclib BLU-222 + Fulvestrant (VELA) Study of BLU-222 in Advanced Solid Tumors Recruiting USA | ITA | GBR 0
NCT05255484 Phase Ib/II LM-108 + unspecified PD-1 antibody LM-108 Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours Terminated USA 0
NCT05262400 Phase II Letrozole + PF-07104091 + PF-07220060 Fulvestrant + PF-07104091 + PF-07220060 PF-07104091 + PF-07220060 A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors Recruiting USA | ESP 7
NCT05262530 Phase Ib/II BNT142 Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors Recruiting USA | GBR | ESP 1
NCT05263180 Phase I EMB-09 A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. Recruiting AUS 1
NCT05266612 Phase I VG2025 A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Subjects With Advanced Malignant Solid Tumors Recruiting USA 0
NCT05267626 Phase Ib/II Aldesleukin + AU-007 AU-007 Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Ra Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer Recruiting USA | AUS 0
NCT05267899 Phase I WGI-0301 A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05268666 Phase Ib/II JBI-802 A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05269316 Phase I IMP9064 Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting USA | AUS 2
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05270213 Phase I RBS2418 RBS2418 Evaluation in Subjects With Unresectable or Metastatic Tumors Recruiting USA 0
NCT05272709 Phase Ib/II TT-702 TT-702 in Patients With Advanced Solid Tumours. (CURATE) Recruiting GBR 0
NCT05275478 Phase Ib/II TNG908 Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors Recruiting USA | FRA 0
NCT05277168 Phase Ib/II SHR-A1904 A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS Recruiting USA | AUS 1
NCT05277402 Phase I ADG116 + Pembrolizumab ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors Completed USA 0
NCT05278975 Phase Ib/II Thiostrepton Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma Recruiting GBR 0
NCT05279300 Phase I CS5001 A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas Recruiting USA | AUS 1
NCT05286801 Phase Ib/II Atezolizumab + Tiragolumab Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Recruiting USA | CAN | AUS 0
NCT05287399 Phase I ASC61 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT05290597 Phase I IBI363 A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas Recruiting AUS 0
NCT05300048 Phase I Serabelisib Nab-paclitaxel + Serabelisib Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Active, not recruiting USA 0
NCT05300438 Phase I TSN084 Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. Recruiting USA 0
NCT05302921 Phase II Ipilimumab + Nivolumab Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors Active, not recruiting USA 0
NCT05303532 Phase III Durvalumab Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (ROSY-D) Enrolling by invitation USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 19
NCT05306444 Phase I HBM7008 CLN-418 Study on Subjects With Advanced Solid Tumors Recruiting USA | AUS 0
NCT05307705 Phase I Abemaciclib + Anastrozole + LOXO-783 Abemaciclib + Exemestane + LOXO-783 Abemaciclib + Letrozole + LOXO-783 LOXO-783 + Paclitaxel Fulvestrant + LOXO-783 LOXO-783 + LY3484356 Abemaciclib + Fulvestrant + LOXO-783 Abemaciclib + LOXO-783 + LY3484356 Letrozole + LOXO-783 LOXO-783 Anastrozole + LOXO-783 Exemestane + LOXO-783 A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT05309187 Phase I IO-202 + Pembrolizumab IO-202 Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors Active, not recruiting USA 0
NCT05311618 Phase I NGM438 NGM438 + Pembrolizumab Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT05315700 Phase Ib/II Carboplatin + ORIC-114 + Pemetrexed Disodium ORIC-114 Ph 1/2 Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration Recruiting USA | CAN | AUS 1
NCT05317078 Phase I AMG 794 A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications Active, not recruiting USA | AUS 1
NCT05318573 Phase II Gemcitabine + Pembrolizumab A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors Recruiting USA 0
NCT05320588 Phase Ib/II BIO-106 BIO-106 + Pembrolizumab A Phase 1/2 Study in Patients With Advanced Cancers Recruiting USA 0
NCT05322408 Phase I HCW9218 HCW9218 in Select Advanced Solid Tumors Active, not recruiting USA 0
NCT05323045 Phase I BYON3521 A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 Recruiting NLD | ITA | GBR | BEL 0
NCT05325866 Phase I Bemarituzumab A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) Recruiting USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 16
NCT05327010 Phase II Talazoparib + ZEN-3694 Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial Recruiting USA 0
NCT05327946 Phase I BI 770371 BI 770371 + Ezabenlimab A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated Recruiting USA | CAN 1
NCT05337735 Phase II XmAb20717 A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Recruiting USA 0
NCT05338346 Phase I ATG-018 A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) Recruiting AUS 0
NCT05340621 Phase Ib/II Binimetinib + OKI-179 NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) Active, not recruiting USA 0
NCT05346484 Phase I CF33-hNIS + Pembrolizumab CF33-hNIS A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST) Recruiting USA | AUS 0
NCT05352750 Phase I SON-1010 Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors Recruiting USA 0
NCT05355701 Phase I Binimetinib + PF-07799933 PF-07799933 Cetuximab + PF-07799933 A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. Recruiting USA | CAN 1
NCT05355753 Phase Ib/II CFT8634 A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors Terminated USA 0
NCT05356741 Phase I AMX-818 + Pembrolizumab AMX-818 To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers Recruiting FRA | ESP | AUS 1
NCT05357898 Phase Ib/II SQZ-eAPC-HPV Pembrolizumab + SQZ-eAPC-HPV Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT05358249 Phase Ib/II JDQ443 + Ribociclib JDQ443 + Trametinib Cetuximab + JDQ443 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03) Recruiting USA | ITA | FRA | ESP | DEU | BEL 2
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05359445 Phase I IMA401 IMA401 TCER in Recurrent and/or Refractory Solid Tumors Recruiting DEU 0
NCT05363605 Phase Ib/II 225Ac-FPI-1966 + Vofatamab A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours Terminated USA | AUS 0
NCT05372614 Phase I Neratinib + Trastuzumab Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene Recruiting USA 0
NCT05372640 Phase I Abemaciclib + ZEN-3694 Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors Recruiting USA 0
NCT05375825 Phase I LMB-100 Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin Withdrawn USA 0
NCT05377528 Phase I AGEN1571 + Balstilimab + Botensilimab AGEN1571 + Botensilimab AGEN1571 + Balstilimab AGEN1571 Study of AGEN1571 in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT05377996 Phase I XMT-1660 A Study of XMT-1660 in Participants With Solid Tumors Recruiting USA 0
NCT05378425 Phase I NTX-1088 NTX-1088 + Pembrolizumab A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab Recruiting USA 1
NCT05379985 Phase I RMC-6236 Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Recruiting USA 0
NCT05381909 Phase I BGB-24714 + Paclitaxel BGB-24714 Study Investigating BGB-24714 as Monotherapy and in Combination With Chemotherapy in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | NZL | AUS 2
NCT05382325 Phase I MK-1484 MK-1484 + Pembrolizumab A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) Recruiting USA | NLD | CAN 1
NCT05382559 Phase I ASP3082 ASP3082 + Cetuximab A Study of ASP3082 in Adults With Previously Treated Solid Tumors Recruiting USA 1
NCT05382936 Phase I SL-901 Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid Tumors Completed GBR 0
NCT05384626 Phase Ib/II NUV-655 A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) Recruiting USA | GBR | FRA | ESP | CAN | AUS 1
NCT05387265 Phase I CX-904 A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors Recruiting USA 0
NCT05388435 Phase Ib/II SKL27969 Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients Terminated USA 0
NCT05389462 Phase I ADCT-601 + Gemcitabine ADCT-601 A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT05394350 Phase Ib/II MK-1088 MK-1088 + Pembrolizumab A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) Terminated USA | CAN 3
NCT05394675 Phase I DS-9606a A Study of DS-9606a in Patients With Advanced Solid Tumors Recruiting USA | GBR 0
NCT05396833 Phase I M1774 Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) Recruiting USA | ESP | CAN 0
NCT05399654 Phase Ib/II TAC-001 A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors (INCLINE-101) Recruiting USA | AUS 0
NCT05405595 Phase I ADG126 ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors Recruiting USA 1
NCT05407675 Phase Ib/II BMS-986408 + Ipilimumab + Nivolumab BMS-986408 + Nivolumab BMS-986408 A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors Active, not recruiting USA | FRA | ESP | CAN 1
NCT05410145 Phase I D3S-001 A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation Recruiting USA | AUS 3
NCT05415098 Phase I APG-5918 Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05417321 Phase Ib/II HB0036 A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors Recruiting USA 1
NCT05419817 Phase II Pembrolizumab + Sitravatinib Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Withdrawn 0
NCT05430555 Phase Ib/II TK-8001 A Phase 1/2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/Metastatic MAGE-A1+ Solid Tumors (IMAG1NE) Terminated NLD | GBR | ESP | DEU | BEL 0
NCT05431270 Phase I PT199 PT199 + unspecified PD-1 antibody Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor Recruiting USA 0
NCT05431582 Phase I Bevacizumab + Pembrolizumab + ZN-c3 Bevacizumab + ZN-c3 Phase I Study of ZN-c3 and Bevacizumab +/- Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors Withdrawn 0
NCT05434234 Phase I YL201 A Study of YL201 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05435339 Phase Ib/II GEN1053 A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy Active, not recruiting USA | ESP 0
NCT05438329 Phase Ib/II DB-1305 First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors Recruiting USA 2
NCT05443126 Phase Ib/II EP0031 A Study of EP0031 in Patients With Advanced RET-altered Malignancies Recruiting USA | GBR | ESP 0
NCT05450562 Phase Ib/II Atezolizumab + SAR444200 SAR444200 Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors Recruiting USA | CAN 3
NCT05458219 Phase I IBI343 A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors Recruiting AUS 0
NCT05462717 Phase I RMC-6291 Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Recruiting USA | ITA | FRA | ESP | AUS 8
NCT05468359 Phase Ib/II Atezolizumab + Bevacizumab + Cyclophosphamide + Sorafenib Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients Recruiting USA 0
NCT05469490 Phase I Navoximod + NLG802 Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors Withdrawn 0
NCT05471856 Phase I BI 1703880 + Ezabenlimab A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) Recruiting USA | GBR | ESP 1
NCT05472220 Phase I Alpelisib + Carboplatin Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma Withdrawn 0
NCT05479812 Phase I WTX-124 Pembrolizumab + WTX-124 Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05480865 Phase I BBP-398 + Sotorasib SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (Argonaut) Recruiting NLD | ITA | FRA | ESP | AUS 2
NCT05483400 Phase II Atezolizumab + Tiragolumab Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN) Recruiting NLD 0
NCT05483530 Phase I HLX60 + Serplulimab A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting AUS 0
NCT05485974 Phase I HBI-2438 A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation Recruiting USA 1
NCT05487170 Phase Ib/II RNK05047 A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) Recruiting USA 0
NCT05487235 Phase I Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | NZL | ESP | CAN | AUS 4
NCT05489211 Phase II Capecitabine + Datopotamab deruxtecan AZD5305 + Datopotamab deruxtecan + Durvalumab Capecitabine + Datopotamab deruxtecan + Nivolumab Carboplatin + Datopotamab deruxtecan Datopotamab deruxtecan + Fluorouracil AZD5305 + Datopotamab deruxtecan Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + Fluorouracil + Nivolumab Bevacizumab + Datopotamab deruxtecan + Fluorouracil + Leucovorin Bevacizumab + Capecitabine + Datopotamab deruxtecan Datopotamab deruxtecan Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 7
NCT05490472 Phase Ib/II JAB-2485 JAB-2485 Activity in Adult Patients With Advanced Solid Tumors Recruiting USA 1
NCT05491317 Phase Ib/II GEN1042 GEN1042 + Pembrolizumab A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors Recruiting FRA 0
NCT05491928 Expanded access Tempol Treatment of Metastatic Cancer in Terminally Diagnosed Patients Available USA 0
NCT05494762 Phase I BGB-B167 + Tislelizumab Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors Active, not recruiting USA | AUS 0
NCT05494918 Phase I JSKN003 First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors Recruiting AUS 0
NCT05496595 Phase I DCBY02 DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Terminated USA 0
NCT05497453 Phase Ib/II OTX-2002 A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I) Recruiting USA 4
NCT05501821 Phase I KBA1412 + Pembrolizumab KBA1412 Study of KBA1412 in Participants With Advanced Solid Malignant Tumors Recruiting NLD | BEL 0
NCT05509985 Phase I ASKG315 A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors Not yet recruiting AUS 0
NCT05514444 Phase I MK-4464 MK-4464 + Pembrolizumab Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Recruiting USA | NLD | CAN 1
NCT05514496 Phase I NX-019 A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer Recruiting USA 2
NCT05514717 Phase I XMT-2056 A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 Recruiting USA 0
NCT05525247 Phase Ib/II Gemcitabine + SLC-3010 SLC-3010 A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination Recruiting USA | AUS 1
NCT05525455 Phase Ib/II TT-816 TT-816 + unspecified PD-1 antibody A Study in Patients With Advanced Cancers Terminated USA 0
NCT05525559 Phase I ET0038 SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors (FIRST) Not yet recruiting USA 0
NCT05536141 Phase I AB521 A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors (ARC-20) Recruiting USA 1
NCT05537740 Phase I BAY 3375968 + Pembrolizumab BAY 3375968 A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors Recruiting USA | GBR | CAN | BEL 1
NCT05537987 Phase I ICP-723 Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT05538130 Phase I PF-07799544 Encorafenib + PF-07799544 PF-07284890 + PF-07799544 PF-07799544 + PF-07799933 A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors Recruiting USA | CAN 0
NCT05539157 Phase I JCXH-211 Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors Active, not recruiting USA 0
NCT05543629 Phase Ib/II BMS-986442 + Nivolumab BMS-986442 + Docetaxel + Nivolumab BMS-986442 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986442 + Carboplatin + Nivolumab + Paclitaxel A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer Active, not recruiting USA | ITA | ESP | AUS 1
NCT05544552 Phase Ib/II TYRA-300 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301) Recruiting USA | FRA | ESP | AUS 0
NCT05546268 Phase Ib/II MRT-2359 Study of Oral MRT-2359 in Selected Cancer Patients Recruiting USA | CAN 0
NCT05547321 Phase I OMTX705 + Pembrolizumab OMTX705 Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. Recruiting USA | ESP 0
NCT05547906 Phase I ASCA101 Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors Completed USA 1
NCT05548296 Phase Ib/II Prexasertib Gemcitabine + Prexasertib A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Recruiting USA 0
NCT05548634 Phase I TAVO412 A Study of TAVO412 in Patients With Cancer (TAVO412) Recruiting USA 0
NCT05554341 Phase II Nilotinib + Paclitaxel Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial Suspended USA 0
NCT05554367 Phase II Binimetinib + Palbociclib Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Recruiting USA 0
NCT05554380 Phase II Ipatasertib + Paclitaxel Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial Recruiting USA 1
NCT05555251 Phase Ib/II BI-1607 + Trastuzumab BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST) Active, not recruiting GBR | ESP | DEU 0
NCT05557045 Phase I JZP815 A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 Recruiting USA 0
NCT05564377 Phase II Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Recruiting USA 1
NCT05566574 Phase Ib/II RP-3500 A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Recruiting USA 0
NCT05569057 Phase I SIM1811-03 A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Recruiting USA 0
NCT05571969 Phase I Dovitinib + E7449 E7449 Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05577182 Phase I INCA32459 Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies Recruiting USA | ITA | FRA | ESP | BEL 0
NCT05578092 Phase Ib/II Adagrasib + MRTX0902 MRTX0902 A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway Recruiting USA 1
NCT05580770 Phase Ib/II BGB3245 + PD-0325901 Mirdametinib + BGB-3245 in Advanced Solid Tumors Recruiting USA | AUS 0
NCT05581004 Phase I Atezolizumab + RO7502175 RO7502175 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | NLD | ESP | CAN | BEL | AUS 1
NCT05581719 Phase Ib/II Allocetra-OTS Allocetra-OTS + Tislelizumab Allocetra-OTS + Nivolumab A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy Terminated ESP 1
NCT05582850 Phase I DT-9081 DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours (EPRAD) Recruiting FRA | BEL 0
NCT05584111 Phase I STC-15 Oral Administration of STC-15 in Subjects With Advanced Malignancies Recruiting USA 0
NCT05584670 Phase Ib/II SAR445877 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors Recruiting USA | NLD | ESP 1
NCT05584709 Phase I STI-6129 Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors Not yet recruiting USA 0
NCT05585320 Phase Ib/II IMM-1-104 A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05586321 Phase I GEN1056 Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors Active, not recruiting ESP 2
NCT05592626 Phase Ib/II STAR0602 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) Recruiting USA | CAN 0
NCT05593094 Phase I ZN-A-1041 Ado-trastuzumab emtansine + ZN-A-1041 Trastuzumab deruxtecan + ZN-A-1041 Pertuzumab/trastuzumab/hyaluronidase-zzxf + ZN-A-1041 Pertuzumab + Trastuzumab + ZN-A-1041 A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors Recruiting USA 0
NCT05594043 Phase I MK-6598 + Pembrolizumab MK-6598 A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) Recruiting USA | CAN 1
NCT05594875 Phase I SHR-A1921 A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors Active, not recruiting AUS 0
NCT05597839 Phase Ib/II DF9001 DF9001 + Nivolumab Study of DF9001 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05598151 Phase I HM97662 Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors Recruiting AUS 1
NCT05601219 Phase I ADA-011 A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors Recruiting USA 0
NCT05605496 Phase II NP137 + unspecified PD-L1 antibody NP137 + unspecified PD-1 antibody A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) as Add on Therapy in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Immunotherapies (IMMUNONET) Recruiting FRA 0
NCT05605509 Phase II Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 RP-6306 in Patients With Advanced Cancer Recruiting CAN 0
NCT05607498 Phase I EMB-07 First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors Recruiting AUS 1
NCT05614102 Phase I BAY2965501 A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors Recruiting USA | GBR | ESP | BEL 3
NCT05614258 Phase I ADG206 Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors Recruiting AUS 0
NCT05614739 Phase I LOXO-435 + Pembrolizumab LOXO-435 A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3 Recruiting USA | NLD | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT05627063 Phase I ABSK121 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05627960 Phase I AG01 First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies Recruiting USA 0
NCT05631327 Phase I JZP341 JZP341 Phase 1 Dose-Finding Study in Adult Participants With Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT05635643 Phase Ib/II SRF114 Study of SRF114 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05636215 Phase Ib/II Orismilast A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05638295 Phase II Sotorasib Panitumumab + Sotorasib Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) Recruiting USA 0
NCT05639751 Phase I Docetaxel + PRT3789 PRT3789 PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation Recruiting USA | NLD | FRA | ESP 1
NCT05642949 Phase Ib/II MHB036C Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05646797 Phase I ASP2074 A Study of ASP2074 in Adults With Solid Tumors Recruiting USA 1
NCT05650203 Phase I JS006 + JS009 + Toripalimab-tpzi JS009 A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies Withdrawn 0
NCT05650879 Phase I ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002 ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2) Recruiting USA | ITA | FRA | ESP | AUS 2
NCT05651022 Phase I Decoy20 DECOY20 Study in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05652855 Phase Ib/II MHB088C Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05653661 Phase I AP-160 Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05653882 Phase I AB248 + Pembrolizumab AB248 A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors Recruiting USA 0
NCT05661201 Phase I Doxorubicin + Nerofe NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors Recruiting USA 0
NCT05661461 Phase I Nab-rapamycin Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment Recruiting USA 0
NCT05661578 Phase II Atezolizumab + Tiragolumab A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (SKYSCRAPER-11) Recruiting USA | ESP | CAN 9
NCT05662397 Phase Ib/II HST-1011 Cemiplimab + HST-1011 A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody Recruiting USA 0
NCT05668585 Phase Ib/II CFT1946 + Trametinib CFT1946 A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors Recruiting USA | FRA | ESP 0
NCT05669430 Phase I GV20-0251 A Study of GV20-0251 in Patients With Solid Tumor Malignancies Recruiting USA 0
NCT05672459 Phase Ib/II IVS-3001 Cyclophosphamide + Fludarabine A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors Recruiting USA 0
NCT05673928 Phase II Ado-trastuzumab emtansine + Tucatinib A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) Recruiting USA 0
NCT05678010 Phase I AZD1390 A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer Recruiting USA 0
NCT05678998 Phase I WTX-330 WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma Recruiting USA 0
NCT05684965 Phase I XTX301 XTX301 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05686226 Phase II E7 TCR T-cells E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Recruiting USA 0
NCT05687110 Phase I Novobiocin Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes Recruiting USA 0
NCT05687136 Phase I M1774 + Peposertib Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors Recruiting USA 0
NCT05691491 Phase Ib/II M1774 + Temozolomide Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Recruiting USA 0
NCT05694364 Phase I PRGN-3007 Cyclophosphamide Cyclophosphamide + Fludarabine Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies Recruiting USA 0
NCT05694715 Phase I Irinotecan + Niraparib Combination Therapy in Cancers With Mutations in DNA Repair Genes Recruiting USA 0
NCT05698888 Phase I VP301 Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors Terminated USA 0
NCT05700721 Phase II Dostarlimab-gxly + Niraparib Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) Recruiting USA 0
NCT05701527 Phase I EBC-129 + Pembrolizumab EBC-129 A Study of EBC-129 in Advanced Solid Tumours Recruiting USA 1
NCT05702424 Phase I IGM-7354 Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer Active, not recruiting USA 0
NCT05704985 Phase I DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors Recruiting USA 0
NCT05708950 Phase Ib/II KVA12123 + Pembrolizumab KVA12123 A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) Recruiting USA 0
NCT05712889 Phase I VIP236 Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer Recruiting USA | AUS 0
NCT05714553 Phase Ib/II Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Recruiting GBR 0
NCT05715281 Phase II Atezolizumab + Tiragolumab Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial Recruiting USA 0
NCT05716295 Phase Ib/II MDK-703 + unspecified immune checkpoint inhibitor MDK-703 A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1) Active, not recruiting USA 0
NCT05718557 Phase I PYX-106 Study of PYX-106 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05718895 Phase I ATG-022 A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors (CLINCH) Recruiting AUS 1
NCT05722886 Phase II Cobimetinib + Vemurafenib Alectinib Pertuzumab + Trastuzumab Entrectinib Atezolizumab DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE) Recruiting GBR 0
NCT05725291 Phase Ib/II AMT-116 AMT-116 in Patients With Selected Advanced Solid Tumors Recruiting AUS 0
NCT05726864 Phase Ib/II ELI-002 A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P) Recruiting USA 0
NCT05731271 Phase Ib/II TST003 A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors Recruiting USA 0
NCT05731947 Phase Ib/II Revumenib Evaluation of SNDX-5613 in Participants With Colorectal Cancer and Other Solid Tumors Recruiting USA 0
NCT05732831 Phase Ib/II TNG462 Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors Recruiting USA | FRA | ESP 0
NCT05734066 Phase Ib/II Lurbinectedin Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma (EMERGE 101) Recruiting USA | CAN 0
NCT05735080 Phase Ib/II INX-315 Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01) Recruiting USA | AUS 0
NCT05735366 Phase I SAIL66 + Tocilizumab A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT05736731 Phase Ib/II A2B530 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1) Recruiting USA 0
NCT05737706 Phase Ib/II MRTX-1133 Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation Recruiting USA 0
NCT05746897 Phase I NM1F + Pembrolizumab NM1F A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05751798 Phase Ib/II OSE-279 Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas Recruiting FRA | BEL 0
NCT05752552 Phase I DO-2 Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours Recruiting NLD | FRA | BEL 0
NCT05753722 Phase I Pembrolizumab + PRTH-101 PRTH-101 A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies Recruiting USA 0
NCT05756907 Phase Ib/II Atezolizumab + SON-1010 SON-1010 Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer Recruiting USA | AUS 0
NCT05757492 Phase Ib/II CHS-006 + Toripalimab-tpzi Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT05759949 Phase I Fulvestrant + RLY-5836 RLY-5836 Fulvestrant + Palbociclib + RLY-5836 Abemaciclib + Fulvestrant + RLY-5836 Fulvestrant + Ribociclib + RLY-5836 First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors Active, not recruiting USA 0
NCT05761223 Phase Ib/II FB849 FB849 + Pembrolizumab A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 Recruiting USA 0
NCT05763004 Phase I IOS-1002 IOS-1002 + unspecified PD-1 antibody A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors Recruiting AUS 0
NCT05765851 Phase I DS-1103a + Trastuzumab deruxtecan A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors Recruiting USA | FRA | ESP | CAN 0
NCT05768139 Phase Ib/II Fulvestrant + STX-478 STX-478 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05768178 Phase II Cobimetinib + Vemurafenib DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE) Recruiting GBR 0
NCT05768932 Phase I BAL0891 + Carboplatin BAL0891 + Paclitaxel BAL0891 BAL0891 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05769075 Phase I TY-2136b A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations Recruiting USA 0
NCT05769959 Phase Ib/II RO7515629 Study of RO7515629 in Participants With HLA-G Positive Solid Tumors Terminated USA 0
NCT05770037 Phase II Alectinib DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE) Recruiting GBR 0
NCT05770102 Phase II Atezolizumab DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE) Recruiting GBR 0
NCT05770544 Phase II Entrectinib DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. (DETERMINE) Recruiting GBR 0
NCT05774873 Phase I IBI334 IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors Recruiting AUS 0
NCT05775406 Phase I KT-253 Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Recruiting USA 0
NCT05781360 Phase I SIM0237 A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors Recruiting USA 1
NCT05784688 Phase Ib/II Pembrolizumab + TU2218 Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05785728 Phase Ib/II DB-1202 A Phase 1/2 Study of DB-1202 Monotherapy in Advanced Solid Tumors Not yet recruiting 1
NCT05785741 Phase Ib/II DB-1310 A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors Recruiting USA 1
NCT05785754 Phase I DCSZ11 DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Recruiting USA | AUS 0
NCT05786716 Phase II Pertuzumab + Trastuzumab DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations (DETERMINE) Recruiting GBR 0
NCT05786924 Phase I BDTX-4933 A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers Recruiting USA 0
NCT05787587 Phase I IDE161 A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT05788484 Phase I CDX-585 A Study of CDX-585 in Patients With Advanced Malignancies Recruiting USA 0
NCT05789589 Phase Ib/II Azeliragon + Methylprednisolone Azeliragon Azeliragon + Dexamethasone Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (ADORATION) Recruiting USA 0
NCT05791474 Phase Ib/II Capecitabine + Denosumab ATI-2231 + Capecitabine ATI-2231 Bisphosphonate + Capecitabine ATI-2231 With in Advanced Solid Tumor Malignancies Followed by ATI-2231 in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer Withdrawn 0
NCT05797168 Phase Ib/II AZD5305 + AZD5335 AZD5335 Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA) Recruiting USA | GBR | ESP | CAN | AUS 4
NCT05798611 Phase II ART0380 Study of ART0380 in Advanced/Metastatic Solid Tumors Patients (ARTIST) Recruiting USA | FRA 0
NCT05803382 Phase I Capecitabine + ZEN-3694 Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers Recruiting USA 0
NCT05807035 Phase I Radvax Autologous Tumour Vaccine Trial Recruiting AUS 0
NCT05824975 Phase Ib/II GI-102 A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05826600 Phase I OMX-0407 A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically Recruiting ESP 0
NCT05827614 Phase I BBI-355 Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy, in Subjects With Tumors With Oncogene Amplifications (POTENTIATE) Recruiting USA 0
NCT05828459 Phase I Lenalidomide + OT-A201 OT-A201 OT-A201 + Paclitaxel Bevacizumab + OT-A201 OT-A201 + Pomalidomide First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors Recruiting FRA 0
NCT05830097 Phase Ib/II CBP-1019 A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05831995 Phase I ABM-168 Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. Recruiting USA 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT05838768 Phase I HRO761 HRO761 + Tislelizumab HRO761 + Irinotecan Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. Recruiting USA | FRA | ESP | DEU | BEL 5
NCT05839600 Phase I BI 1821736 A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer Recruiting USA | ESP | CAN 1
NCT05840224 Phase I GS-4528 + Zimberelimab GS-4528 Study of GS-4528 in Adults With Solid Tumors Recruiting USA | GBR | ESP | CAN 2
NCT05840510 Phase Ib/II Adagrasib + Nab-rapamycin Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) Recruiting USA 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05846659 Phase II Nivolumab IMSA101 + Nivolumab IMSA101 + Pembrolizumab Pembrolizumab Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies Recruiting USA 0
NCT05856981 Phase I ADU-1805 + Pembrolizumab ADU-1805 Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors Recruiting USA 1
NCT05858164 Phase I BAY2862789 A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors Recruiting USA | AUS 3
NCT05858736 Phase I AI-061 Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (PRESERVE-009) Recruiting AUS 0
NCT05859464 Phase I Pembrolizumab + ZL-1218 ZL-1218 A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05861895 Phase I HF158K1 A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors Recruiting USA 1
NCT05862324 Phase Ib/II TAC01-CLDN18.2 TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) Recruiting USA | CAN 0
NCT05864144 Phase Ib/II Cemiplimab + SNS-101 SNS-101 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05865990 Phase II Patritumab deruxtecan HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) Recruiting ESP | AUT 0
NCT05867121 Phase I Atezolizumab + Gemcitabine + Nab-paclitaxel + RO7496353 Capecitabine + Nivolumab + Oxaliplatin + RO7496353 Nivolumab + Oxaliplatin + RO7496353 + Tegafur-gimeracil-oteracil Potassium Atezolizumab + RO7496353 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | NZL | ITA | ESP | AUS 3
NCT05867251 Phase Ib/II ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin ARTS-021 Study of ARTS-021 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05867303 Phase I RC198 A Study of RC198 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours Recruiting AUS 1
NCT05867420 Phase I ASKG915 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. Recruiting USA 0
NCT05868226 Phase I Evorpacept + Trastuzumab deruxtecan PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI) Recruiting USA 0
NCT05872295 Phase I IKS014 IKS014 in Advanced Solid Tumors That Express HER2 Recruiting AUS 0
NCT05873686 Phase I eCF506 A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers Recruiting USA | GBR 0
NCT05875168 Phase Ib/II DS-3939a First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors Recruiting USA 1
NCT05877599 Phase I NT-175 A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation Recruiting USA 0
NCT05878691 Phase I GRC 54276 + Pembrolizumab Atezolizumab + GRC 54276 GRC 54276 A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. Recruiting USA 1
NCT05879822 Phase II INCB099280 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive Recruiting NZL 9
NCT05886868 Phase I BL0020 Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors Recruiting AUS 1
NCT05886920 Phase I D3S-002 Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations Recruiting USA | AUS 1
NCT05887492 Phase Ib/II Pembrolizumab + TNG260 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Recruiting USA 0
NCT05888831 Phase Ib/II BMS-986449 + Nivolumab BMS-986449 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors Recruiting USA | NLD | ITA | FRA | ESP | BEL 0
NCT05888857 Phase II MEDI5752 A Multicentric Phase II Trial Evaluating MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. (TAYLOR) Not yet recruiting FRA 0
NCT05892718 Phase I HCB101 A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPa-CD47 Pathway, in Solid or Hematological Tumors Recruiting USA 1
NCT05898399 Phase Ib/II Olaparib ART6043 Talazoparib ART6043 + Olaparib ART6043 + Talazoparib Study of ART6043 in Advanced/Metastatic Solid Tumors Patients Recruiting USA 0
NCT05901285 Phase I VAX014 Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT05902520 Phase I AGX148 + Aldesleukin Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (ACT) Recruiting USA 0
NCT05904236 Phase I ICVB-1042 Safety and Tolerability of Intravenous Administration of ICVB-1042 Recruiting USA 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813 Recruiting USA | ESP | AUS 0
NCT05906862 Phase I AMT-253 AMT-253 in Patients With Selected Advanced Solid Tumours Recruiting AUS 0
NCT05907304 Phase I LXH 254 + Trametinib A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations (SEACRAFT-1) Recruiting USA | GBR | CAN | AUS 1
NCT05907980 Phase I Atezolizumab + ROSE12 ROSE12 A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors Recruiting USA 1
NCT05914116 Phase Ib/II DB-1311 A Study of DB-1311 in Advanced/Metastatic Solid Tumors Recruiting USA | AUS 0
NCT05918640 Phase Ib/II Lurbinectedin Lurbinectedin in FET-Fused Tumors (LiFFT) Recruiting USA 0
NCT05919264 Phase Ib/II FOG-001 FOG-001 in Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05919537 Phase Ib/II Docetaxel + HMBD-001 HMBD-001 Gemcitabine + HMBD-001 + Nab-paclitaxel Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Recruiting AUS 0
NCT05923008 Phase Ib/II IBI130 A Phase 1/2 Clinical Study to Evaluate the Safety and Tolerability of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors Recruiting AUS 0
NCT05929235 Phase I FX-909 A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma Recruiting USA 0
NCT05933265 Phase I LP-184 Study of LP-184 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05935098 Phase I BGB-A3055 + Tislelizumab BGB-A3055 A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors Recruiting USA | FRA | AUS 0
NCT05937295 Phase I Fusion-VAC-XS15 Atezolizumab + Fusion-VAC-XS15 FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition (FusionVAC22) Recruiting DEU 0
NCT05938296 Phase I oHSV2-PD-L1/CD3-BsAb oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection Recruiting USA 0
NCT05940571 Phase I MBF-362 First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors Recruiting ESP 0
NCT05941507 Phase Ib/II LCB84 + unspecified PD-1 antibody LCB84 Phase 1/2 Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors Recruiting USA | CAN 0
NCT05944237 Phase Ib/II Atezolizumab + HTL0039732 HTL0039732 HTL0039732 in Participants With Advanced Solid Tumours Recruiting GBR 0
NCT05947474 Phase I ORB-011 ORB-011 In Patients With Advanced Solid Tumors (ORB) Recruiting USA 0
NCT05948826 Phase I TORL-3-600 First in Human Study of TORL-3-600 in Participants With Advanced Cancer Recruiting USA | CAN 0
NCT05948865 Phase I CPO301 A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors Recruiting USA | CAN 0
NCT05949632 Phase Ib/II Axitinib + INCB099280 A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors Recruiting ITA | GBR | FRA | ESP | BEL 1
NCT05954312 Phase I VVD-130037 A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05957081 Phase I Pembrolizumab + PMC-309 PMC-309 Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01) Not yet recruiting AUS 0
NCT05957536 Phase I D3L-001 A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors Recruiting USA 1
NCT05958121 Phase Ib/II IMA402 IMA402 T Cell-Engaging Receptor Molecule (TCER) in Recurrent and/or Refractory Solid Tumors Recruiting DEU 0
NCT05970497 Phase I KB707 A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05975073 Phase Ib/II AMG193 + IDE397 A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors Recruiting USA | AUS 0
NCT05980416 Phase I EO-3021 Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 Recruiting USA 1
NCT05981703 Phase I BGB-26808 + Tislelizumab A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Recruiting USA | NZL | AUS 1
NCT05985083 Phase I IMM47 A Study Of IMM47 In Subjects With Advanced Solid Tumors Recruiting AUS 0
NCT05985161 Phase II Selinexor A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors Recruiting USA 0
NCT05989724 Phase I SON-DP A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT05991349 Phase Ib/II IBI129 A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors Recruiting AUS 0
NCT05999994 Phase II Docetaxel + Gemcitabine + Ramucirumab Cyclophosphamide + Ramucirumab + Vinorelbine Cyclophosphamide + Vinorelbine Irinotecan + Temozolomide Abemaciclib + Irinotecan + Temozolomide Docetaxel + Gemcitabine A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE) Recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 1
NCT06003621 Phase II Atezolizumab + Tiragolumab Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP) Recruiting AUS 0
NCT06004245 Phase I RO7589831 A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Recruiting USA | GBR | ESP | CAN | BEL 1
NCT06005740 Phase I TORL-4-500 First in Human Study of TORL-4-500 in Participants With Advanced Cancer Recruiting USA 0
NCT06005974 Phase II TAK-733 A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation Recruiting USA 0
NCT06007482 Phase I ES009 A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting AUS 0
NCT06014502 Phase I IMGS-001 Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Recruiting USA 0
NCT06014658 Phase I MBRC-101 Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors Recruiting USA 0
NCT06016179 Phase I Tocilizumab Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer Recruiting USA 0
NCT06021626 Phase I CRD3874 A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer Recruiting USA 0
NCT06022029 Phase I ONM-501 Cemiplimab + ONM-501 A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (ON-5001) Recruiting USA 0
NCT06026410 Phase I Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806 KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) Recruiting USA 0
NCT06028074 Phase Ib/II GIM-122 Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies Recruiting USA 0
NCT06031441 Phase I RO7566802 Atezolizumab + RO7566802 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | AUS 0
NCT06034860 Phase I MT-8421 + Nivolumab MT-8421 Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types Recruiting USA 0
NCT06035744 Phase I CLN-617 + Pembrolizumab CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06039384 Phase I Adagrasib + INCB099280 A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Recruiting USA | ITA | GBR | ESP | CAN 0
NCT06040541 Phase I RMC-9805 Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Recruiting USA 0
NCT06046066 Phase I NM6603 A Phase 1 Study of NM6603 in Advanced Solid Tumors Recruiting USA 0
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06051695 Phase Ib/II A2B694 A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) Recruiting USA 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06058988 Phase II Trastuzumab deruxtecan Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Recruiting USA 0
NCT06063317 Phase I CF33-CD19t Blinatumomab + CF33-CD19t A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) (OASIS) Recruiting USA 0
NCT06063681 Phase I SR-8541A A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors Recruiting AUS 0
NCT06065059 Phase Ib/II TNG348 Olaparib + TNG348 Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors Recruiting USA 0
NCT06066424 Phase I Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) Recruiting USA 0
NCT06074497 Phase I KGX101 A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT06077877 Phase Ib/II GSK4524101 + Niraparib GSK4524101 Niraparib A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors Recruiting USA | CAN 0
NCT06082960 Phase I GS-9911 + Zimberelimab GS-9911 Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors Recruiting USA | CAN | AUS 0
NCT06083883 Phase I Cyclophosphamide + Fludarabine + NY-ESO-1 TCR/IL-15 NK Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 Suspended USA 0
NCT06096974 Phase I TEB-17231 Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS Not yet recruiting USA 0
NCT06098651 Phase I DCR-STAT3 A Study of DCR-STAT3 in Adults With Solid Tumors Recruiting USA 0
NCT06104488 Phase I RO5126766 A Study of Avutometinib for People With Solid Tumor Cancers Recruiting USA 0
NCT06105021 Phase Ib/II AFNT-211 Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor Recruiting USA 0
NCT06108479 Phase I DF6215 Study of DF6215 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06120283 Phase I BGB-43395 BGB-43395 + Letrozole BGB-43395 + Fulvestrant BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors Recruiting USA | AUS 0
NCT06126276 Phase II Neratinib Neratinib + Palbociclib Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) Recruiting USA 0
NCT06128551 Phase I RMC-6236 + RMC-6291 Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors Recruiting USA 0
NCT06130254 Phase I Adagrasib + Olaparib Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers Recruiting USA 0
NCT06130553 Phase Ib/II AZD3470 A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours (PRIMROSE) Recruiting USA | NLD | FRA | ESP | AUS 3
NCT06131398 Phase I AMG 355 + Pembrolizumab AMG 355 A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Recruiting USA | AUS 0
NCT06132503 Phase I LP-284 A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors Recruiting USA 0
NCT06147037 Phase I FPI-2053 + FPI-2068 A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours Recruiting USA | CAN 0
NCT06150183 Phase Ib/II BNT314 + Pembrolizumab BNT314 Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors Recruiting USA | GBR 0
NCT06154291 Phase Ib/II XON7 FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) Recruiting FRA | BEL 0
NCT06158958 Phase I ABBV-303 + Budigalimab ABBV-303 A Study of Adverse Events, How Intravenously (IV) Infused ABBV-303 Moves Through the Body, and Change in Disease State, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adult Participants With Advanced Solid Tumors Recruiting USA 1
NCT06160752 Phase I TYRA-200 Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201) Recruiting USA 0
NCT06161493 Phase I Niraparib + ZEN-3694 ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors Recruiting USA 0
NCT06161558 Phase I Erlotinib + Lenvatinib Axitinib + Erlotinib Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors Not yet recruiting USA 0
NCT06162221 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Pembrolizumab + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6236 Cisplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Pembrolizumab + RMC-6291 Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC Recruiting USA 0
NCT06163391 Phase I SOT201 A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer Recruiting USA | FRA | ESP | BEL 1
NCT06167317 Phase I GS-0201 + Sacituzumab govitecan-hziy GS-0201 Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06170190 Phase Ib/II IBI133 A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours Recruiting AUS 0
NCT06171178 Phase I ASP1012 + Pembrolizumab ASP1012 A Study of ASP1012 in Adults With Solid Tumors Recruiting USA 0
NCT06171750 Phase I ANK-101 Phase I Study of ANK-101 in Advanced Tumors (ANCHOR) Recruiting USA 0
NCT06171789 Phase Ib/II PRO1107 PRO1107 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06172894 Phase I APN401 PBMC-based Leukocyte Immunotherapy (PALINDROM) Recruiting AUT 0
NCT06177171 Phase I Decitabine and Cedazuridine + Olaparib Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors Not yet recruiting USA 0
NCT06179160 Phase I Cetuximab + INCB161734 + Retifanlimab INCB161734 A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation Recruiting USA | ITA | FRA | ESP | CAN | BEL | AUS 0
NCT06182579 Phase I RiMO-401 Phase I Study of RiMO-401 With Radiation in Advanced Tumors Recruiting USA 0
NCT06184035 Phase Ib/II 177Lu-SN201 A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer (Tumorad) Recruiting AUS 0
NCT06187402 Phase Ib/II LM-24C5 A Study of LM-24C5 For Advanced Solid Tumors Recruiting USA 0
NCT06188208 Phase I Pembrolizumab + VVD-130850 VVD-130850 A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors Recruiting USA | AUS 0
NCT06191796 Phase Ib/II AB521 + Nivolumab + XL092 AB521 + XL092 Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) Recruiting USA 0
NCT06198426 Phase Ib/II IBI3004 A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT06199908 Phase I AMT-562 AMT-562 in Patients With Selected Advanced Solid Tumors Not yet recruiting AUS 0
NCT06205706 Phase Ib/II BI-1910 + Pembrolizumab BI-1910 BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors Recruiting ESP 3
NCT06208124 Phase Ib/II IMM-6-415 A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors Recruiting USA 0
NCT06208657 Phase Ib/II GDC-0084 + Irinotecan + Temozolomide Pimasertib Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Not yet recruiting CAN | AUS 0
NCT06218914 Phase I NT-112 A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation Recruiting USA 0
NCT06220864 Phase I SNV1521 SNV1521 in Participants With Advanced Solid Tumors Not yet recruiting USA 0
NCT06226766 Phase Ib/II JSKN033 JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors Recruiting AUS 0
NCT06227377 Phase I QTX3034 Cetuximab + QTX3034 QTX3034 in Patients With KRAS G12D Mutation Recruiting USA 0
NCT06232408 Phase I RP-1664 LIONS (PLK4 Inhibitor in Advanced Solid Tumors) Recruiting USA 0
NCT06234098 Phase Ib/II AT-1965 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors Recruiting USA 0
NCT06234397 Phase I BH3120 Dose Escalation and Expansion Study of BH3120 in Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT06234423 Phase I CUSP06 A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors Recruiting USA 0
NCT06239467 Phase I OKI-219 + Trastuzumab OKI-219 Fulvestrant + OKI-219 First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (PIKture-01) Recruiting USA 0
NCT06240728 Phase I NPX887 A Study of NPX887 for Participants With Solid Tumors Known to Express HHLA-2/B7-H7 Recruiting USA 0
NCT06241456 Phase I Cetuximab + FT825 Bendamustine + Cisplatin + Docetaxel FT825 Cyclophosphamide + Fludarabine FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors Recruiting USA 0
NCT06242470 Phase I MGC026 A Study of MGC026 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06244485 Phase I DS-3201b + Trastuzumab deruxtecan Datopotamab deruxtecan + DS-3201b A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors Recruiting USA 0
NCT06244771 Phase Ib/II FMC-376 A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER) Recruiting USA 0
NCT06244992 Phase Ib/II PTT-936 + unspecified PD-L1 antibody PTT-936 + unspecified PD-1 antibody PTT-936 PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT06246643 Phase II Regorafenib A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies Recruiting FRA | ESP 4
NCT06249048 Phase Ib/II Pembrolizumab + STX-001 STX-001 Phase 1/2 Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab Not yet recruiting USA | AUS 0
NCT06253520 Phase I Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer Recruiting USA 0
NCT06253871 Phase I IAM1363 IAM1363 + Trastuzumab A Phase 1/1b Study of IAM1363 in HER2 Cancers Recruiting USA 0
NCT06254807 Phase I CT-0525 CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors Recruiting USA 0
NCT06257264 Phase I BG-68501 + Fulvestrant BG-68501 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors Recruiting USA | AUS 0
NCT06258304 Phase I GIGA-564 A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting USA 0
NCT06259552 Phase I SPX-303 A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors (SPX-303) Recruiting USA 0
NCT06264921 Phase I NKT3447 A Phase 1 Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06265688 Phase I CX-2051 First In Human Study of CX-2051 in Advanced Solid Tumors Recruiting USA 0
NCT06265727 Phase Ib/II SYS6002 A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors Recruiting USA | GBR | ESP 1
NCT06270082 Phase I IK-595 Study of IK-595 in RAS- or RAF-altered Advanced Tumors Recruiting USA 0
NCT06270706 Phase I Pembrolizumab + PLN-101095 PLN-101095 A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT06277219 Phase Ib/II LAT010 + unspecified PD-1 antibody LAT010 A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) (LIGHTSPEED-1) Not yet recruiting USA 0
NCT06279130 Phase II Balstilimab Balstilimab + Botensilimab Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) Recruiting NLD 0
NCT06281678 Phase II IBI363 A Study of IBI363 in Subjects With Advanced Solid Malignancies Not yet recruiting USA 0
NCT06287463 Phase Ib/II DCC-3084 Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway Not yet recruiting USA 0
NCT06287918 Phase I 3HP-2827 A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumours With FGFR2 Alterations Not yet recruiting USA 0
NCT06299163 Phase I NM32-2668 NM32-2668 in Adult Patients With Selected Advanced Solid Tumors Recruiting USA 0
NCT06299761 Phase I BBI-825 Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications (STARMAP) Recruiting USA 0
NCT06299839 Phase I PAS-004 PAS-004 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06302140 Phase I CHR-3996 CHR-3996 + Valganciclovir A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers Recruiting ESP 0
NCT06302426 Phase I INI-4001 + Nivolumab Cemiplimab + INI-4001 INI-4001 + Pembrolizumab INI-4001 Atezolizumab + INI-4001 Avelumab + INI-4001 Durvalumab + INI-4001 Trial of INI-4001 in Patients With Advanced Solid Tumours Not yet recruiting AUS 0
NCT06302621 Phase I Afatinib + Pemigatinib Pemigatinib + Afatinib in Advanced Refractory Solid Tumors Not yet recruiting USA 0
NCT06307795 Phase I ANS014004 A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors Not yet recruiting USA 0
NCT06311578 Phase I JNJ-87704916 Cetrelimab + JNJ-87704916 A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors Recruiting USA 0
NCT06320405 Phase Ib/II Paclitaxel + Retifanlimab + SNDX-6352 Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors Not yet recruiting USA 0
NCT06326411 Phase I NST-628 A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628) Recruiting AUS 0
NCT06328673 Phase I DM919 DM919 + Pembrolizumab A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors Recruiting USA 0
NCT06328738 Phase I ELVN-002 + Eribulin + Trastuzumab Capecitabine + ELVN-002 + Trastuzumab ELVN-002 + Paclitaxel + Trastuzumab Capecitabine + ELVN-002 + Oxaliplatin + Trastuzumab ELVN-002 + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab ELVN-002 + Trastuzumab ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer Recruiting USA 0
NCT06334432 Phase Ib/II NUV-1511 Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors Recruiting USA 0
NCT06336148 Phase I ACTM-838 A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors Not yet recruiting AUS 0
NCT06337630 Phase I M1774 + PLX038 A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors (POP-ART) Not yet recruiting FRA 0
NCT06349408 Phase Ib/II IBI3001 IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT06352359 Phase I ONC 841 Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors Not yet recruiting USA 0
NCT06365918 Phase I VG2025 Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis Not yet recruiting USA 0